201-14886



COURTNEY M. PRICE VICE PRESIDENT CHEMSTAR

December 9, 2003

RECEIVED OPPT CBIC

## Via US Mail and e-mail

Mr. Mike Leavitt, Administrator U.S. Environmental Protection Agency P.O. Box 1473 Merrifield, VA 2211

Re: Rubber and Plastic Additives (RAPA) Panel, Consortium No.

HPV Chemical Challenge Program Submission 1,3-diphenylguanidine (CAS number 102-06-7)

Dear Mr. Leavitt:


The RAPA Panel of the American Chemistry Council is pleased to submit the attached documents to EPA's High Production Volume (HPV) Chemical Challenge Program (Program) to fulfill our commitment for one of the 36 chemicals RAPA is voluntarily sponsoring in the Program. The RAPA Panel includes the following member companies: Alco Chemicals; Bayer Polymers LLC; Ciba Specialty Chemicals Corporation; Crompton Corporation; Eliokem, Inc.; Flexsys America L.P.; The Goodyear Tire & Rubber Company; The Lubrizol Corporation; Noveon, Inc.; and, R.T. Vanderbilt Company, Inc.

In this submission, please find documents submitted by the Ministère de l'Environnement et de l'Aménagement du Territoire, representing France as the sponsor country for 1,3-diphenylguanidine (CAS no. 102-06-7) in the Organization for Economic Cooperation and Development (OECD) Screening Information Data Set (SIDS) program. The SIDS documents consists of the SIDS Initial Assessment Profile (SIAP), the SIDS Initial Assessment Report (SIAR) and robust summaries of studies conducted on 1,3-diphenylguanidine in an IUCLID-formatted document.

The conclusion of the SIDS review was that 1,3-diphenylguanadine is a candidate for further work, specifically testing in road dust to assess environmental concentrations of the compound resulting from abrasion of rubber compounds in motor vehicle tires. Such testing is beyond the scope of the US HPV Program.

This submission also is being sent electronically to the following e-mail addresses:

Oppt.ncic@epa.gov Chem.rtk@epa.gov



Mike Leavitt RAPA-HPV December 9, 2003 Page 2 of 2

If you require additional information, please contact the RAPA Panel's technical contact, Dr. Anne P. LeHuray at (703) 741-5630 or anne\_lehuray@americanchemistry.com.

Sincerely yours,

Courtney M. Price Vice President, CHEMSTAR

Attachments

#### RECOMMENDATIONS OF THE SPONSOR COUNTRY

This chemical is a candidate for further work

#### SUMMARY CONCLUSIONS OF THE SIAR

#### Exposure

Diphenylguanidine is a solid with a melting Point in the region of 145-150°C. Its boiling point is greater than 170°C. Vapour pressure is relatively low (174 x 10<sup>6</sup> kPa at 20°) and solubility in water varies greatly with the pH of the medium from 475 mg/l to 1 g/l at pH 7 and 25°C, to 519 g/l at strongly acid pH and 20°C. At higher pHs the solubility does not appear to decrease significantly. The change in solubility is due to the ionisation state of the substance. There are two protonation steps. The log pKa of the first protonation occurs at 10.12 but the second is unknown. The log Kow is measured as 1.69 but the pH of test is unknown. Probably this result relates to the protonated molecule but whether in cationic or dicationic form not known. A calculated value is 2.9

The expected production volume of 1,3-Diphenylguanidine in year 2000 is 2400 tonnes/year in Europe, 2400 tonnes/year in the USA, an amount of 5300 tonnes/year for Asia and 11100 tonnes per year for the world.

1,3-diphenylguanidine is used as a primary accelerator in vulcanisation of rubber, as secondary accelerator for sulfur-containing compounds such as thiazoles, sulfenamides and thiurams and as a minor use as a primary material for standardising acids.

Depending on the specific application, the concentration of 1,3-diphenylguanidine used in the production of rubber compounds may vary from 0.25% to 2.0% by weight.

#### Health effects

- 1,3-Diphenylguanidine is absorbed rapidly after oral uptake but only slowly after dermal application. The substance is metabolised quickly and eliminated in the urine and faeces. No information is available on the mode of action.
- 1,3-diphenylguanidine is moderately toxic by ingestion, the oral LD50 is 350-850 mg/kg b.w. for the rat. By dermal route, 1,3-diphenylguanidine is practically non toxic, the dermal LD0 is > 2,000 mg/kg b.w. in the rabbit. After oral administration, the symptoms were normally of a nervous character, but post mortem examination revealed liver effects (dark colour) and severe irritation of the gastro-intestinal tract.

Three sub-chronic 13-week toxicity feeding studies in rats or mice have shown an increase of the mortality rate in rats at high dose (3000 ppm) and a decrease of food consumption in rats (as of 500-750 ppm) and body weight gain in rats and mice (as of 500-750 ppm) due to the poor palatability of the 1,3-Diphenylguanidine-treated feed. Treatment -related effects on the organs and the haematological, clinical-chemical parameters and urinalysis were not observed. The NOAEL/LOAEL lies at 500/750 ppm (32/50 mg/kg bw/d) and 150/500 ppm (11/37 mg/kg bw/d) for rats and 500/750 ppm (75/114 mg/kg bw/d) in mice. Based on these data, a conservative NOAEL can be established at 32 mg/kg bw/d for rats and 75 mg/kg/d for mice.

Most of the *in vitro* and *in vivo* investigations available give no indication of a genotoxic effect. A carcinogenicity study which would meet present standards is not available.

Previous and unreliable reproductive toxicity studies in male mice and hamsters indicated a negative influence on fertility of 1,3-diphenylguanidine, which may have been due to impurities in the test substance. Taken into account the reliable studies, where 1,3-diphenylguanidine was tested with a purity of 97.7% to 99.9%, representative of the industrial product, 1,3-diphenylguanidine did not affect the fertility of male mice when administered by gavage up to the maximal tested dose level of 16 mg/kg/d. In addition to the results of the feeding sub-chronic studies on the rat and mouse, special studies for recognising reproductive toxic effects were also performed. Comparisons of the parameter changes with the results of tests with feed withdrawal infer that the effects observed in the 1,3-Diphenylguanidine-treated animals in high concentration groups are a result of the

poor general state of health (malnutrition, exhaustion) of the animals and not a direct toxic effect on the reproductive organs. Very conservative NOAELs, based on the effects on the reproductive organs, secondary to malnutrition and exhaustion, can be established at 32 mg/kg bw/d for rats and from 16 to 231 mg/kg bw/d for mice.

In female rats and mice foetotoxic, but not teratogenic, effects were seen after the oral administration of maternotoxic doses. In the rat study the NOEL was given as 5 mg/kg bw for the dams and 25 mg/kg bw for the foetuses. In the mouse study the NOEL was given as 4 mg/kg bw for the dams and > 10 mg/kg bw for the foetuses

1,3-Diphenylguanidine is irritating to the eye and non-irritating to the skin.

Human cases have shown that contact dermatitis patients, for whom a rubber intolerance was often present, occasionally reacted positively to 1,3-diphenylguanidine in the patch test. Taken into account the negative Guinea pig maximisation assay, it can be infer that the positive reactions observed in human patients with contact dermatitis reflected cross-reactions rather than a direct sensitising effect of 1,3-diphenyl guanidine. In man, earlier and unconfirmed studies described the following symptoms after workplace exposures to 1,3-Diphenylguanidine: eye and mucous membrane irritation, gastric and bilious complaints and disturbed liver metabolism.

#### Environment

1,3-diphenylguanidine has three forms: unionised, primarily protonated and secondarily protonated. The pKa at which the first protonation occurs is 10.12 while the pKa for the second protonation is unknown and as this will be less than 10.12 it is not known whether this state will be reached at normal environmental pHs between 6 and 8. This leads to problems in determining the environmental fate of the substance.

Due to the relatively high solubility (approx. 0.5 g/l) at environmental pHs (6 to 9), low octanol water partition coefficient (<3) and low volatility of 1,3-Diphenylguanidine the substance is not expected to adsorb to sediment and will mainly be present in the aqueous phase. A bioconcentration test on fish provided a BCF of <2. The substance is therefore likely to remain bioavailable and, although not readily biodegradable, has been shown to mineralise rapidly in the presence of adapted micro-organisms. Based on the above the substance can be considered inherently biodegradable. Bioaccumulation in biota is not expected for this substance.

1,3-diphenylguanidine has been shown to be toxic to fish and algae and harmful to daphnia in several acute studies (fish: 96 h LC50 = 4.2-11 mg/l; algae: EC50 = 1.7-7.5 mg/l; daphnid: 48 h EC50 = 17-62.4 mg/l). The PNEC can be determined using the NOECs from the algae (0.3 mg/l) and daphnid chronic (1.9 mg/l) studies (excluding the EbC50 results), by applying an uncertainty factor of 50. The resulting PNEC would be  $6 \text{ \mug/l}$ .

A terrestrial plant study conducted on monocotyledons and dicotyledons did not show a high level of concern for DPG in these species

Due to its main use as a vulcanisation activator during which process it is incorporated in the rubber compound but much reverts after processing, leaching of DPG may occur from rubber compounds but the substance represents a relatively low percentage of content in the finished product (1-2%). DPG may be of concern locally in aqueous discharge from production and downstream use sites as well as due to releases from rubber articles containing DPG.

#### NATURE OF FURTHER WORK RECOMMENDED

#### Human health

No further works are recommended

#### Environment

Based on current information no clear conclusion can be drawn. While the fate properties suggest that the substance will not bioaccumulate in the environment and that degradation will occur, the PNEC, be it based on flora or fauna is relatively low and the downstream use is such that the substance is likely to be found (within or outside polymer matrix) in the environment mainly due to abrasion from car tyres.

In the absence of knowledge on the leaching behaviour of the substance from abraded rubber compounds, further work to provide a reasonable estimate of the environmental concentration is considered necessary.

# IUCLID

## **Data Set**

**Existing Chemical** 

CAS No.

**EINECS Name** 

EC No.

**TSCA Name** Molecular Formula : ID: 102-06-7

: 102-06-7

: 1,3-diphenylguanidine

: 203-002-1 : Guanidine, N,N'-diphenyl-

: C13H13N3

Producer related part

Company **Creation date**  : Atofina : 06.11.2000

Substance related part

Company

Creation date

: Atofina

: 06.11.2000

Status

Memo

Printing date

Revision date

: 14.11.2001

Date of last update

14.11.2001

Chapter: 1, 2, 3, 4, 5, 6, 7, 8, 10

Number of pages

: 146

Chapter (profile) Reliability (profile)

Flags (profile)

ld 102-06-7 Date 14.11.2001

#### 1.0.1 APPLICANT AND COMPANY INFORMATION

lead organisation Type

Name M.L.P.C.

Contact person

Date

BP 2 Street

40370 RION DES LANDES Town

France Country

Phone

**Telefax** : **Telex** : Cedex : Email : Homepage

Source ECB - Existing Chemicals Ispra (VA)

non confidential Flag

07.11.2000

cooperating company Type Name Akzo Chemicals b.v.

Contact person

**Date** 

Street Stationsplein 4, PO Box 247

Town 3800AE Amersfoort

Country Netherlands

Phone

Telefax

Telex

Cedex

Email

Homepage

Source ECB - Existing Chemicals Ispra (VA)

Flag non confidential

07.11.2000

Type cooperating company

Name Monsanto plc

**Contact person** 

Date

Street

Town RG24 OUL Basingstoke

Country United Kingdom

**Phone** 

**Telefax** Telex Cedex Email : Homepage

Source ECB - Existing Chemicals Ispra (VA)

non confidential Flag

07.11.2000

ld 102-06-7 **Date** 14.11.2001

#### 1.0.2 LOCATION OF PRODUCTION SITE, IMPORTER OR FORMULATOR

#### 1.0.3 IDENTITY OF RECIPIENTS

#### 1.0.4 DETAILS ON CATEGORY/TEMPLATE

#### 1.1.0 SUBSTANCE IDENTIFICATION

#### 1.1.1 GENERAL SUBSTANCE INFORMATION

Purity type :

Substance type : organic Physical status : solid

**Purity** : ca. 97.5 % w/w

Colour : Odour :

Flag : non confidential

12.09.2001 (1)

Purity type : Substance type :

Physical status : solid Purity : > 96 % w/w

Colour : Odour :

**Remark** : 96% is the minimum acceptable purity of the batch. In

practice analysis shows 97-98.5%

12.09.2001 (2)

Purity type :

Substance type
Physical status
: solid
Purity: > 99 % w/w

Colour :

Odour :

12.09.2001 (3)

#### 1.1.2 SPECTRA

#### 1.2 SYNONYMS AND TRADENAMES

#### 1,2-DIPHENYLGUANIDINE

23.10.1995

#### 1,3-DIPHENYLGUANIDINE

23.10.1995

Source

ld 102-06-7 **Date** 14.11.2001

DENAX		
23.10.1995		
DFG		
23.10.1995		
DPG		
23.10.1995		
GUANIDINE, 1,3-DIPHENYL-		
05.09.2001		
GUANIDINE, N,N'-DIPHENYL-		
23.10.1995		
MELANILINE		
23.10.1995		
N,N'-DIPHENYLGUANIDIN		
06.09.2001		
N,N'-diphenylguanidine		
23.10.1995		
SYM-DIPHENYLGUANIDINE		
23.10.1995		
Vulkacit D		
23.10.1995		
VULKAZIT		
06.09.2001		
Source		M.L.P.C. RION DES LANDES
05.09.2001		ECB - Existing Chemicals Ispra (VA)
Source	:	M.L.P.C. RION DES LANDES ECB - Existing Chemicals Ispra (VA)
05.09.2001		
Source	:	Monsanto plc Basingstoke
05.09.2001		ECB - Existing Chemicals Ispra (VA)

: Monsanto plc Basingstoke

ld 102-06-7 **Date** 14.11.2001

ECB - Existing Chemicals Ispra (VA)

05.09.2001

#### 1.3 IMPURITIES

Purity CAS-No

EC-No
EINECS-Name : Others and uni
Molecular formula : ca. .7 % w/w : Others and unknown

06.09.2001

CAS-No : 7732-18-5
EC-No : 231-791-2
EINECS-Name : water
Molecular formula :
Value :

06.09.2001

 Purity
 :

 CAS-No
 :
 62-53-3

 EC-No
 :
 200-539-3

 EINECS-Name
 :
 aniline

 Molecular formula
 :

Value : <.04 % w/w

06.09.2001

#### 1.4 ADDITIVES

## 1.5 TOTAL QUANTITY

#### 1.6.1 LABELLING

## 1.6.2 CLASSIFICATION

#### 1.6.3 PACKAGING

#### **USE PATTERN** 1.7

#### 1.7.1 DETAILED USE PATTERN

## 1.7.2 METHODS OF MANUFACTURE

ld 102-06-7 **Date** 14.11.2001

#### 1.8 REGULATORY MEASURES

#### 1.8.1 OCCUPATIONAL EXPOSURE LIMIT VALUES

**Remark**: No occupational exposure limit has been set.

06.09.2001

Remark : No data available on Occupational Exposure Limit Values on

the referred chemical.

Source : M.L.P.C. RION DES LANDES

ECB - Existing Chemicals Ispra (VA)

23.10.1995

#### 1.8.2 ACCEPTABLE RESIDUES LEVELS

#### 1.8.3 WATER POLLUTION

#### 1.8.4 MAJOR ACCIDENT HAZARDS

#### 1.8.5 AIR POLLUTION

## 1.8.6 LISTINGS E.G. CHEMICAL INVENTORIES

#### 1.9.1 DEGRADATION/TRANSFORMATION PRODUCTS

#### 1.9.2 COMPONENTS

## 1.10 SOURCE OF EXPOSURE

**Remark**: Batch process. The powder in suspension is extracted by a

centrifugal dryer. The final product is obtained after flash

dryer and cyclone.

Effluents containing powder in suspension are puirfied in a

waster tip treatment. Wet wastes are burning in an

incinerator.

In the atmospher, dust only appears on the area of the

process unit.

If dust on soil, recuperation and incineration.

06.09.2001

#### 1.11 ADDITIONAL REMARKS

ld 102-06-7 **Date** 14.11.2001

## 1.12 LAST LITERATURE SEARCH

1.13 REVIEWS

ld 102-06-7 **Date** 14.11.2001

#### 2.1 MELTING POINT

**Value** : 142 °C

Sublimation : Method :

Year : GLP :

**Test substance** : other TS: DPG no indication of purity

**Remark**: No further information available

**Reliability** : (2) valid with restrictions

06.09.2001 (4)

**Value** : 145 - 147 °C

Sublimation : Method : Year :

GLP

**Test substance** : other TS: DPG no indication of purity

06.09.2001 (5)

Value :  $= 147 - 150 \,^{\circ}\text{C}$ Decomposition : no, at  $^{\circ}\text{C}$ 

**Sublimation**: no

Method : other: Differential Scanning Calorimetry

Year : 2001 GLP : no

**Test substance** : other TS: commercial grade

Reliability : (1) valid without restriction
Flag : Critical study for SIDS endpoint

05.09.2001 (6)

**Value** : 147 °C

**Reliability** : (2) valid with restrictions

06.09.2001 (7)

**Value** : 148 - 148.5 °C

Sublimation Method

**Year** : 1926

GLP :

Test substance :

**Reliability** : (2) valid with restrictions

06.09.2001 (8)

**Value** : 149 - 150 °C

Sublimation

Method :

**Year** : 1992

GLP : Test substance :

**Reliability** : (2) valid with restrictions

06.09.2001 (9)

ld 102-06-7 **Date** 14.11.2001

**Value** : 150 °C

Sublimation

Method

**Year** : 1985

GLP

Test substance

**Reliability** : (2) valid with restrictions

06.09.2001 (10) (11)

**Value** : 151.6 °C

Sublimation

Method

**Year** : 1989

GLP :

Test substance

06.09.2001 (12)

#### 2.2 BOILING POINT

**Value** : > 170 °C at 1013 hPa

**Decomposition** : yes **Method** :

Year : 1985

GLP

**Test substance** : other TS: DPG no indication of purity

Result : No further information
Reliability : (2) valid with restrictions

06.09.2001

**Value** : > 200 °C at 1013 hPa

**Decomposition**: yes

Method : other: Differential Scanning Calorimetry

**Year** : 2001 **GLP** : no

**Test substance** : other TS: DPG no indication of purity

**Remark**: The exact boiling point temperature is not well determined

because the DSC graph does not show a clearly defined threshold. We just notice that the curve goes up instead of being straight (see attached graph). The analysis equipment

used does not allow to go up to 300°C.

Attached document:BP chromatogram dpg.docReliability:(1) valid without restrictionFlag:Critical study for SIDS endpoint

05.09.2001 (6)

#### 2.3 DENSITY

Type : density

**Value** : 1.13 g/cm³ at 20 °C

Method

**Year** : 1985

GLP

**Test substance** : other TS: DPG no indication of purity

ld 102-06-7 **Date** 14.11.2001

**Reliability** : (2) valid with restrictions

06.09.2001 (10) (13)

Type : density

Value : 1.19 g/cm³ at 20 °C

Method Year

GLP

**Test substance**: as prescribed by 1.1 - 1.4

**Reliability** : (2) valid with restrictions

06.09.2001 (4)

#### 2.3.1 GRANULOMETRY

#### 2.4 VAPOUR PRESSURE

Value : .0000000174 hPa at 20 °C

Decomposition

**Method** : other (calculated)

Year

GLP

**Test substance**: as prescribed by 1.1 - 1.4

**Remark** : data extrapolated from measurements at 87-128 degree C

**Reliability** : (2) valid with restrictions

Flag : Critical study for SIDS endpoint

06.09.2001 (4)

**Value** : .0000000409 hPa at 25 °C

Decomposition

**Method** : other (calculated)

**Year** : 1988

GLP

**Test substance**: as prescribed by 1.1 - 1.4

**Remark**: data extrapolated from measurements at 87-128 degree C

**Reliability** : (2) valid with restrictions

06.09.2001 (14)

#### 2.5 PARTITION COEFFICIENT

Partition coefficient

**Log pow** : 1.69 at °C

pH value

**Method** : other (measured)

Year : 1992 GLP : no data

**Test substance** : as prescribed by 1.1 - 1.4

**Result** : 4 measurements of log Pow were made:

1.76 1.65 1.81 1.54

However, as no pH was reported it is not possible to

ld 102-06-7 Date 14.11.2001

determine the state of ionisation of DPG during this

The values can only be used as an indication of log Pow. 1-4 mg test substance dissolved in 2 ml n -octanol by

**Test condition** 

addition of 20 ml water; HPLC-analysis

Reliability (3) invalid

06.09.2001 (15)

Partition coefficient

2.9 at °C Log pow

pH value

Method other (calculated)

Year 2001

GLP

Test substance other TS: modeled data

Result The result is presumed to be an indication of the log Pow of

DPG in an unionised state

Reliability (2) valid with restrictions

06.09.2001 (16)

## 2.6.1 SOLUBILITY IN DIFFERENT MEDIA

Solubility in

Value .217 g/l at 30 °C

Ha value 10 concentration at °C

**Temperature effects** 

Examine different pol.

at 25 °C pKa

Description

Stable

Deg. product

Method

Year 1989

GLP

Test substance as prescribed by 1.1 - 1.4

Reliability (2) valid with restrictions

06.09.2001 (17)

Solubility in

Value < 1 g/l at 21 °C

pН value

concentration at °C

**Temperature effects** 

Examine different pol.

pKa at 25 °C

Description Stable

Deg. product Method

Year 1985 **GLP** no data

**Test substance** other TS: DPG no indication of purity

06.09.2001 (10)

Solubility in

ld 102-06-7 **Date** 14.11.2001

**Value** : 1.5 g/l at 20 °C

pH value :

concentration : at °C

Temperature effects

Examine different pol.

**pKa** : at 25 °C

Description : Stable :

Deg. product Method

**Year** : 1974 **GLP** : no

**Test substance** : other TS: DPG no indication of purity

**Reliability** : (2) valid with restrictions

06.09.2001 (18)

Solubility in

**Value** : 1 g/l at 25 °C

pH value :

concentration : at °C

Temperature effects

Examine different pol.

**pKa** : at 25 °C

Description :

Stable : Deg. product :

Method

**Year** : 1992 **GLP** : no data

**Test substance** : other TS: no indication of purity

**Reliability** : (2) valid with restrictions

06.09.2001 (9)

Solubility in

**Value** : 22 g/l at 20 °C

pH value

concentration : at °C

Temperature effects

Examine different pol.

**pKa** : at 25 °C

Description Stable

Deg. product

Method

**Year** : 1974 **GLP** : no

**Test substance** : other TS: DPG no indication of purity

**Test substance** : DPG x H3PO4

**Reliability** : (2) valid with restrictions

06.09.2001 (18)

Solubility in

**Value** : 43.28 g/l at 20 °C

pH value

concentration : at °C

Temperature effects

Examine different pol. :

**pKa** : at 25 °C

Description

ld 102-06-7 **Date** 14.11.2001

Stable :
Deg. product :
Method :

**Year** : 1974 **GLP** : no

**Test substance** : other TS: DPG no indication of purity

**Test condition**: Strongly acid conditions increasing water solubility

Test substance : (DPG)2 x H2SO4

**Reliability** : (2) valid with restrictions

06.09.2001 (18)

Solubility in

**Value** : 519 g/l at 20 °C

pH value

concentration : at °C

Temperature effects

Examine different pol.

**pKa** : at 25 °C

Description

Stable

Deg. product

Method

**Year** : 1974 **GLP** : no

**Test substance** : other TS: DPG no indication of purity

**Test condition**: strongly acid conditions increasing water solubility

**Test substance** : DPG x HCl

**Reliability** : (2) valid with restrictions

:

:

06.09.2001 (18)

Solubility in

Value : = 860 mg/l at 25 °C

pH value : = 7 concentration : at °C

Temperature effects

Examine different pol.

**pKa** : at 25 °C

Description : Stable : Deg. product :

 Method
 :

 Year
 :
 1980

 GLP
 :
 ves

**Test substance**: as prescribed by 1.1 - 1.4

**Method**: measurements made at pH 5, 7 and 9 using Campbell method.

Substance was allowed to equilibrate for 7 or 8 days at

25°C.

Saturated solution was exracted with methylene chloride (4 x

2 ml) and extract measured by HPLC.

**Result** : At pH 5 the substance was observed to have completely

decomposed and no data was obtained. Decomposition was proposed as a brown residue was formed while "DPG is light grey" and the fact that DPG kept dissiving no matter how

much was added.

Solubilities at pH 7 and 9 were based on two measurements so

wide standard errors were obtained:

ld 102-06-7 **Date** 14.11.2001

pH7 860 +/ - 110

**Reliability** : (2) valid with restrictions

06.09.2001 (19)

Solubility in

Value : = 1470 mg/l at 25 °C

pH value : = 9 concentration : at °C

Temperature effects

Examine different pol. :

**pKa** : at 25 °C

Description :
Stable :
Deg. product :
Method :

Year : 1980 GLP : yes

**Test substance**: as prescribed by 1.1 - 1.4

**Method**: measurements made at pH 5, 7 and 9 using Campbell method.

Substance was allowed to equilibrate for 7 or 8 days at

25°C.

Saturated solution was exracted with methylene chloride (4 x

2 ml) and extract measured by HPLC.

**Result** : At pH 5 the substance was observed to have completely

decomposed and no data was obtained. Decomposition was proposed as a brown residue was formed while "DPG is light grey" and the fact that DPG kept dissiving no matter how

much was added.

Solubilities at pH 7 and 9 were based on two measurements so

wide standard errors were obtained:

pH9 1470 +/- 380

**Reliability** : (2) valid with restrictions

06.09.2001 (19)

Solubility in

**Value** : = 475 mg/l at 20 °C

pH value : = 7

concentration : 1015 mg/l at 60 °C

Temperature effects :

Examine different pol.

**pKa** : at 25 °C

**Description** : other:DPG is slightly soluble in water at pH 7 and basic pH (11). At acid pH

DPG is transformed into DPG chlorhydrate which is very soluble in water.

Stable

Deg. product

Method : other: comparable to OECD guideline n°. 105 (NFT 20-046 AFNOR 1985)

**Year** : 2001 **GLP** : no

**Test substance**: as prescribed by 1.1 - 1.4

Result : Solubility

Temp (°C) pH 7 pH11 422 422 10 20 475 485 30 537 541 40 701 680 60 1009 1015

90

ld 102-06-7 **Date** 14.11.2001

**Test condition**: The NF T 20-046 method was used, instead of NF T 20-045

method, although 1,3-diphenylguanidine is slightly soluble.

**Attached document** : solubility curve dpg.doc

**Conclusion**: The results of this method are good and the results are used

in industrial production.

(1) valid without restriction

Reliability : (1) valid without restriction
Flag : Critical study for SIDS endpoint

06.09.2001 (20)

#### 2.6.2 SURFACE TENSION

#### 2.7 FLASH POINT

 Value
 : 170 °C

 Type
 : closed cup

 Method
 : other: DIN 51578

Year

GLP : yes

**Test substance**: as prescribed by 1.1 - 1.4

Reliability : (1) valid without restriction
Flag : Critical study for SIDS endpoint

06.09.2001 (4)

#### 2.8 AUTO FLAMMABILITY

## 2.9 FLAMMABILITY

#### 2.10 EXPLOSIVE PROPERTIES

#### 2.11 OXIDIZING PROPERTIES

#### 2.12 DISSOCIATION CONSTANT

#### 2.13 VISCOSITY

#### 2.14 ADDITIONAL REMARKS

**Remark**: dissociation constant (pKa): 10.12 at 25 degree C for first

protonation

The pKa at which the second protonation occurs is still

unknown but will be inferior or equal to the first.

11.09.2001 (21)

ld 102-06-7 **Date** 14.11.2001

#### 3.1.1 PHOTODEGRADATION

Type : water Light source :

**Light spectrum** : nm

**Relative intensity**: based on intensity of sunlight

**Result**: No photolysis was found due to exposure to sunlight for 7 d.

No loss was found in dark controls.

**Test condition** : 1 mg/l solutions of DPG in water were prepared in milli-Q

water with 1% acetonitrile. The solutions were placed in test tubes at a 60° angle from horizontal and exposed to

sunlight for 7 d.

Dark controls were mintained at 23°C.

After the test some samples were analysed immediately while

others were refrigerated until analysis.

Analysis

Extraction with methylene chloride and analysis by HPLC

**Conclusion** : Study valid with restrictions as light intensity was not

measured and no subjective indication of weather conditions provided. No information is given on the pH of solutions

used during the test.

The results are supported by the low extinction coefficient

of DPG in the sunlight region (E300 nm <100).

**Reliability** : (2) valid with restrictions

26.09.2001

INDIRECT PHOTOLYSIS

Sensitizer : OH

Conc. of sensitizer : 1000000 molecule/cm<sup>3</sup>

Rate constant : = .0000000000085 cm³/(molecule\*sec)

**Degradation** : = 50 % after 2.3 hour(s)

**Remark**: Calculated from Atmospheric Oxidation Programme V.1.89.

Syracuse Corp.

Flag : Risk Assessment

13.07.2001

#### 3.1.2 STABILITY IN WATER

 Type
 : abiotic

 t1/2 pH4
 : at °C

 t1/2 pH7
 : at °C

 t1/2 pH9
 : at °C

Deg. product

Method: otherYear: 1984GLP: no data

**Test substance** : other TS: no indication of purity

**Remark**: Hydrolysis of test substance (0.3 g/l resp. 0.03 % of weight

in water) at various pH values at 80 degree C: no hydrolysis at pH 3.5 after 500 h; 18.1 % at pH 7.0 after 1000 h; t1/2

ld 102-06-7 **Date** 14.11.2001

at pH 10.5 ca. 168 h; hydrolysis products:

N,N'-diphenyl-urea and aniline (IR- and UV-spectroscopy)

Reliability

: (2) valid with restrictions

26.09.2001 (22)

#### 3.1.3 STABILITY IN SOIL

#### 3.2.1 MONITORING DATA

**Type of measurement**: background concentration

:

Media : biota

Concentration

Method :

Remark : Japanese EPA investigated 42 water and sediment samples in

Japan in 1978. Samples not directly contaminated

byindustrila emissions. No DPG determined at a LOD of 2 to 5 µg/l for water and 100 to 500 µg/kg in sediment. reported in

BUA report no. 96: N,N'-diphenylguanidine

**Reliability** : (2) valid with restrictions

06.09.2001 (23)

#### 3.2.2 FIELD STUDIES

#### 3.3.1 TRANSPORT BETWEEN ENVIRONMENTAL COMPARTMENTS

#### 3.3.2 DISTRIBUTION

#### 3.4 MODE OF DEGRADATION IN ACTUAL USE

#### 3.5 BIODEGRADATION

Type : aerobic Inoculum : activated sludge

Concentration : 100 mg/l related to Test substance

related to

Contact time

Degradation: = 0 ( $\pm$ ) % after 14 day(s)Result: other: not readily biodegradable

Deg. product

Method : OECD Guide-line 301 C "Ready Biodegradability: Modified MITI Test (I)"

**Year** : 198

GLP :

**Test substance** : other TS: no indication of purity

Method : Test type: MITI test

Sludge concentration: 30 mg/l unadapted activated sludge

Substance concnetration: 100 mg/l

Reliability : (1) valid without restriction

06.09.2001 (24)

ld 102-06-7 **Date** 14.11.2001

Type : aerobic

**Inoculum** : aerobic microorganisms

**Concentration** : 20 mg/l related to Test substance

related to

Contact time

**Degradation** : 18 ( $\pm$ ) % after 3 day(s)

Result

Deg. product

Method: otherYear: 1988GLP: no data

**Test substance** : other TS: no indication of purity

**Remark**: Screening test with microorganisms of river water from not

environmental polluted regions (COD < 3 ppm); 5 ml of a 0.2 % peptone solution (pH 7.0) was mixed with 4.9 ml river water and 0.1 ml aqueous solution of test substance (dissolved in water, acetone or DMSO; final concentration: 20 mg/l); measurement of turbidity at 610 nm of optical

density

**Test condition** : 30 degree C **Reliability** : (4) not assignable

11.09.2001 (25)

Type : aerobic

**Inoculum** : activated sludge, domestic, adapted

Contact time : 28 day(s)

Degradation: ca. 75 (±) % after 28 day(s)Result: inherently biodegradable

Deg. product : not measured

Method : other: equivalent to OECD 301 D

Year : 1988 GLP : no data

**Test substance** : as prescribed by 1.1 - 1.4

Method : Experiment 1

Closed bottle test Unadapted sludge

0.8 2.4 8.0 24 mg/l DPG solutions

Measured after 5, 10 and 20 d

Experiment 2

Closed bottle test

Adapted sludge (aerated for 14 d in contact with DPG)

0.8 2.4 8.0 24 mg/l DPG solutions

Measured after 5, 10 and 20 d

Result : Expt

No degradation observed within 20 d at any concentration

Expt 2

Results based on % degradation after X d

Conc (mg/l) T (d) 5 10 20 0.8 0 62 74 2.4 0 66 76 8.0 16 >LOQ >LOQ 24 >LOQ >LOQ >LOQ 18/146

ld 102-06-7 **Date** 14.11.2001

>LOQ = all available oxygen used. No measurement possible : Rapid mineralisation of DPG by adapted micro-organisms

Reliability : (1) valid without restriction
Flag : Critical study for SIDS endpoint

06.09.2001 (26)

Type : aerobic

Inoculum: activated sludge, adaptedConcentration: 20 mg/l related to Test substance

related to

Contact time

Conclusion

**Degradation** :  $= 55 - 71 (\pm) \%$  after 28 day(s)

**Result** : other: data suggest that this material is intrinsically biodegradable

Deg. product

**Method** : other: see test conditions

Year : 1979 GLP : no data

**Test substance**: as prescribed by 1.1 - 1.4

**Result**: Flasks with DPG:

21 mg 71% of ThOD 20 mg 68% of ThOD 20 mg 55% of ThOD

Flasks with DPG plus HgCl2:

21 mg 5% of ThOD

**Test condition**: Draft method Nr 2 for the proposed standard for the

determination of the ultimate biodegradability of organic chemicals, August 1979, ASTM Committe E35.24.

Inoculum: Aclimated SCAS supernatant

Method similar to sturm test OECD 301B except that the

flasks were shaken.

Preparation

100 ml of acclimated bcterial inoculum mixed with 900 ml of

mineral salt medium in 2l Ehlenmeyer flask.

The solution was aerated and 20 to 21 mg of DPG added to test flasks. No substance added to control. One flask

contained 21 mg DPG and 50 mg/l HgCl2.

CO2 produced was trapped by Ba(OH)2 suspended within the

flasks. No aeration is provided during the study. Periodically (e.g. 3, 7, 14, 21, 28 and 35 d) the flasks were unstoppered and the Ba(OH)2 analysed for CO2. Fresh

barium solution was replaced at each sample time.

The duration of the DPG test was consideed to be 28 d but no

exact study length is provided in the report.

**Conclusion** : Considered as valid with restrictions as method followed a

defined norm but no study duration was provided in the report. However, the duration is expected to be either 28 or

35 d.

**Reliability** : (2) valid with restrictions

06.09.2001 (27)

Type : aerobic

Inoculum: other: screen filtered river waterConcentration: 1 mg/l related to Test substance

ld 102-06-7 **Date** 14.11.2001

related to

Contact time : 14 day(s)

Degradation : (±) % after

**Result** : other: primarily degradable

**Kinetic of testsubst.** : 0 day(s) = 0 %

3 day(s) ca. 3 % 7 day(s) = 78 % 14 day(s) = 100 %

%

**Control substance** : other: quinoline

Kinetic : %

: not measured

Method

Deg. product

Year : 1980 GLP : no data

**Test substance**: as prescribed by 1.1 - 1.4

Method : Closed 4 I bottle half filled with 2 I of screen filled

river water containing 20 ml of (1 g/l) potassium phosphate

buffer (pH 7.5) and 50 µl/litre of DPG stock solution

(containing 40 mg/ml DMSO).

Final concentration DPG = 1 mg/l Final concentration DMSO =  $25 \mu l/l$ 

Steril control with autoclaved river water.

Positive control of 4 ml of 2 mg/ml quinoline into buffered

river water.

Incubation temperature: 21-25°C.

Analysis

DPG analysed at each sample time using HPLC. Sample adjusted

to pH>10 with NaOH and extracted with CH2Cl2 (2 x 5 ml).

Quantified using 1.5% ethanoic acid/48.5% ethanol/50% hexane

through a silica 100 µl loop column.

Flow rate: 2 ml/min detector: 254 nm UV

**Result** : DPG residues were measured:

time sterile control DPG 0 0.82 0.82 3 0.84 0.81 7 0.96 0.21 14 0.81 0

**Conclusion**: Primary degradation complete within 14 days at a

concentration of 1 mg/l DPG in filtered river water.

No mineralisation was determined in this study.

**Reliability** : (2) valid with restrictions

27.06.2001 (28)

#### 3.6 BOD5, COD OR BOD5/COD RATIO

BOD5

Method :

**Year** : 1960

ld 102-06-7 **Date** 14.11.2001

Concentration: related toBOD5: mg/lGLP: no

**Remark**: BOD5: 2.3 % (referred to TOD); no further information

available

**Reliability** : (2) valid with restrictions

06.09.2001 (29)

#### 3.7 BIOACCUMULATION

**Species**: Cyprinus carpio (Fish, fresh water)

**Exposure period** : 42 day(s) at 25 °C

Concentration: .1 mg/lBCF: < 2</th>Elimination: no data

Method : OECD Guide-line 305 C "Bioaccumulation: Test for the Degree of

Bioconcentration in Fish"

Year : 1992 GLP : no data

**Test substance** : other TS: no indication of purity

**Remark**: Exposure of test organisms for 6 weeks in a flow-through

system (0.2-0.8 l/min); no solvent; BCF determined as below

the limit of detection; no further

information available

**Test condition** : 6-8 mg O2/l; test concentration analyzed twice a week

**Reliability** : (1) valid without restriction

06.09.2001 (9)

**Species**: Cyprinus carpio (Fish, fresh water)

**Exposure period** : 42 day(s) at 25 °C

Concentration: .01 mg/lBCF: < 20</th>Elimination: no data

Method : OECD Guide-line 305 C "Bioaccumulation: Test for the Degree of

Bioconcentration in Fish"

Year : 1992 GLP : no data

**Test substance** : other TS: no indication of purity

**Remark**: Exposure of test organisms for 6 weeks in a flow-through

system (0.2-0.8 l/min); no solvent; BCF determined as below

the limit of detection; no further

information available

**Test condition** : 6-8 mg O2/l; test concentration analyzed twice a week

Reliability : (1) valid without restriction
Flag : Critical study for SIDS endpoint

06.09.2001 (9)

#### 3.8 ADDITIONAL REMARKS

#### 4.1 ACUTE/PROLONGED TOXICITY TO FISH

Type : flow through

**Species** : Cyprinus carpio (Fish, fresh water)

Exposure period

Unit :

Limit test

Analytical monitoring : no data
Method : other
Year : 1963
GLP : no

**Test substance**: other TS: no indication of purity

**Remark** : effect after a single oral application of test substance in

gelatine capsules;

3.2; 6.0 and 8.7 mg/kg bw: no effects within 114 h;

9.5 and 17 mg/kg bw: not specified symptoms after < 120 h,

recovery after < 312 h;

5.6 mg/kg bw: mortality after 71 h;

9.5 and 70 mg/kg bw: not specified symptoms after >= 22 h,

mortality after 125 h

no further information available

**Test condition** : 18 degree C

**Conclusion** : gavage of fish cannot be considered as relevant for aquatic

ecotoxicological hazard assessment

Reliability : (3) invalid

06.09.2001 (30)

Type : other: static or semistatic test
Species : Oryzias latipes (Fish, fresh water)

 Exposure period
 : 48 hour(s)

 Unit
 : mg/l

 LC50
 : 10

 Limit test
 :

**Analytical monitoring**: no data

Method : other: Japanese Industrial Standard (JIS K 0102-1986-71)

"Testingmethods for industrial waste water"

Year : 1992 GLP : no data

**Test substance** : other TS: no indication of purity

**Remark** : LC50 referred to nomimal concentration; no further

information available

**Test condition** : solvent not specified

Conclusion : not considered valid for hazard assessment only because of

short length of study (48 h); unacceptable test methodology.

**Reliability** : (3) invalid

06.09.2001 (9)

Type : static

**Species**: Lepomis macrochirus (Fish, fresh water)

**Exposure period** : 96 hour(s) **Unit** : mg/l

NOEC : <7.5 measured/nominal

**LC50** : = 9.6 calculated

LC100 : = 14 measured/nominal

Limit test

Analytical monitoring : no

Method : other: static method : US EPA Ecological Research series 660/3-75009

ld 102-06-7 4. Ecotoxicity Date 14.11.2001

Year : 1979 GLP yes

**Test substance** : as prescribed by 1.1 - 1.4

Remark : 24h LC50 = 18 mg/l

48h LC50 = 17 ma/l

Result : Nominal T.S. concentrations:

0, 7.5, 14, 24, 42, 75, mg/l

Nominal Mortality concentrations 24 48 72 96 0 0 0 0 0 7.5 0 0 0 2 0 0 9 10 14 24 10 10 10 10 42 10 10 10 10 75 10 10 10 10

Concentration of solvent at 75 mg/l DPG = 1000 mg/l. Only lowest test solution contained <100 mg/l of solvent.

Solvent control was not included

This is not thought to have had a major impact upon the test results as 20 % mortality was noted at 96 h at the lowest concentration.

Sub-lethal effects were noted as "loss of equilibrium" from 48 h at 14 mg/l and from 72 h in all surviving groups

Reference substance test included (antimycin A). The 96 h LC50 (0.029 µg/l) was reported as being within limits quoted

in literature

**Test condition** species/Supplier: Bluegill sunfish from Ossage Catfisheries

Inc, Missouri, USA Statistical method: probit

Test fish (control at termination): length 29.9 mm S.D. 3.54 mm weight 0.72 g S.D. 0.29 g

Diluion water: well water with hardness 255 mg/l as CaCO3; alkalinity 368 mg/l as CaCO3; conductivity 50 µOhms/cm; TOC no information; TSS not measured; pH = 8.2; Chlorine not measured.

Stock solution: prepared at 150 g/l in acetone. Diluted

directly into the final test solutions Exposure vessels: 40 I aquaria containing 30 I test solution

no. of replicates: 1 rep per concentration and 10 fish per

vessel

Test conditions:

Nominal 0 hours 48 hours 96 hours conc. T°C DO pH T°C DO pH T°C DO pH Ω 22 7.9 8.2 22 7.3 8.2 22 3.8 8.3 7.5 22 8.3 8.2 22 7.8 8.3 22 4.3 8.3

14 22 7.6 8.3

24 22 8.3 8.3

Conclusion Three negative points compromise the validity of the study:

- 1) No analytical information
- 2) static test system

3) The oxygen concentration at 96 h

but due to the stability of the substance (abiotically as well as biotically) and the low log Pow of this substance the nominal concentrations were likely to have been

maintained over the test period.

The oxygen concentration in the only surviving test group at the end of the study was below the levels considered acceptable for fish ecotoxicity testing (4.3 mg/l). However, the control oxygen concentration was even lower (3.8 mg/l)

and no mortality was observed in this group.

The results of this study are therefore considered valid

with restrictions.

**Reliability** : (2) valid with restrictions

06.09.2001 (31)

Type : static

Species : Leuciscus idus (Fish, fresh water)

 Exposure period
 : 48 hour(s)

 Unit
 : mg/l

 LC100
 : 10

 Limit test
 :

Analytical monitoring : no

Method : other: Bestimmung der akuten Wirkung von Stoffen auf Fische. Arbeitskreis

"Fischtest" im Hauptausschuss "Detergentien" (15.10.73)

**Year** : 1975 **GLP** : no

**Test substance**: as prescribed by 1.1 - 1.4

**Remark**: direct weight; range finding test

**Conclusion** : Endpoint calculated from a full range finding study. This

endpoint is not considered valid for hazard assessment -

refer to 96 h endpoint.

Reliability : (3) invalid

06.09.2001 (4)

Type : static

**Species**: Leuciscus idus (Fish, fresh water)

 Exposure period
 : 72 hour(s)

 Unit
 : mg/l

 LC0
 : 1

 Limit test
 :

Analytical monitoring : no

Method : other: Bestimmung der akuten Wirkung von Stoffen auf Fische. Arbeitskreis

"Fischtest" im Hauptausschuss "Detergentien" (15.10.73)

**Year** : 1975 **GLP** : no

**Test substance**: as prescribed by 1.1 - 1.4

Remark : direct weight

**Conclusion** : Endpoint calculated from a full range finding study. This

endpoint is not considered valid for hazard assessment -

refer to 96 h endpoint.

Reliability : (3) invalid

06.09.2001 (4)

Type : static

Species : Oncorhynchus mykiss (Fish, fresh water)

**Exposure period** : 96 hour(s) Unit : mg/l

**NOEC** : = 5.6 measured/nominal

LC50 : = 11 calculated

LC100 : = 18 measured/nominal

Limit test

Analytical monitoring : no

Method : other: Static method : US EPA Ecological Research series 660/3-75009

**Year** : 1979 **GLP** : yes

**Test substance**: as prescribed by 1.1 - 1.4

Remark : 24 and 48h LC50 = 18 mg/l Result : Nominal T.S. concentrations:

0, 3.2, 5.6, 10, 18, 32 mg/l

Nominal Mortality concentrations 24 48 72 96 0 0 0 0 0 3.2 0 0 0 0 0 5.6 0 0 0 0 10 2 3 3 4 18 3 3 6 10

10 10 10 10

Concentration of solvent in highest test solution = 213 mg/l

All other solutions contained <120 mg/l of solvent

Solvent control was not included

This is not thought to have had an impact upon the test

results.

Sub-lethal effects were noted as "loss of equilibrium" from

48 h at 10 and 18 mg/l.

Reference substance test included (antimycin A). The 96 h LC50 (0.029  $\mu$ g/l) was reported as being within limits quoted

in literature

**Test condition**: species/Supplier: rainbow trout from Spring Creek Hatchery,

Lewistown, Montana, USA Statistical method: probit

Test fish (control at termination): length 29.3 mm S.D. 2.26 mm weight 0.26 g S.D. 0.07 g

Diluion water: well water with hardness 255 mg/l as CaCO3; alkalinity 368 mg/l as CaCO3; conductivity 50  $\mu$ Ohms/cm; TOC no information; TSS not measured; pH = 8.2; Chlorine not

measured.

Stock solution: prepared at 150 g/l in acetone. Diluted

directly into the final test solutions

Exposure vessels: 15 l

no. of replicates: 1 rep per concentration and 10 fish per

vessel

Test conditions:

Nominal 0 hours 48 hours 96 hours conc. T°C DO pH T°C DO pH T°C DO pH T°C DO pH O 12 8.8 8.0 12 8.7 8.2 12 8.9 8.2 3.2 12 9.1 8.4 12 8.9 8.3 12 9.2 8.4

5.6

10 12 8.3 8.4

32 12 9.5 8.2 12 9.0 8.1

**Conclusion**: Two negative points compromise the validity of the study:

1) No analytical information

2) static test system

but due to the stability of the substance (abiotically as well as biotically) and the low log Pow of this substance the nominal concentrations were likely to have been

maintained over the test period.

The results of this study are considered valid with

restrictions.

**Reliability** : (2) valid with restrictions

06.09.2001 (32)

Type : static

**Species**: Pimephales promelas (Fish, fresh water)

Exposure period : 96 hour(s)
Unit : mg/l

NOEC : = 3.2 measured/nominal LC50 : = 4.2 calculated

**LC100** : = 5.6 measured/nominal

Limit test

**Analytical monitoring**: no

Method : other: static method : US EPA Ecological Research series 660/3-75009

**Year** : 1979 **GLP** : ves

**Test substance**: as prescribed by 1.1 - 1.4

**Remark** : 24h LC50 = 7.2 mg/l

48h LC50 = 6.4 mg/l

**Result** : Nominal T.S. concentrations:

0, 1.0, 1.8, 3.2, 5.6, 10 mg/l

Nominal		Mo	orta	ality		
concentration	ons	2	24	48	72	96
0	0	0	0	0		
1.0	0	0	0	0		
1.8	0	0	0	0		
3.2	0	0	0	0		
5.6	1	2	8	10		
10	9	10	1	0 10	)	

Concentration of solvent in highest test solution = 66 mg/l

Solvent control was not included

Sub-lethal effects were noted as "loss of equilibrium" from 24 h at 5.6 and 10 mg/l and from 48 h at 3.2, 5.6 mg/l.

Reference substance test included (antimycin A). The 96 h LC50 (0.028  $\mu$ g/l) was reported as being within limits quoted

in literature

**Test condition**: species/Supplier: Fathead minnows from Fattig Fish Hatchery,

Brady, Nebraska, USA Statistical method: probit

Test fish (mean control at termination):

length 23.3 mm weight 0.2 g

Diluion water: well water with hardness 255 mg/l as CaCO3; alkalinity 368 mg/l as CaCO3; conductivity 50 µOhms/cm; TOC

no information; TSS not measured; pH = 8.2; Chlorine not

measured.

Stock solution: prepared at 150 g/l in acetone. Diluted

directly into the final test solutions

Exposure vessels: contained 15 I test solution

no. of replicates: 1 rep per concentration and 10 fish per

vessel

Water chemistry:

Nominal 0 hours 48 hours 96 hours conc. T°C DO pH T°C DO pH T°C DO pH T°C DO pH 1.0 22 9.6 8.2 22 7.3 8.2 22 6.8 8.1 2.0 22 6.5 8.2 22 6.8 8.2

10 22 9.6 8.3

**Conclusion**: Two negative points compromise the validity of the study:

1) No analytical information

2) static test system

but due to the stability of the substance (abiotically as well as biotically) and the low log Pow of this substance the nominal concentrations were likely to have been

maintained over the test period.

The results of this study are considered valid with

restrictions.

Reliability : (2) valid with restrictions
Flag : Critical study for SIDS endpoint

06.09.2001 (33)

#### 4.2 ACUTE TOXICITY TO AQUATIC INVERTEBRATES

Type : static

Species : Daphnia magna (Crustacea)

Exposure period : 24 hour(s)
Unit : mg/l

 NOEC
 : 22 measured/nominal

 EC0
 : 3.9 calculated

 EC50
 : 73.6 calculated

 EC100
 : 177 calculated

Analytical monitoring : no

Method : other: UBA-Verfahrensvorschlag "Bestimmung der Schwimmunfaehigkeit

beimWasserfloh "Daphnia magna" (EC0, EC50, EC100; statisches

System) (Mai,1984)

**Year** : 1990 **GLP** : yes

**Test substance**: as prescribed by 1.1 - 1.4

Remark : EC50 as geometric mean of nominal concentrations; 24 h EC50

of organisms to reference substance

(potassium dichromate) was 3 mg/l as opposed to the average

24 h EC50 reported in the EC directive of 1.5 mg/l.

Given the relatively high stability and water solubility of the test substance and the normal variation between intra-

and inter-laboratory test results, the study is not

considered invalid by the reviewer.

**Result**: Nominal T.S. concentrations:

0, 1.4, 2.8, 5.5, 11, 22, 44, 88, 177 mg/l

Nominal	Mortality 24 h
concentrati	ions No. %
0	0 0
1.4	0 0
2.8	0 0
5.5	0 0
11	0 0
22	0 0
44	2 10
88	13 65
177	20 100

Results are provided in the report which do not correspond.

Therefore, the EC0 is taken as 3.9 mg/l calculated the EC100 as 125 mg/l calculated and the EC50 as 73.6 mg/l with 95% confidence limits of 61.4-88.4 mg/l) recalculated using pooled data provided in the report and using the probit method

The concentration at which no immobility was seen was 22 mg/l although at this level only 10% immobilisation was observed which is within the limits accepted for the control without invalidating the study. If this is taken into account the concentration at which no unacceptable immobility was observed was 44 mg/l.

The concentration at which 100% immobility was observed was 177 mg/l.

177 m

: species/Supplier: Daphnia magna STRAUS. No strain reported Supplier: Bundesgesundheitsamtes, Berlin, Germany

Statistical method: probit

Culture methods: Daphnids between 6 and 24 h old used for testing.

Diluion water: Elendt synthetic medium

Test conditions: pH 7.8-8.3 T°C 20.5 -20.9

Stock solution: prepared at 200 mg/l, heated to 50°C for one hour and allowed to cool for one hour while stirring.

Diluted directly into the final test solutions

Exposure vessels: no vessels

no. of replicates: 2 reps per concentration and 10 daphnids

per vessel

Test substance Conclusion

Test condition

: purity: 73.8 %

The lack of analytical information compromises the validity of the study but due to the stability of the substance (abiotically as well as biotically) and the low log Pow of this substance the nominal concentrations were likely to have been maintained over the test period.

,

The results of this study are considered valid with

restrictions.

**Reliability** : (2) valid with restrictions

06.09.2001 (34)

Type : static

Species : Daphnia magna (Crustacea)

Exposure period : 48 hour(s)
Unit : mg/l

**NOEC** : = 5.6 measured/nominal

EC50 : = 17 calculated

**EC100** : = 32 measured/nominal

Analytical monitoring : no

Method: other: static method: APHA 1975 US EPA Ecological Research series

660/3-75009

 Year
 : 1979

 GLP
 : yes

**Test substance** : as prescribed by 1.1 - 1.4

**Remark** : 24h EC50 = 33 mg/l

**Result**: Nominal T.S. concentrations:

0, 3.2, 5.6, 10, 18, 32 mg/l

Nominal Mortality concentrations 24 h 48 h 0 0 0 0 0 0000 0 + acetone 3.2 0000 5.6 0000 10 0 0 1 2 18 0065 32 5 4 10 10

Concentration of solvent at 32 mg/l DPG = 1600 mg/l. Only lowest test solution contained <100 mg/l of solvent.

Solvent control at 1600 mg/l included

This is not thought to have had a major impact upon the test

results.

No reference substance test included.

**Test condition**: species/Supplier: Daphnia magna cultured at ABC fa cilities.

No strain reported Statistical method: probit

Culture methods: adult daphnids fed on trout chow and alfalfa (PR-11) daily until 24 h prior to testing. Daphnids

less than 24 h old used for testing.

Photoperiod: 16h daylight: 8 h dark

Diluion water: well water with hardness 255 mg/l as CaCO3; alkalinity 368 mg/l as CaCO3; conductivity 50  $\mu$ Ohms/cm; TOC no information; TSS not measured; pH = 8.2; Chlorine not

measured.

Stock solution: prepared at 150 g/l in acetone. Diluted

directly into the final test solutions

Exposure vessels: 250 ml glass beakers containing 200 ml

test solution

no. of replicates: 2 reps per concentration and 10 daphnids

per vessel

Water chemistry (at end of test):

D.O 8.8 mg/l

pH 7.9

T°C reported as maintained at 20°C (+/-1°C) but not

confirmed by measurement

Effect measured: immobilisation

Conclusion : The lack of analytical information compromises the validity

of the study but due to the stability of the substance (abiotically as well as biotically) and the low log Pow of this substance the nominal concentrations were likely to

have been maintained over the test period.

The results of this study are considered valid with

restrictions.

Reliability : (2) valid with restrictions
Flag : Critical study for SIDS endpoint

06.09.2001 (35)

#### 4.3 TOXICITY TO AQUATIC PLANTS E.G. ALGAE

Species : Scenedesmus subspicatus (Algae)

Endpoint : biomass Exposure period : 72 hour(s) Unit : mg/l

**EC10** : = .013 calculated **EC50** : = 2.6 calculated

Limit test

**Test condition** 

Analytical monitoring : no

Method : other: cell multiplication inhibition test according to DIN 38412, part 9

Year : 1990 GLP : yes

**Test substance** : as prescribed by 1.1 - 1.4

Method : Following DIN norm 38 412 Teil 9

Result : Cell count

Nominal o	oncs 2	24h 48ł	n 72h	% biomass
0.01	58889	267778	845556	8.7
0.032	57778	230000	800000	16.5
0.1	58889	234444	775556	17.3
0.32	55556	210000	727778	23.8
1.0	51111	190000	744445	25.8
3.2	53333	111111	432222	55.2
10.0	21111	42222	51111	91.9
32.0	14444	14444	13333	98.7
100.0	10000	10000	8889	100.1

Control response satisfactory (>factor of 16)

No reference substance test included. species/Supplier: No strain reported

origin: Pflazenphysiologisches Institut der Universität,

3400 Göttingen

Statistical method: probit

Culture methods: constant temperature (23+/-  $2^{\circ}$ C) and continuous illumination (120  $\mu$ E/m2s). Algal culture maintained in suspension by magnetic stirrer.

Diluion water: millipore deionised water used to prepare culture water.

Stock solution: Agitated for two hours at 50°C. No further

information

Exposure vessels: 300 ml glass beakers containing 100 ml

test solution

no. of replicates: no information

Nominal T.S. concentrations:

0, 0.01, 0.032, 0.1, 0.32, 1.0, 3.2, 10, 32, 100 mg/l

#### Test conditions:

T°C 23°C

pH values T0 T72 0 7.6 8.9 0.01 7.6 8.8 0.032 7.6 8.9 0.1 7.6 8.7 0.32 7.6 8.3 1.0 7.7 8.0 8.0 3.2 7.7 10 7.9 7.9 32 8.2 8.2 100 8.4 8.3

Effect measured: biomass

Attached document : 102067alg.doc

**Reliability** : (2) valid with restrictions

06.11.2001 (36)

**Species**: Scenedesmus subspicatus (Algae)

Endpoint : growth rate
Exposure period : 72 hour(s)
Unit : mg/l

**EC10** : = 2.1 calculated **EC50** : = 7.5 calculated

Limit test

Analytical monitoring : no

Method : other: cell multiplication inhibition test according to DIN 38412, part 9

**Year** : 1990 **GLP** : yes

**Test substance** : as prescribed by 1.1 - 1.4

Method : Following DIN norm 38 412 Teil 9

Result : Cell count

Nominal concs 24h 48h 72h % growth rate 0.01 58889 267778 845556 1.17 57778 230000 800000 2.40 0.032 0.1 58889 234444 775556 3.09 0.32 55556 210000 727778 4.51 190000 744445 1.0 51111 4.01 3.2 53333 111111 432222 16.11 42222 10.0 21111 51111 63.66 14444 32.0 14444 13333 93.59

100.0 10000 10000 8889 102.62

Control response satisfactory (>factor of 16)

No reference substance test included. **Test condition**No reference substance test included.

species/Supplier: No strain reported

origin: Pflazenphysiologisches Institut der Universität,

3400 Göttingen

Statistical method: probit

Culture methods: constant temperature (23+/-  $2^{\circ}$ C) and continuous illumination (120  $\mu$ E/m2s). Algal culture maintained in suspension by magnetic stirrer.

Diluion water: millipore deionised water used to prepare culture water.

Stock solution: Agitated for two hours at 50°C. No further

information

Exposure vessels: 300 ml glass beakers containing 100 ml

test solution

no. of replicates: no information

Nominal T.S. concentrations:

0, 0.01, 0.032, 0.1, 0.32, 1.0, 3.2, 10, 32, 100 mg/l

Test conditions:

T°C 23°C

pH values T0 T72 0 7.6 8.9 0.01 7.6 8.8 0.032 7.6 8.9 7.6 8.7 0.1 0.32 7.6 8.3 7.7 8.0 1.0 3.2 7.7 8.0 10 7.9 7.9 32 8.2 8.2 100 8.4 8.3

Effect measured: growth rate

**Reliability** : (2) valid with restrictions

06.09.2001 (37)

Species: Selenastrum capricornutum (Algae)Endpoint: other: growth (no. of cells or chlorophyll a)

**Exposure period** : 96 hour(s) Unit : mg/l

**NOEC** : = .3 measured/nominal **EC50** : = 1.4 - 1.7 calculated

Limit test

Analytical monitoring : no

Method : other: Static method US EPA, 1971, Algae assay procedure : bottle test

**Year** : 1979 **GLP** : ves

**Test substance** : as prescribed by 1.1 - 1.4

ld 102-06-7 4. Ecotoxicity Date 14.11.2001

Remark Determination of cell multiplication by cell counter.

In vivo chlorophyll EC50 24h > 5.6 mg/l

48h = 3.5 mg/l72h = 2.0 mg/l96h = 1.4 mg/l

Init Inoc. = 20 000 cells/ml; 2800 lux; Carrier: DMF; 24°C

Result : Chlorophyll a determination

Fluorimeter reading (window setting)

24h 48h 72h (30)(10)(3) (1)

Nominal concs 1 2 3 1 2 3 1 2 3 1 2 3 47 49 54 60 58 68 99 92 98 45 44 51 0 0 + dmf53 50 53 64 68 60 99 98 91 49 51 46 0.3 51 52 55 58 60 60 88 84 85 43 42 42 0.6 53 52 52 47 45 47 68 64 67 32 27 30 1.0 50 52 52 43 45 41 51 54 51 20 22 19 3.2 48 46 48 34 31 35 42 40 45 19 16 20

45 46 45 28 31 26 30 32 29 9 10 7 5.6

Cell growth determination

cell counts (in no. of haemocytometer squares) 96h

Nominal concs 1 2 3 mean (x10 000)

0 74 73 84 (in 2) 38.8 0 + dmf79 82 75 (in 2) 39.3 0.3 75 73 76 (in 2) 37.3 57 51 53 (in 2) 26.8 0.6 1.0 35 34 30 (in 2) 16.5 3.2 55 51 58 (in 4) 13.7 5.6 37 40 38 in 4 9.6

EC50s based on chlorophyl a determination:

24h >5.6 mg/l 48h 3.5 mg/l (0.2-56) 72h 2.0 mg/l (0.2-17) 96h 1.4 mg/l (0.2-7.4)

96h EC50 based on cell number = 1.7 mg/l (0.4-7.4)

NOEC not calculated but based on available data can be taken as 0.3 mg/l at both 72 and 96h (for chlorophyl a and growth rate data at 96h).

Concentration of solvent at 5.6 mg/l DPG = 1000 mg/l.

Solvent control at 1000 mg/l included

This is not thought to have had a major impact upon the test results.

Control response satisfactory (initial cell count (20 000): final cell count (mean 388 000) = 194 divisions).

No reference substance test included.

No growth curves provided.

species/Supplier: Selenastrum capricornutum obtained from US EPA Environmental Research Laboratory, Oregan, USA and

maintained in stock at BMRL. No strain reported

Statistical method: probit

Culture methods: As recommended by EPA (1971).

33/146

Test condition

Diluion water: no information

Stock solution: prepared in dimethylformamide. Secondary stock solutions prepared by serial dilution. Secondary stock

used to prepare the test solutions.

Exposure vessels: 125 ml glass beakers containing 50 ml test

solution

Initial cell density: 20 000 cells/ml Illumination approximately 3800 lux no. of replicates: 3 reps per concentration

Nominal T.S. concentrations: 0, 0.3, 0.6, 1.0, 3.2, 5.6 mg/l

Test conditions: (at beginning and end of test):

pH 7.3-7.6

T°C reported as 24 +/-1°C (no measurements)

Effect measured: inhibition of growth measured as chlorophyll a concentration or cell numbers at each

concentration.

**Conclusion**: The lack of analytical information compromises the validity

of the study but due to the stability of the substance (abiotically as well as biotically) and the low log Pow of this substance the nominal concentrations were likely to

have been maintained over the test period.

The results of this study are considered valid with

restrictions.

Reliability : (2) valid with restrictions
Flag : Critical study for SIDS endpoint

06.09.2001 (38)

# 4.4 TOXICITY TO MICROORGANISMS E.G. BACTERIA

Type : aquatic

**Species**: activated sludge, industrial

 Exposure period
 : 3 hour(s)

 Unit
 : mg/l

 EC50
 : 147

 Analytical monitoring
 : no

Method : OECD Guide-line 209 "Activated Sludge, Respiration Inhibiton Test"

**Year** : 1989 **GLP** : no

**Test substance** : as prescribed by 1.1 - 1.4

Remark : Not adapted inoculum (content: 6 g dry substance/l) from a

laboratory treatment plant

Result : Conc respiration (% inibition based on mean control)

Ref sub 1 20 20 73.3

**Test condition**: Nominal concentrations:

0, 1, 3.2, 5.6, 10, 18, 32, 56, 100, 180, 320, 560, 1000,

1800, 3200, 5600 and 10000 mg/l

One control measurement at begining and one at endof test

Tested using 6 g/l activated sludge in aerobic conditions

Reference substance: 3,5-dichlorophenol tested at 1 and 20

mg/l

Stock concentration and preparation: no information

Test duration: 3 hours

Water chemistry:

Temperature pH 0 20.4 7.8 100 21.3 8.1 21.2 180 8.3 320 21.3 8.3 560 21.2 8.3 1000 21.1 8.3 8.0 1 (ref) 20.3 25 (ref) 20.6 8.1 21.3 8.2

Conclusion : No information on test solution preparation but accepted as

validity 1 as report indicates that OECD guidelines were

followed

Reliability : (1) valid without restriction
Flag : Critical study for SIDS endpoint

06.09.2001 (39)

Type : aquatic

Species : Escherichia coli (Bacteria)

Exposure period

 Unit
 : mg/l

 EC50
 : 202.8

 Analytical monitoring
 : no data

 Method
 : other

 Year
 : 1975

 GLP
 : no data

**Test substance**: as prescribed by 1.1 - 1.4

**Remark**: Inhibiton of specific steps of protein-biosynthesis as a

result of a non-competitive inhibition of

phenylalanyl-tRNA-synthetase; in vitro-test with homogenized cells; 50 % inhibition at a molar ratio of inhibitor/amino acid of 3.2 (L-phenylalanyl concentration 49.5 mg/l); no

further information available

**Conclusion**: Not considered valid for use in hazard assessment -

inapropriate methodology

Reliability : (3) invalid

06.09.2001 (40)

Type : aquatic

Species : other bacteria: Pre-cleaned activated sludge in particle-free communal

wastewater (BOD5: 250 mg/l; NH4-N/l: 50-80 mg)

 Exposure period
 : 4 hour(s)

 Unit
 : mg/l

 EC75
 : > 50

 Analytical monitoring
 : yes

ld 102-06-7 4. Ecotoxicity Date 14.11.2001

Method : other: Quantitative determination of the nitrification rate, colorimetric

measurement of the NO2/NO3 concentration; static test system

Year 1966 **GLP** 

**Test substance** : as prescribed by 1.1 - 1.4

Remark : EC75 related to the effective concentration which caused a

decrease in the 1st step of the nitrification rate (NH4 to

NO<sub>2</sub>)

Test condition : 25 degree C; pH 7.6-7.8 Reliability : (2) valid with restrictions

26.09.2001 (41)

#### **CHRONIC TOXICITY TO FISH**

### 4.5.2 CHRONIC TOXICITY TO AQUATIC INVERTEBRATES

**Species** Daphnia magna (Crustacea)

**Endpoint** reproduction rate

Exposure period 21 day(s) Unit : mg/l **NOEC** = .6**LCEC** = 1.9EC50 : > 1.9 - 6

**Analytical monitoring** : yes

Method OECD Guide-line 202, part 2 "Daphnia sp., Reproduction Test"

Year 1990 GLP yes

**Test substance** : as prescribed by 1.1 - 1.4

Remark : EC50 of immobilization/mortality or reproduction rate resp.:

> 1.9 - < 6.0 mg/l;

at 0.6 - 1.9 mg/l: decreasing of reproduction rate by 4.1 or

19.8 % resp.;

at 6.0 - 60 mg/l: 100 % mortality after 5 d;

**HPLC-analysis** 

Result : No adult mortality up to 1.9 mg/l. All adults died within 7

days from 6 mg/l onwards.

Control

Number of neonates per replicate

1 2 3 4 5 6 7 8

9 46 47 45 31 46 57 43 45

10 11

12 72 81 76 80 79 90 84 66

13

19 8 25 37 263 3 18 19 14

15

16 117 126 131 95 106 162 120 113

17

18

19 148 165 134 175 161 186 121 127

20

**Id** 102-06-7

Date 14.11.2001

21 125 41 3 74 53 38 46

mean 105.4 93.6 82.8 98.4 94.2 99.6 84.8 83.2

0.6 mg/l

Day Number of neonates per replicate

1 2 3 4 5 6 7 8

9 33 44 16 22 48 32 10 21

10 11

12 77 75 78 68 78 62 70 58

13

14 34 17 52 33 3 40 62 65

15

16 119 100 62 102 108 116 111 86

17 18

19 112 121 88 144 141 112 107 106

20

21 106 103 100 68 41 72 110 128

mean 96.2 92 79.2 87.4 83.8 86.8 94 92.8

1.9 mg/l

Day Number of neonates per replicate

1 2 3 4 5 6 7 8

9 3

10 11

12 51 56 37 37 60 38 36 40

13

14 45 54 70 68 63 54 42 61

15

16 93 125 106 102 126 63 100 38

17

18

19 119 96 63 55 77 110 78 145

20

21 63 102 99 90 112 103 95

mean 62.2 78.8 75.6 72.2 83.2 75.4 71.8 75.8

EC50 immobilisation = 1.9 -6.0 mg/l

EC50 reproduction = 1.9-6.0 mg/l

Based on the results of a Dunnetts test the lowest concentration at which an effect was observed was 1.9 mg/l

Therefore the NOEC = 0.6 mg/l

Daphnia magna STRAUS in parthenogenetically reproducing condition

Origin: Budesgesundheitsamtes, Berlin, Germany

Age at start of test: 6-24 h

test type: semistatic

19.7-21.8 degree C;

37 / 146

Test condition

pH 7.7-8.8

O2 concentration: 8.2-10.5 mg/l

Test containers: glass beakers containing 250 ml of test

solution. Not aerated.

Test medium: Elendt synthetic daphnid medium

Stock concentration: 300 mg/l

Lighting conditions: 16h:8h light:dark ratio

Light intensity: 2700 lux

No. of daphnids per group: 5

No. of reps per group: 8

Room temperature: 20-22°C

Feeding conditions: Concentrated algae (Scenedesmus subspicatus) cultures added to daphnid cultures at a specific number of cells per day (up to 6 700 000)

Reliability : (1) valid without restriction
Flag : Critical study for SIDS endpoint

06.09.2001 (42)

#### 4.6.1 TOXICITY TO SEDIMENT DWELLING ORGANISMS

#### 4.6.2 TOXICITY TO TERRESTRIAL PLANTS

Species : Lactuca sativa (Dicotyledon)

Endpoint : emergence
Exposure period : 3 day(s)
Unit : mg/l
Method : other
Year : 1965
GLP : no data

**Test substance** : other TS: no indication of purity

Result : No effect compared to negative control at 0.21 mg/l.

At 2.1 and 21.1 mg/l germination induction of 57 or 104 % respectively occurred compared to positive control.

In a test carried out in parallel using tobacco cells no influence of test concentrations on cell multiplication

could determined;

**Test condition** : Effect of different test concentrations on germination of

seedlings compared to a negative (1 ml water; 20 %

germination rate) and a positive control (1 ml germ -inducing

kinetin solution (5 \* 10E-5 mol/l);

Temperature: 25 degree C

static test on prepared filter paper in the dark

(preincubation for 24 h; afterwards illumination with red

light; incubation for another 48 h)

Light intensity set to induce negative control germination

rate of 20%

Positive control gave a corresponding 85-95 % germination at

the same light intensity.

**Conclusion**: Induction of germination cannot be considered a valid

endpoint for hazard assessment

**Reliability** : (3) invalid

06.09.2001 (43)

Species : Avena sativa (Monocotyledon)

Endpoint : growth
Exposure period : 16 day(s)
Unit : mg/kg soil dw

NOEC : = 316 meas ured/nominal

**EC50** : = 1169 calculated

Method : other: BBA Guideline "Phtytotoxicity test to a monocotyledonous plant

species (Avena sativa L.) and a dicotyledenous plant species (Brassica

rapa ssp. rapa [DC.] Metzg.) " adopted March 1984

**Year** : 1995 **GLP** : no

**Test substance**: other TS: DPG purity 97%

**Remark**: Emergence not determined

Result :

All seedlings places in spiked or control soil emerged by day 9 of the test. All control plants emerged by day 3 of

the test.

EC50 = 1169 mg/kg based on plant fresh weight LOEC = 1000 mg/kg based on plant fresh weight NOEC = 316 mg/kg based on plant fresh weight

LOEC based on observed toxic effects = 31.6 mg/kg - brown leaf tips observed in 12 out of 20 plants, however, at 10 mg/kg this symptom was noted in 3 out of 20 plants, while 1 out of 20 was observed to have yellow leaves.

LC50 cannot be calculated as no plant mortality was found at any concentration.

The only toxic effects noted at any of the concentrations in any of the plants were sedlings smaller than controls, brown leaf tips, yellowing of leaves (one plant at one concentration) and height of seedlings about 1 cm

(significantly lower than control).

The reference substance (Trichloraoacetic acid)

NOEC 10 mg/kg dw LOEC 100 mg/kg

Effect on mortality LC50 31.6 mg/kg

Based on observations on effcts the LOEC for TCA was 100

mg/kg

Validity criteria were respected (fresh wt of controls >800 mg and control produced 100% healthy seedling

**Test condition** : Administration method:

Seeds places on moist filter paper and placed in closed stainless steel vessels at room temperature in the dark for

53 h prior to test

Germinated seeds were used for the test

ld 102-06-7 4. Ecotoxicity Date 14.11.2001

> 5 germinated seeds per vessel, 4 replicates per concentration

Concentrations: Test substance

0 1, 3.16, 10, 31.6, 100, 316, 1000 mg/kg soil (dry wt)

Reference substance (Trichloroacetic acid)

0.1, 1, 10, 100, 1000 mg/kg soil

The concentrations were applied once at test initiation.

Total test exposure time was 16 days equivalent to 14 days after emergence of 50% of the control

Light/dark cycle: 16/8 h

intensity:

280-290 µE/sec.m2 (400-700 nm) first 6 d 210-220 µE/sec.m2 (400-700 nm) T7-10 d 160-170 µE/sec.m2 (400-700 nm) T10-16

Temperature: mean 23.1°C max. 30.2°C min 15.2°C (recorded every 30 min)

Containers:

Plastic rectangular beakers 7X10X10

Soil: standard unsterilised OC content 2.32+/-0.38%

Particle size <0.02 mm) 12.1 +/-2.3%

pH value 5.6+/-0.2 Total N 0.23+/-0.03% dw

max water content 48+/-7 g/100g dw

Water loss was compensated by daily addition of demineralised water

Satistics: ANOVA with Bonferroni multiple range test for

growth test results for NOEC

Probit analysis using Finey's method for EC50s

Conclusion No analysis of test concentrations and no conclusions

provided on the results of the reference substance

However, given the stability of the substance and the details provided in the study report, the test is considered

valid.

Reliability (1) valid without restriction Flag Critical study for SIDS endpoint

06.09.2001 (44)

Species Brassica rapa (Dicotyledon)

Endpoint growth Exposure period : 16 day(s) : mg/kg soil dw Unit

NOEC : = 100 measured/nominal

EC50 : = 358 calculated

Method : other: BBA Guideline "Phtytotoxicity test to a monocotyledonous plant

species (Avena sativa L.) and a dicotyledenous plant species (Brassica

rapa ssp. rapa [DC.] Metzg.) " adopted March 1984

Year 1995 **GLP** no

**Test substance**: as prescribed by 1.1 - 1.4

Remark Result

**Test condition** 

: Emergence not determined

 All seedlings places in spiked or control soil emerged by day 9 of the test. All control plants emerged by day 3 of the test.

EC50 = 358 mg/kg based on plant fresh weight LOEC = 316 mg/kg based on plant fresh weight NOEC = 100 mg/kg based on plant fresh weight

LOEC based on observed toxic effects = 100 mg/kg - dry leaf edges observed in 12 out of 20 plants, however, at 31.6 mg/kg this symptom was noted in 1 out of 20 plants.

LC50 cannot be calculated as no plant mortality was found at any concentration.

The toxic effects noted at any of the concentrations in any of the plants were seedlings smaller than controls, yellow leaf edges, yellowing of leaves (1 out of 20 was observed to have yellow leaves at one time point at one concentration) dry leaf tips or leaves, and at the highest concentration only, height of seedlings about 1 cm (significantly lower than control) and chlorosis of the leaves.

The reference substance (Trichloraoacetic acid)

NOEC 10 mg/kg dw LOEC 100 mg/kg

Effect on mortality LC50 31.6 mg/kg

Based on observations on effcts the LOEC for TCA was 100  $\,$ 

mg/kg

Validity criteria were respected (fresh wt of controls >800 mg and control produced > 80% healthy spedlings

mg and control produced >80% healthy seedlings

: Administration method:

Seeds places on moist filter paper and placed in closed stainless steel vessels at room temperature in the dark for

53 h prior to test

Germinated seeds were used for the test

5 germinated seeds per vessel, 4 replicates per

concentration

Concentrations: Test substance

0 1, 3.16, 10, 31.6, 100, 316, 1000 mg/kg soil (dry wt)

Reference substance (Trichloroacetic acid)

0.1, 1, 10, 100, 1000 mg/kg soil

The concentrations were applied once at test initiation.

Total test exposure time was 16 days equivalent to 14 days after emergence of 50% of the control

Light/dark cycle: 16/8 h

intensity:

280-290 μE/sec.m2 (400-700 nm) first 6 d 210-220 μE/sec.m2 (400-700 nm) T7-10 d 160-170 μE/sec.m2 (400-700 nm) T10-16

ld 102-06-7 4. Ecotoxicity Date 14.11.2001

Temperature: mean 23.1°C max. 30.2°C min 15.2°C (recorded

every 30 min)

Containers:

Plastic rectangular beakers 7X10X10

Soil: standard unsterilised OC content 2.32+/-0.38%

Particle size <0.02 mm) 12.1 +/-2.3%

pH value 5.6+/-0.2 Total N 0.23+/-0.03% dw

max water content 48+/-7 g/100g dw

Water loss was compensated by daily addition of

demineralised water

Satistics: ANOVA with Bonferroni multiple range test for

growth test results for NOEC

Probit analysis using Finey's method for EC50s

No analysis of test concentrations and no conclusions Conclusion

provided on the results of the reference substance

However, given the stability of the substance and the details provided in the study report, the test is considered

valid without restriction. (1) valid without restriction

Critical study for SIDS endpoint

07.09.2001 (44)

**Species** other terrestrial plant: Vicia faba

Endpoint other

**Exposure** period

Reliability

Flag

Unit mg/l Method other Year 1972 GLP no data

Test substance as prescribed by 1.1 - 1.4

Remark Influence of 1-10 mg/l test substance in vitro on

mitosis-cycle (G1-,

S- and G2-phase) in root cells of the field bean (Vicia

faba).

Cells were pretreated for 3 h in 0.02 % colchicine, and transferred to aerated water for 5, 10 or 16 h to allow the cells to reach different stages of DNA sythesis at the

time of treatment.

The cells were exposed to 0.1, 1.0, 5.0 or 10 mg/l for 30

mins under intensive aeration; after

washing the cells were transferred into a erated water again

for another 5-29 h. The nmitosis index was calculated

: A reduced mitosis index was observed.

Result

0.43-9.48 with concentration dependence;

control: 13.94

aberrations of chromosomes at 5-55 % depending on mitotic

phase of cells was also noted

Conclusion in vitro study not suitable for use in hazard assessment -

inappropriate methodology

Reliability (3) invalid

06.09.2001 (45)

#### 4.6.3 TOXICITY TO SOIL DWELLING ORGANISMS

Type : artificial soil

**Species** : soil dwelling microorganisms

**Endpoint**: other

Exposure period :

Unit

Method: otherYear: 1984GLP: no data

**Test substance**: other TS: no indication of purity

**Remark** : Effect of test substance (concentration not specified) on

growth rate of soil microorganisms both applied on a polycarbonate membrane or embeded in a epoxyde resin (Araldit) on aluminium foil resp.; indirect (by membrane

pores) or direct contact with a not specified soil

(moistured John Innes No. 1 soil) resp.; no colony formation

within the test period of 3 months; no further information available

Conclusion : Not valid for hazard assessment - inappropriate methodology

**Reliability** : (3) invalid

06.09.2001 (46)

Type : other

**Species** : soil dwelling microorganisms

 Endpoint
 : mortality

 Exposure period
 : 4 day(s)

 Unit
 : other

 LC50
 : <= .1</td>

 Method
 : other

 Year
 : 1984

 GLP
 : no data

**Test substance** : other TS: no indication of purity

**Remark**: Inoculation of aqueous soil extract (3.0 \* 10E+7 ind./ml) in

nutrient agar containing the test substance (concentration not specified but probably 0.1%); incubation for 4 and 14 d; LD50: < or = 0.1 % referred to growth rate of control;

no further information available

**Test condition** : 25 degree C

**Conclusion** : Single effect concentration providing response of LD50 > or

= 1 g/l.

**Reliability** : (2) valid with restrictions

06.09.2001 (46)

#### 4.6.4 TOX. TO OTHER NON MAMM, TERR, SPECIES

**Species**: other avian: see remarks

**Endpoint** : mortality

Exposure period

 Unit
 : mg/kg bw

 LC50
 : >100

 Method
 : other

 Year
 : 1983

 GLP
 : no data

**Test substance** : other TS: no indication of purity

**Remark**: No acute effects at max. applied dose (100 mg/kg bw by

gavage) on

three species of songbirds: red winged blackbirds (Agelaius

phoeniceus), Starlings (Sturnus

vulgaris) in 1971 and Passer domesticus in 1983; single oral

application of

test substance (dissolved in propylene glycol) after a

settling in-phase of 2-6 weeks; no further information available

**Reliability** : (2) valid with restrictions

06.09.2001 (47) (48)

### 4.7 BIOLOGICAL EFFECTS MONITORING

# 4.8 BIOTRANSFORMATION AND KINETICS

## 4.9 ADDITIONAL REMARKS

#### 5.0 TOXICOKINETICS, METABOLISM AND DISTRIBUTION

#### 5.1.1 ACUTE ORAL TOXICITY

Type : LD50

**Value** : = 290 - 420 mg/kg bw

Species : rat Strain :

Sex : male/female

Number of animals : 30

Vehicle : other: 5.0% in corn oil

Doses

Method : other: Younger Laboratory standard protocol

Year : 1977 GLP : no Test substance : no data

**Result** : LD50 = 350 mg/kg.

Signs of intoxication: reduced appetite and activity (one to three days in survivors), increasing weakness, collapse, and

death.

Gross autopsy of decedents: hemorrhagic areas of the lungs,

liver discoloration and gastrointestinal inflammation.

Source : MLPC, Rion-des-Landes, France

**Reliability** : (2) valid with restrictions

Flag : Critical study for SIDS endpoint

06.09.2001 (49)

Type : LD50

**Value** : = 320 - 662 mg/kg bw

Species : rat Strain :

Sex : male Number of animals : 100

Vehicle : other: corn oil

Doses :

Method: otherYear: 1977GLP: noTest substance: no data

**Result** : LD50 = 460 mg/kg

Observed toxic symptoms; 100 mg/kg: slight ataxia;

130 mg/kg: at 20-30 min. p.a. decrease of spontaneous motor

activity, irregular respiration and hind limb ataxia

(symptoms disappeared within 1 day);

>=170 mg/kg: in addition to above toxic symptoms, dyspnea and ataxia were observed, death occurred mostly 1-4 h p.a., toxic symptoms in surviving animals disappeared within 2-3

days.

**Source**: MLPC, Rion-des-Landes, France

Reliability : (2) valid with restrictions

Flag : Critical study for SIDS endpoint

06.09.2001 (50)

Type : LD50

**Value** : = 309 - 477 mg/kg bw

Species : rat Strain :

Sex : female Number of animals : 100

Vehicle : other: corn oil

Doses

Method: otherYear: 1977GLP: noTest substance: no data

**Result** : LD50 = 384 mg/kg.

Observed toxic symptoms; 100 mg/kg: slight ataxia;

130 mg/kg: at 20-30 min. p.a. decrease of spontaneous motor

activity, irregular respiration and hind limb ataxia

(symptoms disappeared within 1 day);

>=170 mg/kg: in addition to above toxic symptoms, dyspnea and ataxia were observed, death occurred mostly 1-4 h p.a., toxic symptoms in surviving animals disappeared within 2-3

days.

Source : MLPC, Rion-des-Landes, France

**Reliability** : (2) valid with restrictions

Flag : Critical study for SIDS endpoint

06.09.2001 (50)

Type : LD50

Value : = 850 mg/kg bw

Species : rat

Strain

Sex : male/female

Number of animals : 21 Vehicle : CMC

Doses

Method : other

Year

GLP : no Test substance : no data

**Result**: Survival time was 2 to 24 hours. In some cases, animals were

prostrated in 15 minutes and remained in a comatose condition for several hours although death did not always result. A short period of convulsions preceded most death. At autopsy the mucosa of the stomach and intestinal tract were found to be severely irritated and the liver and spleen

were exceptionally dark.

Source : MLPC, Rion-des-Landes, France

**Reliability** : (2) valid with restrictions

Flag : Critical study for SIDS endpoint

06.09.2001 (51)

Type : LD50

Value : = 375 mg/kg bw

Species : rat

Strain

Sex : no data

Number of animals

Vehicle : no data

46 /

Doses

Method : other Year :

GLP : no Test substance : no data

**Remark**: Symptoms of toxicity: increased muscle tension, spasms of

the limbs, liver damage (no further information available)

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (52) (53)

Type : LD50

Value : ca. 500 mg/kg bw

Species : rat Strain :

Sex : no data
Number of animals : 7

Vehicle : other: propylene glycol

Doses

Method: otherYear: 1947GLP: noTest substance: no data

**Source**: MLPC, Rion-des-Landes, France

Reliability : (3) invalid

06.09.2001 (54)

Type : other: minimum lethal dose

Value :

Species : rat Strain :

Sex : no data

Number of animals

Vehicle : no data

Doses

Method: otherYear: 1971GLP: noTest substance: no data

Remark : 1 % emulsion was given to adult rats and to 2-week-old rats;

symptoms of toxicity appeared rapidely (20-30 min.) and included unsteady walk and flabbiness, followed by spasmodic

jerking of the limbs and sharp increases of pain

sensitivity, the body muscles were tensed; death occurred during the first and second day of the experiment; young rats were more sensitive than adult animals (no further

information available).

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (55)

Type : other: maximum tolerable dose

Value : = 250 mg/kg bw

Species : rat Strain :

Sex : no data

Number of animals

Vehicle : no data

Doses :

Method : other

Year :

GLP : no Test substance : no data

**Source**: MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (52) (56)

Type : LDLo

**Value** : = 500 mg/kg bw

Species : rat

Strain :

Sex : no data

Number of animals

Vehicle : no data

Doses

Method: otherYear:GLP: noTest substance: no data

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (52)

Type : LD50

Value : = 323 mg/kg bw

Species : rat Strain :

Sex : no data

Number of animals

Vehicle : no data

Doses

Method: otherYear: GLP: noTest substance: no data

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (57)

Type : LD50

Value : = 290 mg/kg bw

Species : mouse

Strain :

Sex : no data

Number of animals

Method

Vehicle : no data

Doses

Year : GLP : no

**GLP** : no **Test substance** : no data

Source : MLPC, Rion-des-Landes, France

other

**Reliability** : (4) not assignable

27.12.2000 (53)

Type : LD100

**Value** : = 450 mg/kg bw

Species : mouse

Strain

Sex : no data

Number of animals

Vehicle : no data

Doses

Method : other

Year :

GLP : no Test substance : no data

**Source**: MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

26.06.2001 (53)

**Type** : other: maximum tolerated dose

Value : = 250 mg/kg bw

Species : mouse

Strain

Sex : no data

**Number of animals** 

Vehicle : no data

Doses :

Method : other Year :

GLP : no Test substance : no data

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (52) (56)

Type : LD50

Value : = 258 mg/kg bw

Species : mouse

Strain

Sex : no data

Number of animals

Vehicle : no data

Doses

Method : other

Year

GLP : no data
Test substance : no data

**Source**: MLPC, Rion-des-Landes, France

Reliability : (4) not assignable

26.06.2001 (57)

Type : LD50

**Value** : = 520 mg/kg bw

Species : mouse

Strain

Sex : no data

Number of animals

Vehicle : no data

Doses

Method : other

Year

GLP : no data
Test substance : no data

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (58)

Type : LD50

Value

Species : mouse

Strain

Sex : no data

Number of animals

Vehicle : no data

Doses :

Method : other

Year

GLP : no Test substance : no data

**Remark** : LD50 (m): 150 (120-188) mg/kg bw

LD50 (f): 211 (176-253) mg/kg bw

**Source** : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (59)

Type : LD50

Value : = 246 mg/kg bw

Species : rabbit

Strain

Sex : no data

Number of animals

Vehicle : no data

Doses

Method : other

Year

GLP : no Test substance : no data

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (57)

Type : other: minimal lethal dose

**Value** : = 250 mg/kg bw

Species : rabbit

Strain

Sex : no data

Number of animals

Vehicle : no data

Doses :

Method : other Year :

GLP : no

Test substance : no data

**Source**: MLPC, Rion-des-Landes, France

Reliability : (3) invalid

27.12.2000 (60)

Type : LD50

Value : = 250 mg/kg bw

Species : rabbit

Strain

Sex : no data

Number of animals

Vehicle : no data

Doses

**Method** : other

Year

GLP : no Test substance : no data

Source : MLPC, Rion-des-Landes, France

Reliability : (4) not assignable

27.12.2000 (61)

Type : LD50

Value : = 250 mg/kg bw Species : guinea pig

Strain :

Sex : no data

Number of animals

Vehicle: no dataDoses:Method: otherYear:

GLP : no Test substance : no data

**Source**: MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (61)

Type : other: minim al lethal dose

Value : = 250 mg/kg bw Species : guinea pig

Strain

Method

Sex : no data

Number of animals

Vehicle : no data

Doses

Year : GLP : no
Test substance : no data

**Source**: MLPC, Rion-des-Landes, France

other

**Reliability** : (4) not assignable

27.12.2000 (60)

Type : other: emetic dose Value : = 10 mg/kg bw

Species : dog

Strain :

Sex : no data

Number of animals

Vehicle : no data

Doses :

Method : other Year :

GLP : no Test substance : no data

**Remark** : DPG is a powerful emetic in single oral doses as little as

10 mg/kg

**Source**: MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (58)

#### 5.1.2 ACUTE INHALATION TOXICITY

**Type** : LC0 **Value** : = .5 mg/l

**Species** : other: not specified

Strain

Sex : no data

Number of animals : Vehicle : Doses :

**Exposure time** : 30 minute(s)

**Method** : other: no detail available

Year : 1949
GLP : no
Test substance : no data

**Remark** : Slight hypnotic effect (no further information available)

Source : MLPC, Rion-des-Landes, France

Reliability : (3) invalid

06.09.2001 (62)

#### 5.1.3 ACUTE DERMAL TOXICITY

Type : LD0

**Value** : > 2000 mg/kg bw

Species : rabbit

Strain

Sex : male/female

Number of animals : 10

Vehicle : other: none

Doses

Method : other: EEC N°L251/103 part B3, Sept 1984

Year : 1991 GLP : yes Test substance : no data

**Result** : No mortality occured during the study. The most notable

clinical signs were generally limited to transient dermal irritation at the site of test article application. Body

weight gain was exhibited by all animals during the study. At necropsy on day 15, the pancreas or pancreatic lymph nodes of 4/10 animals were noted to have an abnormal red

discoloration. The cause of this finding could not be

determined.

Source : MLPC, Rion-des-Landes, France
Reliability : (1) valid without restriction
Flag : Critical study for SIDS endpoint

06.09.2001 (63)

Type : LD50

Value : > 794 mg/kg bw

Species : rabbit

Strain

Sex : male/female

Number of animals : 6

**Vehicle** : other: 10% in corn oil

Doses

Method: otherYear: 1977GLP: noTest substance: no data

**Result** : Signs of intoxication: reduced appetite and activity (2 to 3

days in survivors), increasing weakness, paralysis, collapse

and death.

Gross autopsy in decedents: liver and spleen discoloration,

enlarged gall blader and slight gastrointestinal

inflammation.

Source : MLPC, Rion-des-Landes, France

Reliability : (3) invalid

06.09.2001 (64)

# 5.1.4 ACUTE TOXICITY, OTHER ROUTES

Type : LD50

**Value** : ca. 25 - 50 mg/kg bw

Species : mouse

Strain

Sex : no data

Number of animals

Vehicle : no data

Doses

Route of admin. : i.p.

Exposure time

Method : no data

Year

GLP : no Test substance : no data

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (65)

Type : LD50

Value : = 75 mg/kg bw

Species : mouse

Strain

Sex : no data

Number of animals

Vehicle : no data

Doses

Route of admin. : i.p.

Exposure time :

Method : no data

Year :

GLP : no Test substance : no data

Source : MLPC, Rion-des-Landes, France

Reliability : (4) not assignable

27.12.2000 (66)

Type : LD100

Value : = 50 mg/kg bw

Species : mouse

Strain

Sex : no data

53,

**Number of animals** 

Vehicle no data

**Doses** 

Route of admin. S.C.

**Exposure time** 

Method no data

Year

**GLP** no Test substance no data

Source MLPC, Rion-des-Landes, France

Reliability (4) not assignable

27.12.2000 (66)

Туре LDLo

Value = 50 mg/kg bw

Species rat

Strain

Sex no data

**Number of animals** 

Vehicle no data

**Doses** Route of admin.

S.C.

**Exposure time** 

Method no data

Year

**GLP** no Test substance no data

MLPC, Rion-des-Landes, France Source

Reliability (4) not assignable

27.12.2000 (67)

Type LDLo

Value = 200 mg/kg bw **Species** guinea pig

Strain

Sex no data

**Number of animals** 

Vehicle other: propylene glycol

**Doses** 

Route of admin. S.C.

**Exposure time** 

no detail available Method

Year 1949 **GLP** : no Test substance no data :

Source MLPC, Rion-des-Landes, France

S.C.

no data

Reliability (3) invalid

06.09.2001 (62)

Type other Value Species rabbit Strain

Sex no data

Number of animals

Vehicle no data

Doses

Route of admin.

**Exposure time** 

Method

Year GLP no

ld 102-06-7 5. Toxicity Date 14.11.2001

**Test substance** no data

Remark 10 mg/kg: no symptoms of toxicity

> 20 mg/kg: convulsions, dyspnoea, rapid breathing 1 h p.a. 50 mg/kg: convulsions, dyspnoea, rapid breathing,

prostration 20 min p.a.

DPG-HCl-solution was applied; 1 animal/dose was treated

Source MLPC, Rion-des-Landes, France

Reliability (4) not assignable

27.12.2000 (67)

Type other

Value

**Species** rabbit

Strain

Sex no data

**Number of animals** 

Vehicle no data **Doses** 

Route of admin. s.c.

Exposure time

Method no data

Year

**GLP** : nο Test substance no data

Remark Influence on blood sugar levels was investigated;

100 mg/kg: transient slight hypoglycemia, followed by a more intense

hyperglycemia

50 mg/kg: hypoglycemia developed more slowly but lasted longer

20 mg/kg: hypoglycemia appeared less constantly

Source MLPC, Rion-des-Landes, France

Reliability (4) not assignable

27.12.2000 (62)

Type LDLo

= 25 mg/kg bw Value

**Species** dog Strain

Sex no data

Number of animals

Vehicle other: propylene glycol

**Doses** 

Route of admin.

**Exposure time** 

Method no detail available

Year **GLP** : no Test substance no data :

Source MLPC, Rion-des-Landes, France

Reliability (3) invalid

06.09.2001 (62)

Type other

Value = 1 mg/kg bw

Species rabbit

Strain

Sex female

Number of animals

Vehicle no data

Doses

Route of admin. i.v. **Exposure time** 

Method no data

Year :

GLP : no Test substance : no data

**Remark** : 2 females were treated.

Symptoms of toxicity (circulatory and respiratory effects): fall in blood pressure, decrease in heart rate, the amplitude of respiration was slightly affected.

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (67)

### 5.2.1 SKIN IRRITATION

Species: rabbitConcentration: undilutedExposure: OcclusiveExposure time: 24 hour(s)

Number of animals : 6 Vehicle :

PDII : 0

Result : not irritating
Classification : not irritating
Method : Draize Test

Year :

GLP : no Test substance : no data

**Method** : 0.5 g was applied as finely ground sample moistened with

water

**Remark** : Primary irritation index = 0.0/8.0 **Source** : MLPC, Rion-des-Landes, France

**Reliability** : (2) valid with restrictions

06.09.2001 (68)

Species : rabbit

Concentration

**Exposure** : no data

Exposure time : Number of animals : Vehicle : PDII :

**Result** : slightly irritating

Classification

Method : Draize Test

Year :

GLP : no Test substance : no data

Remark : no further information available
Source : MLPC, Rion-des-Landes, France

Reliability : (4) not assignable

26.06.2001 (66)

# 5.2.2 EYE IRRITATION

Species: rabbitConcentration: undilutedDose: 20 other: mg

Exposure time : 24 hour(s)
Comment : not rinsed

Number of animals : 6 Vehicle :

Result : sli ghtly irritating
Classification : not irritating
Method : Draize Test

Year :

GLP : no Test substance : no data

Remark : Primary irritation indice : 20.2/110
Source : MLPC, Rion-des-Landes, France

**Reliability** : (2) valid with restrictions

06.09.2001 (69)

Species: rabbitConcentration: undilutedDose: 100 other: mgExposure time: 24 hour(s)Comment: not rinsed

Number of animals : 6

Vehicle

Result : irritating
Classification : irritating
Method : Draize Test

Year :

GLP : no Test substance : no data

Result : Primary irritation indice : 47.6/110
Source : MLPC, Rion-des-Landes, France

**Reliability** : (2) valid with restrictions

06.09.2001 (70)

Species : rabbit

Concentration :
Dose :
Exposure time :
Comment :

Number of animals Vehicle

Result : irritating

Classification

Method : Draize Test

Year :

GLP : no
Test substance : no data

**Remark**: Effects were reversible (48 h); no further information

available

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

26.06.2001 (66)

### 5.3 SENSITIZATION

**Type** : Guinea pig maximization test

Species : guinea pig

**Concentration** : 1<sup>st</sup>: Induction 1 % intracutaneous

2<sup>nd</sup>: Induction 25 % occlusive epicutaneous 3<sup>rd</sup>: Challenge 25 % occlusive epicutaneous

Number of animals : 10

Vehicle: other: paraffin oilResult: not sensitizingClassification: not sensitizing

Method : OECD Guide-line 406 "Skin Sensitization"

**Year** : 1992 **GLP** : ves

**Test substance** : other TS: purity 99.9%

**Method** : Fifteen guinea-pigs were allocated to 2 groups: a control

group 1 of 5 females and a treated group 2 of 10 females. The sensitization potential of the test substance was evaluated after a 10-day induction period during which time the animals were treated with paraffin oil (control group) or the test substance (treated group). On day 1, in presence of Freund's complete adjuvant, 0.1 ml of the test substance at a concentration of 1 % (w/w) in the vehicle was

administered by intradermal route. On day 8, 0.5 ml of the test substance at a concentration of 25% (w/w) in the vehicle was applied by cutaneous route during 48 hours by means of an occlusive dressing. After a period of 12 days without treatment, a challenge cutaneous application of 0.5

ml of the vehicle (left flank) and 0.5 ml of the test substance at a concentration of 25% (w/w) in the vehicle (right flank) were administered to all animals. The test substance and the vehicle were prepared on a dry gauze pad then were applied to the skin and held in place for 24 hours by means of an occlusive dressing. Cutaneous reactions on the challenge application sites were then evaluated 24 and

48 hours after removal of the dressing.

After the final scoring period, the animals were killed. Due to the absence of cutaneous reactions, no skin samples were taken from the challenge application sites from all the animals.

The sensitivity of the guinea-pigs in C.I.T. experimental conditions were checked in recent studies with a positive

sensitizer: Dinitro-2,4-Chlorobenzene.

**Result**: No clinical signs and no deaths were noted during the study.

After 24 and 48 hours following removal of the dressing of the cutaneous challenge application of the test substance,

no cutaneous reactions were recorded.

The guinea-pigs which were used in recent studies showed a

satisfactory sensitization response

Source : MLPC, Rion-des-Landes, France

**Conclusion** : According to the maximization method established by

Magnusson and Kligman, no cutaneous reactions attributable to the sensitization potential of 1,3-DIPHENYLGUANIDINE (DPG), at the concentration of 25% (w/) were observed in

quinea-pigs.

**Reliability** : (1) valid without restriction

27.12.2000 (71)

### 5.4 REPEATED DOSE TOXICITY

Type : Species : rat

Sex : male/female
Strain : Sprague-Dawley

Route of admin. : oral feed Exposure period : 14 days

Frequency of treatm. : continously in diet

Post exposure period : none

**Doses** : 300, 500, 800, 1500 and 3000 ppm (approx. 36, 56, 73, 119 or 200

mg/kg/day)

**Control group** : yes, concurrent no treatment

**LOAEL** : = 300 ppm

Method : other: range finding study

Year : 1980 GLP : yes Test substance : no data

Method : Groups of 5 male and 5 female CD rats were doses with DPG

orally via diet for 2 weeks at constant dose levels of 0, 300, 500, 800, 1500 and 3000 ppm. At the end of this period all the surviving rats were killed and subjected to a

macroscopic post-mortem examination.

Result : Mortality

There were 5 premature decedents (2M and 3F)during the second week of dosing. Three rats were killed in extremis and 2 brats were found dead in their cages. All the

premature decedents were in the top dose group receiving

3000 ppm DPG.

#### Clinical Signs

No abnormalities were detected in the groups receiving 0, 300 and 500 ppm DPG. Animals receiving 800 ppm appeared slightly emaciated during week 2 of dosing. A reduction in body tone, piloerection and emaciation was observed in animals receiving 1500 ppm.

The animals receiving 3000 ppm DPG showed an initial reduction in body tone leading to extreme emaciation by the end of the 2 week dosing period. Ataxia, piloerection,

hunched posture and subdued appearance were observed in some

animals. Hair loss was observed on the abdomens of 2 animals. One animal was observed having uncontrollable muscular spasms and another one having convulsive fits on day 11 of dosing. Both animals were killed in extremis. Hypersensitivity to audio stimuli was observed in the surviving animals during the last 3 days of treatment.

### **Body Weight**

Clear dose related reductions in body weight gain were observed. Animals receiving 3000 ppm DPG showed an actual reduction in body weight over the course of the 2 week dosing period.

#### **Food Consumption**

Dose related reductions in food consumption were observed.

#### Water Consumption

No differences were detected between control animals and those treated with DPG.

#### **Terminal Studies**

No significant gross lesions were present in DPG treated animals.

At 3000 ppm, post mortem examinations revealed reduced spleen size in 2 males and 3 females. A reduction in the

size of the thymus was also observed in one male and one female. The bladder of one female was distended with dark red urine.

Hydronephrosis was observed in the left kidney of one female rat at 800 ppm. Small seminal vesicles were observed for one male at 3000 ppm.

### Organ Weights

Males: slight reductions were observed for the absolute weight of the heart and kidneys (p<0.01) and for the liver and spleen (p<0.05) in animals receiving 500 ppm DPG. Statistically significant reductions (p<0.001) for the absolute weights of the heart, liver, kidneys and spleen were observed in animals receiving 800, 1500 and 3000 ppm. Animals receiving 1500 and 3000 ppm also showed significant reductions in absolute lung (p<0.01) and brain (p<0.05) weights.

Relative organ weight analysis showed significant increases in brain weight in all groups dosed with DPG. The relative weights of the ardrenals in animals receiving 1500 ppm were also increased.

Females: absolute organ weight analysis showed slight reductions (p<0.05) for the brain, liver and lungs in animals receiving 800 ppm and for the liver only in animals receiving 500 ppm. Significant reductions for heart and liver (p<0.001) and slight reductions for adrenals, kidneys, lungs and spleen were observed in animals receiving 1500 ppm. Absolute weights for the brain, heart and spleen were significantly reduced (p<0.001) whilst kidneys and lungs were slightly reduced (p<0.05) in animals receiving 3000 ppm DPG

Relative organ weight analysis showed a statistically significant increase in brain weights (p<0.001) for animals receiving 500 and 1500 ppm DPG.

The differences observed in absolute and relative organ weight profiles between control animals and those treated with DPG are attributed to the reduction in body weight gain shown by the DPG treated animals.

### Source Conclusion

: MLPC, Rion-des-Landes, France

Dosing rats with DPG caused reduced body tone and emaciation at dose levels of 800 ppm and above. Ataxia, piloerection, hunched posture and subdued appearance were also observed in animals receiving 3000 ppm. There were 5 premature decedents in the 3000 ppm dose group. Dose related reductions in food consumption with corresponding decreases in body weight gain were observed in animals receiving DPG. The significant differences observed in organ weight profiles, between control and DPG treated animals, are attributed to the above mentioned reduction in body weight gain.

There is little doubt that the above effects were the direct result of the administration of DPG, it can, however, be speculated that poor palatability of the DPG/diet mixture may have been a contributory factory, the degree of such a contribution being unascertained.

Gross pathological examination did not reveal any gross lesions in the DPG treated animals.

**Reliability** 29.10.2001

(1) valid without restriction

Type :

(72)

Species : rat

Sex: male/femaleStrain: Sprague-Dawley

**Route of admin.** : oral feed **Exposure period** : 90 days

Frequency of treatm. : continously in diet

Post exposure period : none

**Doses** : 50, 150 and 500 ppm (approx. 4, 11 or 37 mg/kg/day)

**Control group** : yes, concurrent no treatment

**NOAEL** : = 150 ppm

Method : OECD Guide-line 408 "Subchronic Oral Toxicity - Rodent: 90-day Study"

**Year** : 1981 **GLP** : yes

**Test substance**: other TS: Monsanto, batch LLN/AS/811920, 97.7%

**Method** : Groups of 15 male and 15 female rats were administered 0, 50, 150 or 500 ppm 1,3-diphenylguanidine in feed that was

available ad libitum forn 13 weeks.

Rats were housed 3 per cage. Animal rooms were maintained at a target temperature of 20°C and a target relative humidity of 50%, with 12 hours of fluorescent light per day and approximately 14 air changes per hour. Feed and water were available ad libitum.

Hematology, clinical chemistry and urinalysis evaluations were performed on 10 rats per sex and exposure level at weeks 6 and 13. Hematology parameters evaluated included: hemoglobin, erythrocytes, packed cell volume, mean cell hemoglobin, mean cell hemoglobin concentration, platelets and leukocyte count and differential. Clinical chemistry parameters evaluated included: urea nitrogen, total protein, albumin, cholesterol, glucose, sodium, potassium, calcium, chloride, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, and lactate dehydogenase. Urinalysis parameters evaluated included: glucose, protein, ketones, urobilinogen, volume/colour/appearence, specific gravity pH, blood pigment and microscopic examination.

Complete necropsies were performed on all animals. The heart, kidneys, liver, lungs, ovaries, prostate gland, spleen, testis, epididymides, thymus, pituitary, adrenals, and thymus were removed and weighed. Organs and tissues were examined for gross lesions and fixed in 10% neutral buffered formalin. Tissues to be examined microscopically were trimmed, embedded in paraffin, sectioned, and stained with hematoxylin and eosin.

Complete histopathologic examinations were performed on all rats in the 0 and 500 ppm groups. Gross lesions and selected tissues were examined in the lower exposure groups. The following tissues were examined: adrenal glands, aortic arch, bladder, brain (three sections), eyes, gross lesions, heart, intestines (caecum, colon, duodenum, jejunum, ileum), kidneys, liver, lung/mainstem bronchi, lymph nodes, skin, spleen, spinal cord/sciatic nerve, stomach (forestomach and glandular stomach), testes (with epididymis and seminal vesicle), thymus, thyroid glands, tongue, trachea and uterus.

Result : OBSERVATION

Mortality

There were 2 unscheduled deaths during the course of the

ld 102-06-7 5. Toxicity Date 14.11.2001

> study: 1 male receiving 500 ppm DPG (in Week 4) and 1 female receiving untreated diet (in Week 13). Neither death could be attributed to dosing with the test compound.

#### Clinical Signs

There were no clinical signs observed that could be attributed to dosing with the test compound.

## **Body Weights**

Males: Rats receiving 500 ppm DPG showed a lower group mean body weight than the control rats from Week 1 of dosing, whereas the other dose groups tended to perform in a similar fashion to the controls. The reduction in the top dose animals was roughly 15% (P<0.001) for the majority of the dosing period. The exceptions were Week 9 (2%, P<0.001), Week 10 (19%, P<0.001) and Week 13 (21%, P<0.001). On the first occasion (Week 9) all groups receiving DPG showed a dose related deviation from the trends showed prior to and after this week. Apart from a depression in food consumption in all groups during Week 9 there appeared to be no obvious cause of this effect. A similar effect was seen in rats receiving 500 ppm DPG only in Week 13; again no cause was evident.

Females: Rats receiving 50 or 150 ppm DPG tended to perform in a similar fashion to the control rats.

The rats receiving 500 ppm DPG showed a significant difference from the controls from Week 1 of dosing (9% reduction, P<0.001). The effect tended to increase as the study went on, reaching a maximum in Week 9 (18% reduction. P<0.001). After this the effect tended to stabilise at approximately 16% (P<0.001).

In Week 9, all groups (including the controls) showed a body weight reduction, followed by a recovery in Week 10. As in the males, there was an accompanying food consumption decrease, but no obvious cause was discovered.

### Food Consumption

Male and female rats receiving 500 ppm DPG showed a reduced food consumption compared with the controls over the dosing period whereas rats receiving 50 or 150 ppm DPG tended to consume comparable quantities to the controls. In Weeks 9 and 13 all groups showed a reduced food consumption when compared to other week's data, no reason for this change could be discovered.

#### Water Consumption

No intergroup differences were observed.

#### LABORATORY INVESTIGATIONS

Haematology

Week 6 - There were slight dose related reductions in both white blood cell count and platelets (11% and 8% respectively when comparing rats receiving 500 ppm DPG and controls; neither being statistically significant). These effects are considered to be of little biological significance due to the large degree of variation between the individuals in any one group. Week 13 - The slight effects seen at Week 6 were not

evident. A doubling of the monocyte count (P<0.05) in rats

receiving 500 ppm DPG when compared to the controls, is thought to be of little biological significance.

#### Females:

Week 6 - There was an increase in white blood cell count (13% in rats receiving 500 ppm DPG when compared to controls), but the large degree of intergroup variation suggests that it is of little biological significance.

Week 13 - Again rats receiving 500 ppm DPG showed an increased white blood cell count when compared to controls, but again there was a large intergroup variation.

# Clinical Chemistry

#### Males:

Week 6 - Rats receiving 500 ppm DPG showed higher BUN levels than controls (13%, P<0.01). Alanine aminotransferase levels showed a slight dose related increase (16%, P<0.05 in rats receiving 500 ppm DPG when compared to controls). Differences were also seen in alkaline phosphatase (P<0.01) and sodium levels (P<0.05) in rats receiving 500 ppm DPG when compared to controls.

All the results were within expected levels and are thought to be of no biological significance.

Week 13 - The effects seen at Week 6 were not evident. Differences were seen in aspartate aminotransaminase (P<0.01) and potassium levels (P<0.01) in rats receiving 150 ppm DPG when compared to controls, but the effects are considered of little biological significance. All results were within expected ranges.

#### Females:

Week 6 - Alkaline phosphatase was increased (P<0.05) in rats receiving 500 ppm DPG, when compared to controls. Reductions were evident in rats receiving 500 ppm DPG, when compared to controls in chloride (P<0.05), total protein (P<0.05), albumin (P<0.01) and calcium levels (P<0.05). Most of the results obtained were within expected ranges and are thought to be of no biological significance.

Rats receiving 50 ppm DPG showed reduced BUN levels (P<0.05) when compared to controls, but this is considered not to be of biological significance.

Week 13 - The effects seen at Week 6 were again evident in chloride (P<0.05), total protein (P<0.05) and albumin levels (P<0.01) in rats receiving DPG, but the reductions were so small as to be of little biological significance. In addition, potassium levels (P<0.05) were increased in rats receiving 500 ppm DPG and calcium levels (P<0.05) decreased in rats receiving 50 ppm DPG, when compared to controls. In both cases the changes were of no biological significance.

#### Urinalysis

## Males:

Week 6 - There was a higher incidence of glucose found in the urine of rats receiving DPG than in controls. The incidence of ketones in the urine was also increased. There was a slight increase in specific gravity and a reduction in volume of urine produced by rats receiving 500 ppm DPG when compared to controls.

All tests for faecal occult blood were negative.

Week 13 - The dose related occurrence of glucose and ketones evident in the urine at Week 6 were not seen again.

The increase in specific gravity and decrease in volume were

present again in rats receiving 500 ppm DPG. There was a slight dose related decrease in pH noted.

#### Females:

Week 6 - No significant intergroup differences were observed. All tests for faecal occult blood were negative. Week 13 - There was a slight increase in specific gravity in rats receiving 500 ppm DPG when compared to controls. Slight dose related decreases in pH and volume were also seen.

#### **TERMINAL STUDIES**

Organ Weights

Males: The absolute organ weights of rats receiving 500 ppm DPG tended to be reduced when compared to controls. In the case of heart (17%), kidney (14%), liver (23%) and spleen (25%) the reductions were highly statistically significant (P<0.001). Absolute lung weight was also decreased (14%, P<0.01). The absolute brain weight of rats receiving 50 ppm DPG was increased (3%, P<0.05) when compared to controls, but this is thought not to be biologically significant. After the body weight effects were taken into account the relative organ weights of rats receiving 500 ppm DPG tended to be increased when compared to controls. Brain (27%) and testes (25%) were found to be highly statistically significant (P<0.001). Heart (7%, P<0.01), kidneys (10%, P<0.01), lungs (9%, P<0.01), adrenals (17%, P<0.05) and pituitary (33%, P<0.05) also showed statistical significance.

Females: The absolute organ weights of rats receiving 500 ppm DPG tended to be reduced compared to control rats. High statistical significance was found in heart (18%, P<0.001), liver (17%, P<0.001) and brain (4%, P<0.01). Less significant effects were seen in adrenals (17%, P<0.05) and lungs (8%, P<0.05). Kidneys were also reduced in weight (12%) when compared with the controls, but did not show statistical significance.

On taking account of body weight effects, there was an increase in relative organ weight when compared to controls in brain (19%, P<0.001), lungs (13%, P<0.001), uterus (34%, P<0.01) and spleen (32%, P<0.05).

### Pathology Findings

No macroscopic intergroup differences of any significance were observed at necropsy and histopathological examination showed no specific lesion that could be attributed to dosing with Diphenylguanidine.

There was a small range of background lesions in all groups. They included

- i) a mild interstitial pneumonitis,
- ii) slight mammary hyperplasia (males only),
- iii) small inflammatory lesions in prostate and pancreas,
- iv) renal pelvic dilatations,
- v) small foci of renal tubular calcification (females only).

One animal receiving 500 ppm DPG showed multiple mononuclear foci in the liver; the aetiology of these is unknown, but they are not considered to be treatment related. Several animals had ocular inflammatory foci, probably associated with blood sampling; these lesions were mild in nature, with the exception of one animal receiving 500 ppm DPG.

- : MLPC, Rion-des-Landes, France
- : Dosing rats with Diphenylguanidine in the diet at a

Source Conclusion

concentration of 500 ppm produced a marked reduction in growth rate of both males and females, with respect to controls. The food consumption of these animals was also reduced, when compared to the controls. The effects were most pronounced over the first few weeks of dosing, suggesting that the cause may partly be due to the unpalatability of the test substance.

Dose levels of DPG up to 500 ppm did not cause an increase in mortality or the appearance of any abnormal clinical signs.

Laboratory investigations revealed small differences between rats receiving DPG and the controls in both haematological and clinical chemical parameters, but as the same effects were not present at both Weeks 6 and 13 they are considered to be of little or no significance. Male rats receiving 500 ppm DPG tended to produce more concentrated urine than the controls at Weeks 6 and 13, with a slightly reduced pH on the latter occasion. Female rats at the same dose level also showed a slight aciduria, but at Week 13 only. These effects were only slight and could not be attributed to any obvious structural change to the kidney as seen on histopathological examination. The changes seen lacked a dose response and were of marginal magnitude, thereby confirming their insignificance.

The terminal studies revealed no dose related lesions; those lesions found were spread across the dose groups with roughly equal incidence and are considered to be common findings in rats of this age and strain.

Reliability : (1) valid without restriction
Flag : Critical study for SIDS endpoint

29.10.2001 (73)

Type : Species : rat

Sex: male/femaleStrain: Fischer 344Route of admin.: oral feedExposure period: 2 weeksFrequency of treatm.: ad libitumPost exposure period: none

**Doses** : 250, 500, 750, 1500 and 3000 ppm (22, 45, 64, 121 and 200 mg/kg/d in

males and 23, 44, 65, 127 and 166 mg/kg in females)

**Control group** : yes, concurrent no treatment

**Method** : other: range-finding toxicity study, see comment

**Year** : 1995 **GLP** : yes

**Test substance** : other TS: purity 98.9% +/- 0.6%

**Method** : In the 2-week studies, groups of five male and five female

rats and mice were administered 0, 250, 500, 750, 1,500. or 3,000 ppm 1,3-diphenylguanidine in feed that was available

ad libitum.

Rats were housed five per cage. Animal rooms were maintained at 69° to 75° F and 35% to 65% relative humidity, with 12 hours of fluorescent light per day and approximately 10 air changes per hour. Feed and water were available ad libitum.

Because of the limited stability of the

1,3-diphenylguanidine feed mixtures, feeders were changed

daily, 7 days per week.

The rats were observed twice daily for mortality/morbidity and clinical signs of toxicity. Clinical observations and indvidual body. Complete necropsies were performed on all animals. The heart, right kidney, liver, lungs, ovaries, prostate gland, seminal vesicles, spleen, right testis, and thymus were removed and weighed. Organs and tissues were examined for gross lesions and fixed in 10% neutral buffered formalin. Tissues to be examined microscopically were trimmed, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Histopathologic examinations were performed on all tissues with gross lesions.

Result

All rats survived to the end of the 2-week study. The final mean body weights and body weight gains of males and females exposed to 1,500 or 3,000 ppm 1,3-diphenylguanidine were notably less than those of the control groups. During the second week of the study, clinical signs of toxicity were observed in males and females in the 3,000 ppm groups and included ruffled fur and thin appearance.

During the first week of the study rats exposed to 3,000 ppm consumed 35% less feed than controls and the final mean body weights of these groups remained the same or decreased slightly from their initial values. During the second study week, feed consumption by the 3,000 ppm groups increased relative to controls and body weight gains increased but the final mean body weights remained lower than controls. Feed consumption and final mean body weights of groups receiving 750 or 1,500 ppm were also lower than the controls during both study weeks; however, animals in these groups gained weight continuously during the study.

The pattern of organ weight changes observed during the 2-week study was not indicative of chemical-related toxicity. Absolute organ weights of male rats that received 3,000 ppm were uniformly lower than controls due to the markedly reduced final mean body weights of this group. Ovarian weights of females that received 750 or 1,500 ppm were lower than controls, however final mean body weights of both groups were also lower than the controls. Relative liver weights of males that received 500 or 1,500 ppm and relative kidney weight of females that received 750 ppm were greater than those of the controls but the influences were small in magnitude, not exposure related, and not considered biologically meaningful.

No gross lesions associated with exposure to 1,3-diphenylguanidine were observed in male or female rats. No microscopic examination was conducted.

Source : MLPC, Rion-des-Landes, France

**Reliability** : (2) valid with restrictions

29.10.2001 (74)

Type :

Species : rat

Sex: male/femaleStrain: Fischer 344Route of admin.: oral feedExposure period: 13 weeksFrequency of treatm.: ad libitumPost exposure period: none

**Doses** : 250, 500, 750, 1500 and 3000 ppm (17, 32, 50, 100, 181 mg/kg/d in males

and 17, 32, 49, 95, 184 mg/kg/d in females)

**Control group** : yes, concurrent no treatment

**NOAEL** : = 500 ppm **LOAEL** : = 750 ppm

Method : other: equivalent to OECD guide-line 408

**Year** : 1995 **GLP** : yes

Method

**Test substance** : other TS: purity 98.9% +/- 0.6%

Groups of 10 male and 10 female rats were administered 0, 250, 500, 750, 1,500, or 3,000 ppm 1,3-diphenylguanidine in feed that was available ad libitum. Additional rats (10 males and 10 females per exposure group) were used in a

supplemental clinical pathology study.

Rats were housed five per cage. Animal rooms were maintained at 69° to 75° F and 35% to 65% relative humidity, with 12 hours of fluorescent light per day and approximately 10 air changes per hour. Feed and water were available ad libitum. Because of the limited stability of the 1,3-diphenylguanidine feed mixtures, feeders were changed daily, 7 days per week.

The rats were observed twice daily for mortality/morbidity and clinical signs of toxicity. Clinical observations were recorded weekly. Individual body weights were recorded at the start of the study, weekly thereafter, and at the end of the study. Feed consumption was recorded daily for 5 consecutive days per week for 13 weeks.

Hematology and clinical chemistry evaluations were performed on 10 male and 10 female supplemental rats per group at Days 5 and 21 and at study te rmination (Week 13). For these evaluations, rats were anesthetized with CO2, and blood samples were collected from the retroorbital sinus. Samples for hematology analysis were placed in tubes containing potassium EDTA, and samples for clinical chemistry evaluations were placed in similar tubes devoid of anticoagulant. The latter samples were allowed to clot at room temperature; the samples were then centrifuged and serum was removed.

Complete necropsies were performed on all animals. The heart, right kidney, liver, lungs, ovaries, prostate gland, seminal vesicles, spleen, right testis, and thymus were removed and weighed. Organs and tissues were examined for gross lesions and fixed in 10% neutral buffered formalin. Tissues to be examined microscopically were trimmed, embedded in paraffin, sectioned, and stained with hematoxylin and eosin.

Complete histopathologic examinations were performed on all rats in the 0 and 3,000 ppm groups, on all rats in the 1,500 ppm groups, and on all animals that died early. Gross lesions and selected tissues were examined in the lower exposure groups. The following tissues were examined: adrenal glands, brain (three sections), esophagus, femur with marrow, gross lesions, heart, intestines (large: cecum, colon, rectum; small: duodenum, jejunum, ileum), kidneys, liver, lunglmainstem bronchi, lymph nodes (mandibular, mesenteric), mammary gland with adjacent skin, nasal cavity

and turbinates (three sections), ovaries, pancreas, parathyroid glands, pituitary gland, preputial or clitoral glands, prostate gland, salivary glands, skin, spleen, spinal cord/sciatic nerve, stomach (forestomach and glandular stomach), testes (with epididymis and seminal vesicle), thigh muscle, thymus, thyroid glands, trachea, urinary bladder, uterus, and vagina (females in vaginal cytology studies only). The uterus and prostate gland were examined in the lower exposure groups.

At the end of the 13-week studies, vaginal cytology and sperm motility evaluations were performed on all base-study rats in the 0, 500, 750, and 1,500 ppm groups. Methods were those outlined in the National Toxicology Program's Technical Protocol for Sperm Morphology and Vaginal Cytology Evaluation in Toxicity Testing for Rats and Mice (NTP, 1987). Beginning 12 days prior to sacrifice, the vaginal vaults of 10 females from each exposure group were lavaged, and the aspirated lavage fluid and cells were stained with toluidine blue. Relative numbers of leukocytes, nucleated epithelial cells, and large squamous epithelial cells were determined and used to ascertain estrous cycle stage (Le., diestrus, proestrus, estrus, or metestrus).

Sperm motility was evaluated at necropsy in the following manner. The left testis and epididymis were weighed. The tail of the epididymis (cauda epididymis) was then removed from the corpus epididymis and weighed. Test yolk (rats) or Tyrode's buffer (mice) was applied to slides, and a small incision was made at the distal border of the cauda epididymis. The sperm effluxing from the incision were dispersed in the buffer on the slides, and the numbers of motile and nonmotile spermatozoa were counted for five fields per slide by two observers.

Following completion of sperm motility estimates, each left cauda epididymis was placed in buffered saline solution. Caudae were finely minced and swirled, and the tissue was incubated and then heat fixed. Sperm density was then determined microscopically with the aid of a hemacytometer. To quantify spermatogenesis, testicular spermatid head count was determined by removing the tunica albuginea and homogenizing the left testis in 10% dimethyl sulfoxide in phosphate-buffered saline. Homogenization-resistant spermatid nuclei were counted using a hemacytometer. Six males and all females in the 3,000 ppm groups died or

were killed moribund before the end of the 13-week study; all rats in the lower exposure groups survived to the end of the study. Mean body weights of male and female rats that were exposed to 1,500 or 3,000 ppm were markedly lower than those of controls throughout the 13-week study. Mean body weights of the 3,000 ppm groups decreased during the first week of the study for males and the first 2 weeks of the study for females before starting to increase. No final mean body weight or body weight gain was determined for female rats administered 3,000 ppm 1,3-diphenylguanidine due to 100% mortality in this exposure group.

Clinical signs of toxicity were noted primarily in rats in the 1,500 and 3,000 ppm groups beginning at Week 2. The majority of rats in these groups appeared thin and had ruilled fur, with discolorations of the tail, ears, and scrotum or vaginal area. Salivation, hypoactivity, and

Result

convulsions and seizures were also observed in some male and female rats in these groups, and abnormal posture (staggering) was noted in most males and females. Other clinical signs observed in these groups included hyperactivity, hunched posture, ptosis, ataxia, dyspnea, and bristly hair.

Average feed consumption decreased as exposure concentrations increased above 500 ppm with feed consumption 34% to 40% less than the controls during the 13-week study period in males and females that received 3,000 ppm. During the first week of the study feed consumption by groups receiving 3,000 ppm were 57% and 63% lower than control for males and females respectively, indicating poor palatability at this exposure concentration.

Organ weights for groups receiving 750 ppm or greater were significantly lower than those of the controls and were the result of low body weights and low feed consumption by these groups rather than a specific toxic response to 1,3-diphenylguanidine.

In general, changes in hematology parameters were limited to rats receiving 1,500 and 3,000 ppm. A mild polycythemia occurred at Day 5 in the 3,000 ppm male and female rats, and to a lesser extent in the 1,500 ppm females. This was indicated by greater erythrocyte counts, hematocrit values, and hemoglobin concentrations than controls and would be consistent with a relative polycythemia related to dehydration and hemoconcentration. There were slightly lower reticulocyte counts at Day 5 in 3,000 ppm male and female rats and 1,500 ppm females. Other changes in hematology parameters were minor, sporadic, and did not suggest a treatment effect.

Changes in clinical chemistry parameters occurred primarily in the 1,500 and 3,000 ppm groups, although some minor changes were observed in other groups. Greater alkaline phosphatase activity and bile acid concentration than controls occurred in an exposure-related manner in male and female rats. Males exhibited greater increases in activity and at earlier time periods. By Week 13, alkaline phosphatase activity and bile acid concentration were greater than the controls in all groups of exposed rats: these changes are consistent with cholestasis. The lack of an increase of alkaline phosphatase activity in groups that received 3,000 ppm was probably related to inanition and a decreased contribution of the intestinal fraction of alkaline phosphatase to the total serum activity. Total protein, creatinine, cholesterol, and triglyceride concentrations in the 1,500 and 3,000 ppm groups were lower than the controls and these differences are consistent with inanition.

Gross necropsy observations related to 1,3-diphenylguanidine treatment were limited to thinness of the carcass in higher exposure rats. Microscopic changes associated with chemical administration were observed in the bone marrow, thymus, uterus, testes, prostate gland/seminal vesicle, and salivary glands. All of the gross and microscopic changes occurred in the two highest exposure groups and were attributed to the lower feed intake, reduced weight gains, and poor body

condition of these animals.

In the thymus, lymphoid depletion and necrosis were present in several 3,000 ppm females which were found dead or were killed in moribund condition. Depletion of hematopoietic cells in the femoral bone marrow was also variably present in the 3,000 ppm females which died early. Both of these lesions are common in moribund animals and are not considered to be direct toxic effects of chemical administration.

An exposure-related effect in the uterus of females was characterized by an overall reduction in size and was diagnosed as hypoplasia. This finding occurred with greater incidence and severity in the three highest exposure groups. In general, this change was attributed to poor body condition and delayed development due to lower feed consumption; the younger age of those females which died or were killed during the study may have been a reason for the smaller size of the uterus.

Several lesions were noted sporadically in the reproductive organs of 3,000 ppm males. In two of ten 3,000 ppm males, lower numbers of mature spermatozoa were present in the seminiferous tubules than in the controls; lower numbers of spermatozoa were also noted in the epididymal tubules than in the controls. Secretory depletion of the prostate gland and seminal vesicles was observed in several 3,000 ppm males: this difference was characterized by alveolar size smaller than controls and smaller amounts of secretory material within the lumen. Decreased spermatogenesis and secretory depletion of the accessory sex glands were considered secondary to poor body condition. In the salivary glands of several 3,000 ppm males and females, a change diagnosed as cytologic alteration was observed, characterized by smaller size and increased basophilia of the secretory acini. This change was interpreted to be a reflection of physiological atrophy due to reduced feed intake. No specific cause of death could be determined for the early death animals from the 3,000 ppm groups.

Evaluation of male reproductive tissues in groups that received 500, 750, or 1,500 ppm revealed a significant reduction in sperm motility in 1,500 ppm males. Among 750 and 1,500 ppm group females the length of the estrous cycle was greater than the controls.

Source : MLPC, Rion-des-Landes, France Reliability : (1) valid without restriction Flag : Critical study for SIDS endpoint

29.10.2001 (74)

Type : rat
Species : rat
Sex : no data
Strain : no data
Route of admin. : oral feed
Exposure period : 28 days

Frequency of treatm. : continously in diet

Post exposure period : no data

**Doses** : 100 or 1000 ppm (approx. 7 or 75 mg/kg/day)

Control group : no data specified NOAEL : = 100 ppm

**Method** : other

Year :

**GLP** : no data **Test substance** : no data

**Remark**: no further information available

**Result**: 1000 ppm: reduced food consumption, reduced body weight gain

(no details reported)

100 ppm: no substance related effects

Source : MLPC, Rion-des-Landes, France Reliability : (4) not assignable

29.10.2001 (75)

Type : rat
Species : rat
Sex : no data
Strain : no data

Route of admin. : oral unspecified Exposure period : 4 months Frequency of treatm. : no data

Post exposure period

Doses : 32 mg/kg
Control group : yes
Method : other
Year :

GLP : no data
Test substance : no data

**Remark**: Frequency of application not reported; no further

information available.

**Result** : Symptoms of toxicity: increased mortality, anemia,

reticulocytosis, eosinophilia, increased bilirubin concentration; inhibition of the iron containing enzymes catalase and peroxidase; reduced thresholds of nerve and

muscle excitability (no details reported).

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

29.10.2001 (76)

Type :

**Species** mouse : Sex male/female Strain B6C3F1 Route of admin. oral feed : 2 weeks Exposure period : Frequency of treatm. : ad libitum Post exposure period none

**Doses** : 250, 500, 750, 1500 and 3000 ppm (48, 92, 133, 266, 573 mg/kg/d in

males and 53, 112, 150, 303, 691 mg/kg/d in females)

**Control group** : yes, concurrent no treatment

Method : other: range-finding toxicity study, see method section

**Year** : 1995 **GLP** : ves

**Test substance** : other TS: purity 98.9% +/- 0.6%

**Method** : Groups of five male and five female mice were administered

0, 250, 500, 750, 1,500. or 3,000 ppm 1,3-diphenylguanidine

in feed that was available ad libitum.

Mice were housed individually. Animal rooms were maintained at 69° to 75° F and 35% to 65% relative humidity, with 12 hours of fluorescent light per day and approximately 10 air

ld 102-06-7 5. Toxicity Date 14.11.2001

> changes per hour. Feed and water were available ad libitum. Because of the limited stability of the 1,3-diphenylguanidine feed mixtures, feeders were changed daily, 7 days per week, throughout the 2-week and 13-week studies.

Mice were observed twice daily for mortality/morbidity and clinical signs of toxicity. Clinical observations and individual body weights were recorded on Days 1 and 8 and at the end of the studies. Feed consumption was recorded 5 consecutive days per week for 2 weeks.

Complete necropsies were performed on all animals. The heart, right kidney, liver, lungs, ovaries, prostate gland, seminal vesicles, spleen, right testis, and thymus were removed and weighed. Organs and tissues were examined for gross lesions and fixed in 10% neutral buffered formalin. Tissues to be examined microscopically were trimmed, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Histopathologic examinations were performed on all tissues with gross lesions.

All mice survived to the end of the 2-week study. The final mean body weight of female mice in the 3,000 ppm group was 6% lower than the controls; final mean body weights of other exposed groups were similar to controls. Clinical signs of toxicity were observed in a few female mice during the latter part of the study; one female in the 1,500 ppm group appeared thin, and one female each in the 750 and 3,000 ppm groups had hunched posture and appeared thin. The average amounts of feed consumed by females in the 750 and 1.500 ppm groups were slightly lower than the control value; the

average amounts of feed consumed by all other exposed groups were similar to control values.

Only a few significant organ weight changes were observed (data on file at NIEHS). Absolute and relative liver weights of males and females in the 1,500 and 3,000 ppm groups were lower than those of the control groups, and the relative heart weight of females in the 500 ppm group was greater than that of the control group.

No gross or microscopic lesions related to

1,3-diphenylguanidine exposure were observed in male or

female mice.

Source MLPC, Rion-des-Landes, France

Reliability (2) valid with restrictions

06.09.2001 (74)

Type

Result

**Species** mouse Sex male/female Strain B6C3F1 Route of admin. : oral feed 13 weeks Exposure period Frequency of treatm. ad libitum Post exposure period none

Doses 250, 500, 750, 1500 and 3000 ppm (38, 75, 114, 231, 457 mg/kg/d in

males and 46, 93, 141, 285, 577 mg/kg/d in females)

Control group : yes, concurrent no treatment

NOAEL =500 ppm LOAEL = 750 ppm

Method other: NTP protocol, see method section

**Year** : 1995 **GLP** : yes

**Test substance**: other TS: purity 98.9% +/- 0.6%

Method

Groups of 10 male and 10 female mice were administered 0, 250, 500, 750, 1,500, or 3,000 ppm 1,3-diphenylguanidine in feed that was available ad libitum.

Mice were housed individually. Animal rooms were maintained at 69° to 75° F and 35% to 65% relative humidity, with 12 hours of fluorescent light per day and approximately 10 air changes per hour. Feed and water were available ad libitum. Because of the limited stability of the 1,3-diphenylguanidine feed mixtures, feeders were changed daily, 7 days per week, throughout the 2-week and 13-week studies.

Mive were observed twice daily for mortality/morbidity and clinical signs of toxicity. Clinical observations were recorded weekly. Individual body weights were recorded at the start of the study, weekly thereafter, and at the end of the study. Feed consumption was recorded daily for 5 consecutive days per week for 13 weeks.

Complete necropsies were performed on all animals. The heart, right kidney, liver, lungs, ovaries, prostate gland, seminal vesicles, spleen, right testis, and thymus were removed and weighed. Organs and tissues were examined for gross lesions and fixed in 10% neutral buffered formalin. Tissues to be examined microscopically were trimmed, embedded in paraffin, sectioned, and stained with hematoxylin and eosin.

Complete histopath ologic examinations were performed on all mice in the 0 and 3,000 ppm groups, and on all animals that died early. Gross lesions and selected tissues were examined in the lower exposure groups. The following tissues were examined: adrenal glands, brain (three sections), esophagus, femur with marrow, gallbladder, gross lesions, heart, intestines (large: cecum, colon, rectum; small: duodenum, jejunum, ileum), kidneys, liver, lung/mainstem bronchi, lymph nodes (mandibular, mesenteric), mammary gland with adjacent skin, nasal cavity and turbinates (three sections), ovaries, pancreas, parathyroid glands, pituitary gland. preputial or clitoral glands, prostate gland, salivary glands, skin, spleen, stomach (forestomach and glandular stomach), testes (with epididymis and seminal vesicle), thigh muscle (rats only), thymus, thyroid glands, trachea, urinary bladder, uterus, and vagina (females in vaginal cytology studies only). No tissues were designated for examination in the lower exposure groups.

At the end of the 13-week studies, vaginal cytology and sperm motility evaluations were performed all mice in the 0, 250, 750, and 3,000 ppm groups. Methods were those outlined in the National Toxicology Program's Technical Protocol for Sperm Morphology and Vaginal Cytology Evaluation in Toxicity Testing for Rats and Mice (NTP, 1987). Beginning 12 days prior to sacrifice, the vaginal vaults of 10 females from each exposure group were lavaged, and the aspirated lavage fluid and cells were stained with toluidine blue. Relative numbers of leukocytes, nucleated epithelial cells, and large

squamous epithelial cells were determined and used to ascertain estrous cycle stage (Le., diestrus, proestrus, estrus, or metestrus).

Sperm motility was evaluated at necropsy in the following manner. The left testis and epididymis were weighed. The tail of the epididymis (cauda epididymis) was then removed from the corpus epididymis and weighed. Test yolk (rats) or Tyrode's buffer (mice) was applied to slides, and a small incision was made at the distal border of the cauda epididymis. The sperm effluxing from the incision were dispersed in the buffer on the slides, and the numbers of motile and nonmotile spermatozoa were counted for five fields per slide by two observers.

Following completion of sperm motility estimates, each left cauda epididymis was placed in buffered saline solution. Caudae were finely minced and swirled, and the tissue was incubated and then heat fixed. Sperm density was then determined microscopically with the aid of a hemacytometer. To quantify spermatogenesis, testicular spermatid head count was determined by removing the tunica albuginea and homogenizing the left testis in 10% dimethyl sulfoxide in phosphate-buffered saline. Homogenization-resistant spermatid nuclei were counted using a hemacytometer.

All mice survived to the end of the study. Mean body weights of both males and females in the three highest exposure groups (750, 1,500, and 3,000 ppm) were lower than those of the control groups especially during the latter part of the study. Thin appearance was the most frequently reported clinical sign for female mice and was most often observed in the three highest exposure groups. Thin appearance was also observed in male mice in the 3,000 ppm group. Other clinical signs observed in mice in the higher exposure groups included alopecia, abnormal posture, ptosis, and bristly hair.

The average amounts of feed consumed by males and females in all exposed groups were similar to the average amounts consumed by the control groups.

Significantly lower absolute organ weights and greater relative organ weights than controls were observed for several organs in the 1,500 or 3,000 ppm groups. These differences are not indicative of a specific toxic response but appear to be the result of the lower body weights of these groups.

No treatment-related gross or microscopic lesions were observed in male or female mice exposed to 1,3-diphenylguanidine.

Evaluation of male reproductive tissue from animals revealed greater numbers of spermatid heads and lower sperm motility than in the controls in the 3,000 ppm group. In females, estrous cycle length in the 3,000 ppm group was greater than controls.

: MLPC, Rion-des-Landes, France

(2) valid with restrictions

Critical study for SIDS endpoint

Result

Source Reliability Flag 06.09.2001

(74)

Type :

Species: rabbitSex: no dataStrain: no dataRoute of admin.: oral unspecifiedExposure period: 5.5 months

Frequency of treatm.

Post exposure period

Doses : 50 mg/kg

Control group : no data specified

Method : other

Year :

GLP : no data
Test substance : no data

**Remark**: No further information available

**Result** : Symptoms of toxicity: serious damage of the liver,

no data

associated with focal hepatitis; granular dystrophy of the cells of the convuluted kidney tubules; increased bilirubin levels; examination of the blood revealed no other changes

(no details reported)

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (52) (56)

Type :

Species: rabbitSex: no dataStrain: no data

Route of admin. : oral unspecified

**Exposure period** : no data **Frequency of treatm.** : no data

Post exposure period

**Doses** : 10 % of LD100 (no further information available)

Control group : no data specified

Method : other

Year

GLP : no data
Test substance : no data

**Remark**: No further information available

**Result** : Symptoms of toxicity: decreased food consumption, decreased

erythrocyte levels, increased serum-gamma-globulin levels

Source : MLPC, Rion-des-Landes, France

Reliability : (4) not assignable

27.12.2000 (52) (56)

Type : Gog
Species : dog
Sex : no data
Strain : no data

Route of admin. : oral unspecified

**Exposure period**: no data

Frequency of treatm. : multiple (no further information available)

Post exposure period

**Doses** : 5 mg/kg

Control group : no data specified

Method : other

Year

GLP : no data
Test substance : no data

**Remark**: no further information available

**Result**: symptoms of toxicity: reduced levels of bile acids (no

details reported)

**Source**: MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (77)

Type : dog
Species : dog
Sex : no data
Strain : no data

Route of admin. : oral unspecified

Exposure period : 24 days
Frequency of treatm. : 21 times
Post exposure period : no data
Doses : 10 mg/kg/day
Control group : no data specified

Method : other

Year :

GLP : no data
Test substance : no data

Result : A dosage of 10 mg/kg/d administered to 2 dogs in divided

doses for a total of 21 doses in 24 days was reasonably well

tolerated (no details reported).

Source : MLPC, Rion-des-Landes, France

**Reliability** : (3) invalid

27.12.2000 (75)

Type : rat
Species : rat
Sex : no data
Strain : no data
Route of admin. : inhalation
Exposure period : 15 days
Frequency of treatm. : 2 h/day

Post exposure period

Doses: ca. 0.22 mg/lControl group: no data specified

Method : other

Year :

GLP : no data
Test substance : no data

**Remark**: No further information available

**Result** : Symptoms of toxicity: marked disturbance in the intensity of

oxidation-reduction processes; functional changes of nervous system; blood pressure rose briefly (for several days) and

fell than to lower levels than the initial values (no

details reported)

Source : MLPC, Rion-des-Landes, France

Reliability : (3) invalid

11.05.2001 (52) (56)

Type

Species : other: not specified

Sex:no dataStrain:no dataRoute of admin.:inhalationExposure period:4 weeks

Frequency of treatm. : 30 min/day, every second day

Post exposure period

**Doses** : dust, concentation not specified

Control group : no data specified

Method : other: no detail available

Year : 1949
GLP : no
Test substance : no data

Result : no toxic effects were observed
Source : MLPC, Rion-des-Landes, France

Reliability : (3) invalid

06.09.2001 (62)

Туре

Species: guinea pigSex: no dataStrain: no dataRoute of admin.: inhalationExposure period: no data

Frequency of treatm. : repeated (no further information available)

Post exposure period

Doses : 100 mg/l

Control group : no data specified

Method : other

Year

GLP : no data
Test substance : no data

**Result** : all animals died (lethal, no details reported)

Source : MLPC, Rion-des - Landes, France

rabbit

**Reliability** : (4) not assignable

27.12.2000 (78)

Туре

**Species** 

Sex : no data Strain no data Route of admin. dermal : Exposure period no data Frequency of treatm. 10 times Post exposure period no data **Doses** 1000 mg/kg **Control group** no data specified

Method : other

Year

GLP : no data
Test substance : no data

Result : signs of systemic toxicity were not observed (no details

reported)

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (75)

### 5.5 GENETIC TOXICITY 'IN VITRO'

**Type** : Salmonella typhimurium reverse mutation assay

System of testing : Strain TA98, TA100, TA1535 and TA1537

**Test concentration** : 1 to 10000 μg/plate

Cycotoxic concentr.

**Metabolic activation**: with and without

Result : ambiguous

Method: other: Mortelman et al. (1986) Environ Mut, 8 (suppl. 7), 1-119.

Year : 1986 GLP : no data

**Test substance**: other TS: purity 98.9% +/- 0.6%

Result : 1,3-Diphenylquanidine (1 to 10,000 µg/plate) was weakly

mutagenic or equivocal in Salmonella typhimurium strains TA98 and TA100 in the presence of induced hamster or rat liver S9, and an equivocal response was obtained in strain

TA1537 with rat liver S9. No indication of mutagenic

activity was noted in the absence of S9.

Source: MLPC, Rion-des-Landes, FranceReliability: (1) valid without restrictionFlag: Critical study for SIDS endpoint

27.12.2000 (79) (74)

Type : Salmonella typhimurium reverse mutation assay System of testing : Strains TA 1535, TA 1537, TA 1538, TA 98, TA 100

**Test concentration** : 0.1 to 500 μg/plate

Cycotoxic concentr.

**Metabolic activation**: with and without

Result : negative

Method : other: Litton Bionetics Inc. standard protocol

Year : 1976 GLP : no Test substance : no data

Source : MLPC, Rion-des-Landes, France

**Reliability** : (2) valid with restrictions

Flag : Critical study for SIDS endpoint

06.09.2001 (80)

Type : Salmonella typhimurium reverse mutation assay

System of testing : Strains TA98, TA100, TA1535, TA1537 and TA1538

Test concentration : 2 to 500 μg/plate without S9, 20 to 5000 μg/plate with S9

Cycotoxic concentr.

**Metabolic activation**: with and without

Result : negative

**Method** : other: Standard procedure of the Japanese minister of Labour

Year : 1988 GLP : no data Test substance : other TS

Source : MLPC, Rion-des-Landes, France

**Test substance**: Tokyo Kasei Kogyo Co. ltd, lot no. FBR01, garanteed reagent.

Reliability : (2) valid with restrictions
Flag : Critical s tudy for SIDS endpoint

06.09.2001 (81)

Type : Salmonella typhimurium reverse mutation assay

System of testing : Strains TA 98, TA 100

**Test concentration** : 0, 200, 1000 and 5000 (= highest non-toxic concentration) μg/plate

Cycotoxic concentr. :

**Metabolic activation**: with and without

Result : negative

**Method** : other: Ames, B.N. et al., Mutat. Res. 31, 347-364 (1975)

Year : 1975 GLP : no data

**Test substance** : other TS: purity: 96.5 %

**Source** : MLPC, Rion-des-Landes, France

Reliability : (3) invalid

11.05.2001 (82) (83) (84)

Type : Salmonella typhimurium reverse mutation assay System of testing : Strains TA 1535, TA 1537, TA 1538, TA 98, TA 100

**Test concentration** : 0.036 - 36 ug/plate

Cycotoxic concentr.

**Metabolic activation**: with and without

Result : positive

Method: other: according to Ames, B.N. et al., Mutat. Res. 31, 347-364 (1975)

Year : 1975 GLP : no data

Test substance : other TS: several impurities were isolated from the sample used (no details

reported)

**Method** : The standard plate-incorporation assay system contained

approximately 1.5 x 10e8 bacteria with or without in vitro metabolic activation system. Mixed function oxidase (S-9) was prepared as previously described (Ames et al., 1975). The various experimental dosage levels and controls were plated in triplicate. Positive control used for the in vitro activation system was cyclophosphamide; for assays not incorporating S-9 liver fractions, MNNG was used. After 48 hr of incubation at 37°C, the number of his-revertant

colonies was determined. The number of his-revenant plotted

represents colonies in excess of control values.

Result : Lower dosage levels of DPG elicited more histidine

revertants per plate in the absence of in vitro metabolic activation system than similar levels of the compound in the presence of mixed function oxidase. It may also be inferred from the data that Salmonella strains TA100 and 1525 showed stronger mutagenic response than strains TA98, 1537, and 1538. The level of mutagenic response elicited by higher levels of DPG in the presence of mixed function oxidase differs significantly from that generated by similar doses of DPG without metabolic activation. A comparison of dose-response profile of the two systems (with or without metabolic acti vation) clearly suggests that while direct incorporation without metabolic activation yielded less histidine revertants per plate as DPG levels were increased, with metabolic activation, however, there was a gradual but steady increase in the number of revenants per plate with an increase in the dosage level of DPG. The only exception was

strain TA98.

Source : MLPC, Rion-des-Landes, France

Reliability : (3) invalid

The positive effect could be attributed to the impurities of

DPG.

27.12.2000 (85) (86)

Type : Salmonella typhimurium reverse mutation assay System of testing : Strains TA 1535, TA 1537, TA 1538, TA 98, TA 100

**Test concentration**: no data

Cycotoxic concentr. :

**Metabolic activation**: with and without

Result : negative

**Method** : other: Ames, B.N. et al., Mutat. Res. 31, 347-364 (1975)

Year : 1975 GLP : no data

**Test substance** : other TS: purity: technical grade

Source : MLPC, Rion-des-Landes, France

**Reliability** : (3) invalid

27.12.2000 (87)

**Type** : Salmonella typhimurium reverse mutation assay

System of testing : Strains TA 98, TA 100

**Test concentration**: no data

Cycotoxic concentr.

Metabolic activation: with and withoutResult: negativeMethod: other: no data

Year

GLP : no data
Test substance : no data

Remark : no further information available
Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (88)

**Type** : Salmonella typhimurium reverse mutation assay

System of testing : Strains TA 98, TA 100 Test concentration : 1 - 100 ug/plate

Cycotoxic concentr.

**Metabolic activation**: with and without

Result : negative
Method : other: no data

Year

GLP : no data
Test substance : no data

**Source**: MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (89)

**Type** : Escherichia coli reverse mutation assay

System of testing : Strain WP2uvrA

**Test concentration** : 2 to 500 μg/plate without S9, 20 to 5000 μg/plate with S9

Cycotoxic concentr.

Metabolic activation: with and withoutResult: negative

Method : other: Standard procedure of the Japanese minister of Labour

Year : 1988 GLP : no data Test substance : other TS

Source : MLPC, Rion-des-Landes, France

**Test substance**: Tokyo Kasei Kogyo Co. ltd, lot no. FBR01, garanteed reagent.

Reliability : (2) valid with restrictions
Flag : Critical study for SIDS endpoint

06.09.2001 (81)

**Type** : Gene mutation in Saccharomyces cerevisiae

System of testing : Stain D4

**Test concentration** : 1 to 500 μg/plate

Cycotoxic concentr. :

**Metabolic activation**: with and without

Result : negative

Method : other: Litton Bionetics Inc. standard protocol

Year : 1976 GLP : no Test substance : no data

Source : MLPC, Rion-des-Landes, France

**Reliability** : (2) valid with restrictions

06.09.2001 (80)

Type : HGPRT assay System of testing : V79 cells

Test concentration : 100, 200, 500 μg/ml

Cvcotoxic concentr.

Metabolic activation: withoutResult: negative

Method: other: according to van Zeeland, A.A. & Simmons, J.W.I.M., Mutat. Res.35,

129-138 (1976)

Year : 1983 GLP : no data

**Test substance** : other TS: purity: technical grade

**Remark** : Survival rate were 95, 89 and 94% at 100, 200 and 500 μg/ml,

respectively

Source : MLPC, Rion-des-Landes, France

Reliability : (3) invalid

27.12.2000 (90)

Type : Mouse lymphoma assay
System of testing : Mouse lymphoma L 5178Y cells

**Test concentration** : 16.4 to 188 μg/ml without S9, 32.8 to 525 μg/ml with S9

Cycotoxic concentr.

**Metabolic activation** : with and without

**Result** : negative

**Method** : other: Litton Bionetics Inc. standard protocol

Year : 1978 GLP : no Test substance : no data

**Source** : MLPC, Rion-des-Landes, France

Reliability : (2) valid with restrictions

Flag : Critical study for SIDS endpoint

06.09.2001 (91)

Type : Cytogenetic assay
System of testing : CHO cells

**Test concentration** : 0, 125, 250, 500 and 750 μg/ml

Cycotoxic concentr.

Metabolic activation: with and withoutResult: negative

Method : other: 40 CFR 798

**Year** : 1990 **GLP** : yes

**Test substance** : other TS: purity 97.18%

**Source** : MLPC, Rion-des-Landes, France

Reliability : (2) valid with restrictions

Flag : Critical study for SIDS endpoint

27.12.2000 (92)

Type : other: see remarks
System of testing : HeLa-S3 cells
Test concentration : 7.5 ug/l

Cycotoxic concentr. :

Metabolic activation : without

Result

Method : other

Year :

GLP : no data
Test substance : no data

**Remark**: ID50s = 50 % inhibition dose, determined from inhibition of

colony formation of the indicator cells

**Source**: MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (93)

#### 5.6 GENETIC TOXICITY 'IN VIVO'

Type : Cytogenetic assay

Species : rat

Sex: male/femaleStrain: Sprague-Dawley

Route of admin. : gavage

**Exposure period**: single administration

**Doses** : 300 mg/kg (maximum tolerated dose)

Result : negative

Method : OECD Guide-line 475 "Genetic Toxicology: In vivo Mammalian Bone

Marrow Cytogenetic Test - Chromosomal Analysis"

**Year** : 1983 **GLP** : yes

**Test substance**: other TS: purity 97.7%

**Method** : The potential for 1,3-diphenylguanidine to induce

chromosomal aberrations in the bone marrow cells of

Sprague-Dawley rats was tested.

In the range-finding experiment, male and female rats were treated with 1,3-diphenylguanidine at 50, 100, 200, 400,

600, 800, 1000 and 5000 mg/kg body weight.

1,3-Diphenylguanidine was found to be toxic to male rats at 400 mg/kg and higher, and toxic to female rats at 200 mg/kg and at 600 mg/kg and higher as indicated by clinical signs of toxicity and death. The combined male and female LD50 was

determined to be 427.3 mg/kg by the Probit method.

Based on results from the toxicity range-finding

experiments, 1,3-Diphenylguanidine was administered via oral gavage to male and female rats at a target dose of 300 mg/kg body weight (approximately 70% of the combined LD50). Control groups received 10 ml/kg of body weight of vehicle control (corn oil) or a 40 mg/kg of body weight dose of

positive control (cyclophosphamide). Bone marrow was sampled

at 6, 24 and 48 hours after dosing with the vehicle or 1,3-diphenylguanidine. A single sampling time of 24 hours after dosing was used for the cyclophosphamide control group. Slides were scored for increases in the proportion of

aberrant metaphases and in the frequency of

aberrations/cell.

**Result**: In the main cytogenetic experiment, 1,3-diphenylquanidine

was toxic to male and female rats as evidenced by clinical signs of toxicity (hypoactive and nonresponsive) and death. Five male rats and six female rats were found dead within 24 hours of dosing. Statistically significant decreases in mean body weight were observed in the 1,3-diphenylguanidine treated male and female rats at 6 and 24 hours after treatment and in the positive control treated male rats 24

hours after treatment.

No statistically significant increases in the proportion of aberrant cells or aberrations/cell were observed at the 6, 24 and 48 hour time points. Significant induction of toxicity, measured as mitotic index depression, was observed at the 6 h our (35%) and 24 hour (31%) time points. No depression in mitotic index was observed at the 48 hour time

point.

The positive control group (cyclophosphamide) yielded expected positive responses indicating the adequacy of the experimental conditions for the detection of clastogens.

Source: MLPC, Rion-des-Landes, FranceReliability: (1) valid without restrictionFlag: Critical study for SIDS endpoint

29.10.2001 (94)

Type : Micronucleus assay

Species: mouseSex: male/femaleStrain: B6C3F1Route of admin.: oral feedExposure period: 13 weeks

**Doses** : 0, 250, 500, 750, 1500 and 3000 ppm

Result : negative

Method : other: McGregor et al. (1990) Fundam Appl Toxicol, 14, 513-522.

Year : 1990 GLP : no data

**Test substance**: other TS: purity 98.9% +/- 0.6%

Method

A modification of the technique described by MacGregor et al. (1990) was used. At the termination of the 13-week toxicity study, blood was obtained from male and female mice and smears were immediately prepared and fixed in absolute methanol. The methanol-fixed slides were stained with acridine orange and coded. The frequency of micronuclei was determined in 2,000 normochromatic erythrocytes (NCEs) in each of 5 animals per dose group. The criteria of Schmid (1976) were used in defining micronuclei.

The frequency of micronucleated PCEs was analyzed by a statistical software package (ILS, 1990) that employed a one-tailed trend test across dose groups and a t-test for pairwise comparisons of each dose group to the concurrent

control.

Result

: No effect was noted in male mice, but in females, a significant increase in micronucleated normochromatic erythrocytes was noted in the 750 ppm group. Because the trend test for the female data did not yield a significant P value (P>0.025) and the increase in micronucleated normochromatic erythrocytes was noted in only one exposure group, the female mouse data were judged to be equivocal.

Frequency of Micronucleated Erythrocytes in Peripheral Blood of Male and Female Mice AdmInistered 1,3-Diphenylguanidine In Dosed Feed for 13 Weeks

Dose	Micronucl. NCEs/1,000 NCEs	Number
(ppm)		examined

**MALE** 

0 0.38 +/- 0.13 4 250 0.70 +/- 0.20 5

500	1.00 +/- 0.27	5
750	1.20 +/- 0.12	5
1,500	0.70 +/- 0.20	5
3,000	1.30 +/- 0.12	5

**FEMALE** 

0	0.30 +/- 0.12	5
250	1.00 +/- 0.16	5
500	0.80 +/- 0.20	5
750	1.40 +/- 0.19*	5
1,500	1.20 +/- 0.12	5
3,000	1.30 +/- 0.20	5

\*P=0.005

Source: MLPC, Rion-des - Landes, FranceReliability: (1) valid without restrictionFlag: Critical s tudy for SIDS endpoint

27.12.2000 (74)

Type : Micronucleus assay

Species: mouseSex: no dataStrain: no data

Route of admin.

Exposure period : no data

Doses : no data

Result

Method : other

Year :

GLP : no data
Test substance : no data

**Remark**: no further information available

Result : negative

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (86)

**Type** : other: Host mediated mutagenic assay

Species: mouseSex: no dataStrain: C57BLRoute of admin.: i.p.Exposure period: single

**Doses** : 0.036 - 36 mg/kg

Result

**Method** : other: Legator, M.S. et al., Mutat. Res. 26, 456-461 (1974)

Year : 1974 GLP : no data

**Test substance** : other TS: purity: several impurities were isolated from the sample used

(nodetails reported)

Remark : To determine whether or not DPG was detoxified or converted

to some active compound(s), 10 mice per each dosage level

were given single i.p.injections of DPG at a final

concentration of 0.036, 0.36, 3.6 or 36.0 mg/kg body weight. Control animais received single injections (0.2 ml) of 0.005% alcohol. The experimental and control animais were placed in metabolism cages in groups of three. Faeces, urine and peritoneal fluid from the two DPG-treated and two control animais were collected every 24 hr for a period of 4 days and directly assayed for mutagenic activity according

Result

to Ames, B.N. et al., Mutat. Res. 31, 347-364 (1975). Since TA100 provided a greater mutagenic response in the presence of DPG, with or without metabolic activation, that strain was used in the analysis of body fluids and faecal material.

Incubation of Salmonella strain TA100 with peritoneal, urine or faecal material collected from animals given single intraperitoneal injections of DPG yielded sporadic results.

Time-dose-response testing of DPG with peritoneal fluid showed that in a three day recovery period, the number of revenants per plate increased with each advancing day when the initial dosage level was either 0.36 or 3.6 mg/kg. Peritoneal fluids from animals receiving 0.036 mg/kg generated time-dependent decreases in revenants, whereas incubation of TA100 in peritoneal fluid from animals previously exposed to DPG at 36 mg/kg was extremely toxic and thus produced a few revenants per plate. It must be mentioned, however, that despite the time-dependent decrease in revertants per plate when peritoneal fluid from animals treated with 0.036 mg/kg of DPG was incubated with TA100, the mutagenic response of the treatment during the 3-day period was very high.

The urine from animals treated with 0.036 or 0.36 mg/kg generated steady inrease in revertants per plate with time; treatment with 3.6 mg/kg and 36 mg/kg on the other hand, showed time-and dose-dependent decrease in histidine revertants.

Unlike the sporadic mutagenic profile of peritoneal fluid and faeces of treated animals on TA100, the number of revenants generated by faecal material from similarly treated animals showed a definite dose-dependent response. The level of the mutagenic response of the faecal material is also influenced by the time elapsing between time of treatment and collection of faeces.

Faecal material collected within 24 hr post-treatment, and incubated with strain TA 100, resulted in moderate mutagenic res ponses. Faeces collected 48 or 72 hr post-treatment generated significantly higher number of revenants per plate. In addition to the mutagenic activity of the faecal material being time-dependent, histidine revertants per plate show slight increases with an increase in the dose level of DPG.

Dose-response curves based on analyses of peritoneal fluid and urine showed decreases in revenants per plate as the dosage levels of DPG were increased. Unlike the results obtained from the faecal material, histidine revenants produced by urine and peritoneal fluids were sporadic among the different treatment groups.

Analysis of peritoneal fluid showed that the lowest dosage level (0.036 mg/kg) produced the highest number of revenants in the three time-groups (24, 48 or 72 hr). 135, 170 and 210 revertants in excess of concurrent control were produced when peritoneal fluid removed from treated animais (0.036 mg/kg) at 24, 48 and 72 hr post-treated, were respectively incubated with TA 100 strain.

As the dosage level of DPG increased, histidine revenants produced by the three time-groups decreased. The 72-hr

treatment, however, generated the most number of revenants at higher concentrations of DPG.

Dose-response testing of urine from treated and control groups showed that 24 hr-treatment group produced the least revertants when urine from animals exposed to 0.036 or 0.36 mg/kg was used. The highest number or revertants (248/plate) was generated by the 72 hr-groups, with the 48-hr group producing 160. At higher concentrations of DPG (3.6 and 36 mg/kg) the 24 hr-groups produced more histidine revenants

than the other groups.

**Source**: MLPC, Rion-des-Landes, France

Reliability : (3) invalid

27.12.2000 (85)

## 5.7 CARCINOGENICITY

**Species** : mouse **Sex** : male/female

Strain : other: C57BLxDB hybrid

Route of admin. : oral feed
Exposure period : 32 weeks
Frequency of treatm. : continously in diet

Post exposure period : 10-16 weeks
Doses : 4 or 8 mg/kg

Result

**Control group** : yes, concurrent no treatment **Method** : other: no detail available

Year

GLP : no data
Test substance : no data

Remark : 50 male and 50 female C57bl X DB2 hybrid mice/group were

usea.

**Result**: At the termination of dosing no tumors were observed; after

the observation period 3/50 mice of the low dose group developed lymphatic adenocarcinomas, while in the high dose group and the control group no such tumors were observed; treatment also caused enlarged spleens, but this effect subsided after termination of treatment (no further details

available)

Source : MLPC, Rion-des-Landes, France

Reliability : (3) invalid

27.12.2000 (95)

Species: mouseSex: male/femaleStrain: other: ddyRoute of admin.: oral feedExposure period: 21 months

Frequency of treatm. : continuously in diet

Post exposure period : no data

**Doses** : 0, 20, 60, 180 or 540 ppm

Result

Control group : yes Method : other

Year

GLP : no data
Test substance : no data

ld 102-06-7 5. Toxicity Date 14.11.2001

Remark no further information available Source MLPC, Rion-des-Landes, France

Reliability (3) invalid

27.12.2000 (96)

#### 5.8.1 TOXICITY TO FERTILITY

Type other: reproductive organ toxicity

**Species** 

Sex male/female : Strain Fischer 344 Route of admin. oral feed Exposure period : 13 weeks Frequency of treatm. : ad libitum

Premating exposure period

Male

Female

**Duration of test** 13 weeks

No. of generation

studies

500, 750 and 1500 ppm **Doses Control group** yes, concurrent no treatment

NOAEL parental = 750 ppm

Method : other: NTP's Technical Protocol for Sperm Morphology and Vaginal

Cytology Evaluation in Toxicity Testing for Rats and Mice

Year GLP yes

Test substance other TS: purity 98.9% +/- 0.6%

: As part of a 13-week toxicity study (NTP, 1995) groups of 10 Method

male and 10 female rats were administered 0, 250, 500, 750, 1,500, or 3,000 ppm 1,3-diphenylguanidine in feed that was

available ad libitum.

Rats were housed five per cage. Animal rooms were maintained at 69° to 75° F and 35% to 65% relative humidity, with 12 hours of fluorescent light per day and approximately 10 air changes per hour. Feed and water were available ad libitum. Because of the limited stability of the

1,3-diphenylguanidine feed mixtures, feeders were changed daily, 7 days per week, throughout the 2-week and 13-week

studies.

At the end of the 13-week study, vaginal cytology and sperm motility evaluations were performed on all base-study rats in the 0, 500, 750, and 1,500 ppm groups. Methods were those outlined in the National Toxicology Program's Technical Protocol for Sperm Morphology and Vaginal Cytology Evaluation in Toxicity Testing for Rats and Mice (NTP, 1987). Beginning 12 days prior to sacrifice, the vaginal vaults of 10 females from each exposure group were lavaged, and the aspirated lavage fluid and cells were stained with toluidine blue. Relative numbers of leukocytes, nucleated epithelial cells, and large squamous epithelial cells were determined and used to ascertain estrous cycle stage (i.e., diestrus, proestrus, estrus, or metestrus).

Sperm motility was evaluated at necropsy in the following manner. The left testis and epididymis were weighed. The tail of the epididymis (cauda epididymis) was then removed

from the corpus epididymis and weighed. Test yolk was applied to slides, and a small incision was made at the distal border of the cauda epididymis. The sperm effluxing from the incision were dispersed in the buffer on the slides, and the numbers of motile and nonmotile spermatozoa were counted for five fields per slide by two observers.

Following completion of sperm motility estimates, each left

cauda epididymis was placed in buffered saline solution. Caudae were finely minced and swirled, and the tissue was incubated and then heat fixed. Sperm density was then determined microscopically with the aid of a hemacytometer. To quantify spermatogenesis, testicular spermatid head count was determined by removing the tunica albuginea and homogenizing the left testis in 10% dimethyl sulfoxide in phosphate-buffered saline. Homogenization-resistant spermatid nuclei were counted using a hemacytometer. Gross necropsy observations related to 1,3-diphenylguanidine treatment were limited to thinness of the carcass in higher exposure rats. Microscopic changes associated with chemical administration were observed in the uterus, testes, prostate and gland/seminal vesicle. All of the gross and microscopic changes occurred in the two highest exposure groups and were attributed to the lower feed intake, reduced weight gains, and poor body condition of these animals.

An exposure-related effect in the uterus of females was characterized by an overall reduction in size and was diagnosed as hypoplasia. This finding occurred with greater incidence and severity in the three highest exposure groups. In general, this change was attributed to poor body condition and delayed development due to lower feed consumption; the younger age of those females which died or were killed during the study may have been a reason for the smaller size of the uterus.

Several lesions were noted sporadically in the reproductive organs of 3,000 ppm males. In two of ten 3,000 ppm males, lower numbers of mature spermatozoa were present in the seminiferous tubules than in the controls; lower numbers of spermatozoa were also noted in the epididymal tubules than in the controls. Secretory depletion of the prostate gland and seminal vesicles was obsetved in several 3,000 ppm males: this difference was characterized by alveolar size smaller than controls and smaller amounts of secretory material within the lumen. Decreased spermatogenesis and secretory depletion of the accessory sex glands were considered secondary to poor body condition. In the salivary glands of several 3,000 ppm males and females, a change diagnosed as cytologic alteration was observed, characterized by smaller size and increased basophilia of the secretory acini. This change was interpreted to be a reflection of physiological atrophy due to reduced feed intake. No specific cause of death could be determined for the early death animals from the 3,000 ppm groups.

Evaluation of male reproductive tissues in groups that received 500, 750, or 1,500 ppm revealed a significant reduction in sperm motility in 1,500 ppm males. Among 750 and 1,500 ppm group females the length of the estrous cycle was greater than the controls.

Summary of Reproductive Tissue Evaluations In Male F344/N

Result

Rats in the 13-Week Feed Study of 1,3-	Diphenylguanidine.
--	--------------------

Study parameters					
Dose (ppm)	0	500	750	1,500	
n	10	10	10	10	
Weights (g)					
Necropsy body	weiaht (a)				
Nooropoy body	374±6	358±5	347±4**	300±7**	
Left epididymis	(mg)				
. ,	480±10	482±9	496±10	464±8	
Left cauda epid	idymis (mg)	)			
	196±5	199±5	198±6	186±4	
Left testis (mg)					
	1550±20	1560±20	1510±3	0 1480±20	
0					
Spermatid mea		·· \			
Spermatid head		-			
	1109±68		1091±4	4 1084±41	
Spermatid head	`	,			
	1714±98	1631±40	1650±6	3 1600±54	
Spermatid coun					
	85.70±4.9	0 81.55±1.	98 82.48±	3.13 80.0±2.71	
Epididymal spermatozoal measurements					
Motility (%)					
94.76±1.42 92.30±1.76 87.34±3.75 83.69±2.7**					

94.76±1.42 92.30±1.76 87.34±3.75 83.69±2.7\*\*
Concentration (10e6/g caudal epididymal tissue)
331.5±33.2 259.0±29.62# 290.5±26.3 598.2±139

Data presented as mean  $\pm$  standard error. Differences from the control group for epididymal, cauda epididymal, and testis weights, spermatid measurements, and sperm concentration are not significant by Dunn's test. # n=9.

Summary of Estrous Cycle Characterization In Female F344IN Rats in the 13-Week Feed Study of 1,3-Diphenylguanidine.

Study paramet	ers			
Dose (ppm)	0	500	750	1,500
n	10	10	10	9
Necropsy body	y weight (g)		<b></b>	
	204±4	195±3	191±3**	177±2**#
Estrous cycle	length (day	s)		
	4.95±0.0	5 5.00±0.00	6.00±0.33**	5.67±0.44"
Estrous stages	s (% of cycl	e)		
Diestrus	38.2	38.2	44.5	41.8
Proestrus	14.5	19.1	16.4	15.5
Estrus	30.0	24.5	24.5	22.7
Metestrus	17.3	18.2	14.5	20.0

<sup>\*\*</sup> Significantly different (P<0.01) from the control group by Dunnett's test (necropsy body weight only) or Shirley's test.

Necropsy body weights and estrous cycle lengths are presented as mean  $\pm$  standard error. By multivariate analysis of variance, exposed groups do not differ significantly from the control group in the relative length of time spent in

the estrous stages.

# n=10.

" Estrous cycle longer than 12 days or unclear in 1 of 10

\*\* Significantly different (P<0.01) from the control group by Dunnett's test (necropsy body weight only) or Dunn's

test.

Source: MLPC, Rion-des - Landes, FranceReliability: (1) valid without restrictionFlag: Critical study for SIDS endpoint

27.12.2000 (74)

Type : other: reproductive organ toxicity

Species: mouseSex: male/femaleStrain: B6C3F1Route of admin.: oral feedExposure period: 13 weeksFrequency of treatm.: ad libitum

Premating exposure period

Male

Female

**Duration of test** : 13 weeks

No. of generation

studies

Doses : 250, 750 and 3000 ppm
Control group : yes, concurrent no treatment

NOAEL parental : = 750 ppm

Method : other: NTP's Technical Protocol for Sperm Morphology and Vaginal

Cytology Evaluation in Toxicity Testing for Rats and Mice

**Year** : 1995 **GLP** : yes

**Test substance**: other TS: purity 98.9% +/- 0.6%

Method : As part of a 13-week toxicity study (NTP, 1995) groups of 10

male and 10 female mice were administered 0, 250, 500, 750, 1,500, or 3,000 ppm 1,3 -diphenylguanidine in feed that was

available ad libitum.

Mice were housed individually. Animal rooms were maintained at 69° to 75° F and 35% to 65% relative humidity, with 12 hours of fluorescent light per day and approximately 10 air changes per hour. Feed and water were available ad libitum.

Because of the limited stability of the

1,3-diphenylguanidine feed mixtures, feeders were changed daily, 7 days per week, throughout the 2-week and 13-week studies.

At the end of the 13-week studies, vaginal cytology and sperm motility evaluations were performed on all mice in the 0, 250, 750, and 3,000 ppm groups. Methods were those outlined in the National Toxicology Program's Technical Protocol for Sperm Morphology and Vaginal Cytology Evaluation in Toxicity Testing for Rats and Mice (NTP, 1987). Beginning 12 days prior to sacrifice, the vaginal vaults of 10 females from each exposure group were lavaged, and the aspirated lavage fluid and cells were stained with toluidine blue. Relative numbers of leukocytes, nucleated

epithelial cells, and large squamous epithelial cells were determined and used to ascertain estrous cycle stage (i.e., diestrus, proestrus, estrus, or metestrus).

Sperm motility was evaluated at necropsy in the following manner. The left testis and epididymis were weighed. The tail of the epididymis (cauda epididymis) was then removed from the corpus epididymis and weighed. Tyrode's buffer was applied to slides, and a small incision was made at the distal border of the cauda epididymis. The sperm effluxing from the incision were dispersed in the buffer on the slides, and the numbers of motile and nonmotile spermatozoa were counted for five fields per slide by two observers.

Following completion of sperm motility estimates, each left cauda epididymis was placed in buffered saline solution. Caudae were finely minced and swirled, and the tissue was incubated and then heat fixed. Sperm density was then determined microscopically with the aid of a hemacytometer. To quantify spermatogenesis, testicular spermatid head count was determined by removing the tunica albuginea and homogenizing the left testis in 10% dimethyl sulfoxide in phosphate-buffered saline. Homogenization-resistant spermatid nuclei were counted using a hemacytometer.

Result

Summary of Reproductive Tissue Evaluations In Male B6C3F1 Mice in the 13-Week Feed Study of 1,3-Diphenylguanidine.

Study parameters

Dose (ppm)		250	750	3,000
n	10	10	10	10
 Weights (g)				
Necropsy body	weight (g)			
		34.7±0.7	33.8±0.6°	* 29.1±0.3**
Left epididymis	(mg)			
	55±2	61±1	56 ±2	54±2
Left cauda epidi	idymis (mg)	)		
•	22±1	24±1	22±1	21±1
Left testis (mg)				
	123±4	125±3	125 ±3	117±3
Spermatid meas	surements			
Spermatid hea		testis)		
		1733±94	1867±81	2052±104*
Spermatid hea	ds (10e5/te	estis)		
	209±9	,	231±7	237±8
Spermatid cou	nt (mean/1	0e-4 mL su	spension)	
·	•		•	.24 74.18±2.45
Epididymal sper	rmatozoal r	neasureme	ents	
Motility (%) 84. 51.56±11.77*				
Concentration	(10e6/g cai	udal enidid	vmal tissue)	
Concontiation			904±271	676±201

Data presented as mean ± standard error. Differences from the control group for epididymal, cauda epididymal, and tests weights, spermatid heads per tests, spermatid count, and sperm concentration are not significant by Dunn's test.

# n=9.

Metestrus

- \* Significantly different (P<0.05) from the control group by Dunnett's test (necropsy body weight only) or Dunn's test.
- \*\* Significantly different (P<0.01) from the control group by Dunnett's te st.

Summary of Estrous Cycle Characterization In Female B6C3F1 Mice in the 13-Week Feed Study of 1,3-Dlphenylguanldine.

Dose (ppm) 0 250 750 3,0	,000
n 10 10 10 10	)
Necropsy body weight (g)	
29.3±0.7 28.5±0.6 27.4±0.5* 22	22.9±0.2**
Estrous cycle length (days)	
4.30±0.13 4.45±0.16 4.10±0.07 5.	5.15±0.27
Estrous stages (% of cycle)	
Diestrus 33.3 26.7 30.0 28.	8.3
Proestrus 20.8 21.7 20.0 20.	0.0
Estrus 26.7 35.8 29.2 39.	9.2

-----

19.2

Necropsy body weights and estrous cycle lengths are presented as mean ± standard error. By multvariate analysis of variance, exposed groups do not differ significantly from the control group in the relative length of time spent in the estrous stages.

15.8

20.8

12.5

- \* Significantly different (P<0.05) from the control group by Dunnett's test (necropsy body weight only) or Dunn's test.
- \*\* Significantly different (P<0.01) from the control group by Dunnett's test

All mice survived to the end of the study (Table 7). Mean body weights of both males and females in the three highest exposure groups (750, 1,500, and 3,000 ppm) were lower than those of the control groups especially during the latter part of the study (Figure 2). Thin appearance was the most frequently reported clinical sign for female mice and was most often observed in the three highest exposure groups. Thin appearance was also observed in male mice in the 3,000 ppm group. Other clinical signs observed in mice in the higher exposure groups included alopecia, abnormal posture, ptosis, and bristly hair.

The average amounts of feed consumed by males and females in all exposed groups were similar to the average amounts consumed by the control groups.

Significantly lower absolute organ weights than controls were observed for seminal vesicles in the 3,000 ppm group. These differences are not indicative of a specific toxic response but appear to be the result of the lower body weights of these groups.

No treatment-related gross or microscopic lesions were observed in male or female mice exposed to 1,3-diphenylquanidine.

Evaluation of male reproductive tissue from animals revealed greater numbers of spermatid heads and lower sperm motility than in the controls in the 3,000 ppm group. In females,

estrous cycle length in the 3,000 ppm group was greater than

(74)

controls.

Source : MLPC, Rion-des-Landes, France
Reliability : (1) valid without restriction
Flag : Critical study for SIDS endpoint

27.12.2000

**Type** : other: testicular toxicity and male fertility study

Species: mouseSex: male/femaleStrain: CD-1Route of admin.: gavageExposure period: 8 w eeksFrequency of treatm.: 7 days/week

Premating exposure period

Male : 8 weeks Female : none

Duration of test No. of generation

No. or ger

studies

**Doses** : 0.06, 0.25, 1, 4 or 16 mg/kg/day

Control group : yes, concurrent vehicle

NOAEL parental : >= 16 mg/kg bw

Method : other Year : 1989 GLP : ves

**Test substance** : other TS: Purity = 99.9%

Method : An oral testicular toxicity and male fertility study with

1,3-diphenylguanidine was carried out in CD1 mice in two tiers respectively. In the first tier the test substance was administered daily to male mice (25 males/group) by daily oral intubation at dose levels of 0, 0.06, 0.25, 1, 4 and 16 mg/kg body weight per day during an 8-week premating period (7 days per week). Females were not treated during any

period of the study. Within 24 hours after the last

treatment day, 9 to 13 males, randomly taken from each group were killed and subjected to gross examination at autopsy. A selected number of organs were weighed and preserved in formalin. In addition, sperm abnormality evaluation was conducted in the selected males from the control and high dose group. In the second tier the remainder of the males of the control, 4 and 16 mg/kg group was mated (within 14 days after the 8-week dosing period) with untreated females. Reproductive performance, necropsy finding and litter data

were recorded.

Result : During the treatment period a small number of animals of all

groups but the control and 0.06 mg/kg group were found dead or were killed in moribund condition. The cause of death of these animals was not always discernible from gross necropsy observations. In addition, mortality that appeared to be related to dosing err ors was observed in the control group (1 animal), the 0.06 mg/kg (3 animals), the 0.25 mg/kg group

(4 animals), and the 4.0 mg/kg group (1 animal).

No differences in body weights between the various test groups and controls were found that could be related to the

treatment.

Sperm abnormality evaluation showed a slight, but statistically significant increased incidence of sperm cells with folded tails in the high dose group (5% versus 2% in controls). However, since the total number of abnormal

ld 102-06-7 5. Toxicity **Date** 14.11.2001

> sperm cells as well as the number of specified sperm abnormalities was similar in all groups, the observed increased number of sperm cells with

folded tails is considered of doubtful significance.

Gross examination at necropsy of male mice did not reveal any treatment related changes. No significant differences in organ weights occurred between the groups. Microscopic examination of the testes did not show any effect of treatment with N,N'-dipherrylguanidine. on the basis of observed testis weights it was decided to continue the study

with the second tier.

Male and female fertility as well as reproduction

performance were comparable in all groups examined (0, 4.0

and 16.0 mg/kg).

Maternal autopsy findings and litter data did not reveal any

treatment related effect.

Source MLPC, Rion-des-Landes, France

Conclusion Under the conditions of this study 1,3-diphenylguanidine did not exert any

effects on fertility, reproduction capacity or embryonic/foetal development in CD1 mice when administered to male mice at levels up to 16 mg/kg body

weight per day.

Reliability (1) valid without restriction Flag Critical study for SIDS endpoint

14.11.2001 (97)(98)

Type Fertility Species mouse Sex male/female

Strain : other: C57BL/6JxDBA2

Route of admin. drinking water Exposure period up to 15 weeks

Frequency of treatm. continously in drinking water

Premating exposure period

Male : up to 15 weeks Female no exposure **Duration of test** 15 weeks

No. of generation

studies

4 or 8 mg/kg/day **Doses** Control group yes, concurrent vehicle

Method other : Year 1983 **GLP** 

Test substance other TS: There were some impurities in the test material (Bempong,

Jan. 21, 1987, personnal communication).

Method : Ten-week-old hybrid mice (C57BL/J6 X DBA2) weighing 25-30 g

were used. They were maintained on Purina Lab Chow and water

ad libitum. All mice used in the study were weighed before

treatment and during chemical exposure.

Sperm morphology:

Three groups of mice received the following concentrations

of DPG ad libitum: 0.00 (solvent control), 4.0, or 8.0

mg/kg/d. At the appropriate time, animals were sacrificed by cervical dislocation. Sperm were collected from 5 animals per group by dissecting the cauda epididymis to assess the sperm morphology. Groups were compared by using the

chi-square and/or t-test.

uantitative sperm analysis:

Testes were weighed immediately after they were removed.

Solvent control and DPG-treated mice were sacrificed at the appropriate killing times. Suspensions of the content of cauda epididymis of each mouse were prepared by the method of Fiscor and Ginsberg (1980). The number of sperm per preparation was determined in a Makler sperm-counting chamber (Makler, 1978).

#### Histology:

Testes from mice sacrificed 1, 3, 5, 7, 9, and 15 wk after DPG treatment and from concurrent control animals were examined histologically.

## Reproductive study:

Ten-week-old male mice were exposed to 4.0 or 8.0 mg/kg/d DPG prepared in acetic acid at a final concentration of 0.025%. Concurrent solvent control animals were exposed to 0.025% acetic acid prepared in deionized water. Exposure was ad libitum and the duration of exposure was 90 d. After 7 d of exposure, the animals were mated at weekly intervals to 12-wk-old virgin untreated females. All matings were monogamous. Pregnant animals, based on the presence of vaginal plugs, were isolated and housed one per cage. The fertility index, expressed as the ratio of the number of pregnant females to the number of females mated in a specified mating group, was determined. On day 13 of pregnancy the female animais were sacrificed by cervical dislocation, the uteri were removed, and the number of implants and frequencies of early (moles) and late fe tal lethality per pregnancy were determined.

The average levels of morphologically abnormal sperm among the control animals did not show significant differences during the 85 days. In the hybrid mice abnormal sperm morphology ranged from 1.8 to 5.3% with a mean of 3.5%. These figures were derived from 25 measurements of 200 sperm per measurement. A nonlinear increase in the frequency of sperm abnormalities was observed in the DPG-treated mice. The incidence of DPG-induced abnormal sperm in mice exposed to 4 mg/kg/d ranged from 16.2 to 42.4%. For the 8 mg/kg/d treatment group, the range was 38.6 to 75.1%.

Histopathological analysis of control and DPG-treated mice revealed that in the latter group the parietal peritoneum was saturated with fatty tissues and the mesentery and the greater omentum showed the greatest evidence of fatty tissue accumulation. Fatty tissue accumulation and attendant weight gains in DPG-treated mice were the antithesis of testicular growth. Testicular weights decreased significantly after 5, 7, 9, and 15 weeks of treatment, but were not different from the controls after 1 and 3 weeks of treatment. Sperm count in the two treatment groups decreased significantly 7, 9, and 15 wk after treatment. At the higher dose of DPG (8 mg/kg/d) significant differences in sperm counts were noted 5 weeks after treatment. Examination of the epididymis of treated mice showed the presence of germinal cells. With prolongation of DPG treatment, cytological preparations revealed more germinal cells than spermatozoa.

Changes In sperm Count and Testicular Weight in Mice after Continuous Exposure to 1,3-Diphenylguanidine ad libitum.

Mean

Mean testis Sperm Suggested

Result

Dose (mg/kg/	Expos /d) (weeł		weight (mg)	count (10e4/m	meiotic l) stage at time of exposure
0 4 8	1	10	286 293 278	19.59 16.72 16.23	Spermatozoa
0 4 8	3	8	301 285 269	17.62 19.43 16.75	Spermatids
0 4 8	5*	8	289 147 131	17.10 12.84 9.63	Preleptotene late sperma- togonium
0 4 8	7*	8	298 139 124	19.89 9.54 7.61	spermatogonium
0 4 8	9*	8	313 136 121	18.47 9.87 4.68	spermatogonium
0 4 8	15*	10	293 139 112	17.16 7.45 3.19	Spermatogonial stem cells

<sup>\*</sup> significantly different from control.

Histological preparations of testes from DPG-treated mice showed irregularly shaped seminiferous tubules with no defined basement membrane, loss of interstitial cells, and limited numbers of spermatids and spermatozoa in the lumen of the tubules. These observations were in contrast to the histological organization of the control testes. The developmental anomalies of germinal cells coupled with the decreased sperm count might have been responsible for the results obtained in the reproductive study.

Fertility indices, implants per pregnancy, and fetal mortalities per DPG-treated female were not significantly different from the control values during the first 4 weeks. However, after 5 weeks of DPG treatment significant differences (p <0.02) were noted when the treated and control populations were compared. Differences between the two doses of DPG became evident in the 7th week. This trend continued until the 16th week of continuous DPG exposure (data not presented).

Effect of Chronic Exposure to 1,3-Diphenylguanidine on Fertility Index and Dominant Lethality in Mice.

Number of of implants  Period Treatment pregnant						Dead fetuses per pregnancy	
(wk)	(mg/kg/d		Per fe	emale	Total	Early	Late
1	0 4.0 8.0	20/20° 18/120 12/20		11.8 10.3 9.8	 236 186 118	0.54 0.44 0.67	0.35 0.39 0.33

3	0.0	20/19	12.4	248	0.40	0.35
	4.0	16/20	11.1	178	0.05	0.44
	8.0	14/20	10.6	148	0.64	0.43
5	0.0	19/20	12.2	232	0.53	0.37
	4.0	16/20	10.9	175	0.75	0.69
	8.0	11/20	9.3	103	0.91	0.73
7	0	20/120	11.3	236	0.45	0.25
	4	17/20	10.4	177	1.35	1.06
	8	8/20	9.6	77	2.13	1.88

\_\_\_\_\_

Source : MLPC, Rion-des-Landes, France

Reliability : (3) invalid

27.12.2000 (99) (100)

Type : other

Species : Syrian hamster

Sex : male
Strain : other
Route of admin. : drinking water
Exposure period : up to 80 days

Frequency of treatm. : continously in drinking water

Premating exposure period

Male :

Female

**Duration of test** : 80 days

No. of generation

studies

Doses : 4 or 8 mg/kg/day
Control group : yes, concurrent vehicle

Method: otherYear: 1983GLP: no

**Test substance**: other TS: There were some impurities in the test material (Bempong,

Jan. 21, 1987, personnal communication).

**Method** : Twelve-week-old inbred golden Syrian hamsters with an

average weight of 55 g were used. They were maintained on Purina Lab Chow and water ad libitum. Three groups of hamsters received the following concentrations of DPG ad libitum: 0.00 (solvent control), 4.0, or 8.0 mg/kg/d. At the appropriate time, animals were sacrificed by cervical dislocation. Sperm were collected from 5 animals per group by dissecting the cauda epididymis and examined for sperm morphology. Groups were compared by using the chi-square

and/or t-test.

**Result** : The average levels of morphologically abnormal sperm among

the control animais did not show significant differences during the 85 d. In the hybrid hamsters abnormal sperm morphology ranged from 2.0 to 13.6% with a mean of 9.2%. These figures were derived from 25 measurements of 200 sperm per measurement. Fluctuations in the levels of DPG-induced sperm abnormalities were observed in all preparations from day 30 to day 75. From day 75 to the end of the experiment, steady increases in the frequency of anomalous sperm were observed (up to 50 and 80% of abnormal sperm at 4.0 and 8.0 mg/kg/d, respectively). No further information available on

testes weight, cytology and histology

Source : MLPC, Rion-des-Landes, France

**Test substance**: There were some impurities in the test material (Bempong,

Jan. 21, 1987, personnal communication).

Reliability : (3) invalid

27.12.2000 (101) (100)

#### 5.8.2 DEVELOPMENTAL TOXICITY/TERATOGENICITY

Species : rat Sex : female

**Strain** : Sprague-Dawley

Route of admin. : gavage

**Exposure period**: day 6-15 of gestation

Frequency of treatm. : once daily

**Duration of test** : animals were sacrificed on day 20 of gestation

**Doses** : 10, 50, 100, 150 or 200 mg/kg/day

Control group : yes, concurrent vehicle
NOAEL maternal tox. : = 10 mg/kg bw

**Method** : other: range-finding study

Year : 1985 GLP : yes Test substance : no data

**Method** : Potential maternal and embryotoxic effects of DPG were

evaluated in a range-finding teratology study in rats. DPG was admixed in 0.5% aqueous Methocel and administered to five groups of five bred Sprague Dawley COBS CD rats once

daily from gestation days 6 through 15. The route of

administration was oral by gastric intubation. Dosage levels of 10, 50, 100, 150 and 200 mg/kg/day were selected. For comparative purposes, a concurrent control group, also composed of five bred females, was dosed with 0.5% aqueous Methocel the vehicle control, on a comparable regimen at 10 ml/kg. Throughout gestation all rats were observed twice daily for toxicity and body weights were recorded at

appropriate intervals. All surviving animals were sacrificed on gestation day 20 for a scheduled uterine examination.

Result : CLINICAL OBSERVATIONS AND SURVIVAL

All of the animals in the 150 and 200 mg/kg/day study groups and four in the 100 mg/kg/day study group died between gestation days 7 and 11. The cause of death for these 14 rats was attributed to overt toxicity. All of the animals in the 0, 10 and 50 mg/kg/day study groups and one in the 100 mg/kg/day study group survived to the scheduled sacrifice. Clinical observations noted in the animals that did not survive to the scheduled sacrifice included lethargic behaviour, ataxia, prostrate behaviour, tachypne, body cool to the touch, salivation (both before and after dosing), lacrimation of both eyes, dried red material around the eyes and nose, gasping, shallow respiration, decreased defecation and urination, and wet yellow urogenital staining. Alopecia on various body surfaces was a primary clinical observation throughout the study and was not considered compound-related

based on comparable frequencies in all treated groups. Convulsions were noted once in one animal in the 100 mg/kg/day on gestation day 8 (the animal died on gestation

day 11).

In the 50 and 100 mg/kg/day dose groups, clinical observations noted in the surviving animals were similar to those that died. Lethargic behaviour and ataxia occurred in four animals in the 50 mg/kg/day dose group and one animal in the 100 mg/kg/day dose group, primarily during the initial dosing days (gestation days 6-9). Prostrate

behaviour and tachypnea were observed in one animal in each of the 50 and 100 mg/kg/day study groups, again primarily during gestation days 6-9. Dried red material around the nose and mouth, and wet yellow urogenital staining were noted once in the 100 mg/kg/day dose group. Dried red material around the nose was also seen twice in the 50 mg/kg/day study group. Salivation approximately one hour following dosing was observed once in the 50 and 100 mg/kg/day dose groups. Alopecia on various body surfaces was observed similarly in all of the treated groups as well as the control group. Based upon the frequencies in the treated groups, this was not considered compound-related.

## **BODY WEIGHTS**

In the 200 mg/kg/day DPG-treated group, all animals died during the first three days of compound administration. In the 150 mg/kg/day dose group, the only measurement was a body weight loss prior to death.

A mean body weight loss occurred in the 100 mg/kg/day dose group during the first three days of compound administration (gestation days 6-9) as well as the last four days of dosing (gestation days 12-16). This resulted in a loss over the entire treatment period (gestation days 6-16). Following treatment, the mean body weight gain in this dose group was less than the corresponding control group gain (gestation days 16-20). Mean body weights were decreased on gestation days 9, 12, 16 and 20.

A mean body weight loss occurred in the 50 mg/kg/day study group during the first three days of DPG administration, resulting in a markedly decreased gain over the entire treatment period (gestation days 6-16). Following treatment, the mean body weight gain in this dose group was greater than the corresponding control group gain (gestation days 16-20). Mean body weights were decreased on gestation days 9. 12. 16 and 20.

In the 10 mg/kg/day treated group, slight differences in the group mean body weights and group mean body weight gains were not considered compound-related when compared to those in the control group.

## **GESTATION DAY 20 UTERINE EXAMINATION**

No animals in the 150 and 200 mg/kg/day dose groups survived to the scheduled sacrifice and only one animal survived to the scheduled sacrifice in the 100 mg/kg/day group. Administration of DPG throughout the major period of organogenesis had no adverse effect on intrauterine survival in the 10 and 50 mg/kg/day study groups. In both of these treated groups, the mean post-implantation loss and the mean numbers of corpora lutea, implantation sites and viable foetuses were comparable to the control group.

## **NECROPSY EXAMINATIONS**

Necropsy findings for the 14 rats which died were similar. The necropsy examinations of these animals showed congestion of the liver, kidneys, lungs, stomach and intestines, haemorrhagic intestines with loss of epithelium, enlarged adrenal glands, and meningeal or basal haemorrhage of the brain. No gross internal morphological changes were observed at the time of the uterine examination in the 10 and 50 mg/kg/day treated groups.

- : MLPC, Rion-des-Landes, France
- : A total of fourteen animals in this study died. These

animals were in the 100, 150 and 200 mg/kg/day treated groups. Clinical signs of toxicity were observed in the 50, 100, 150 and 200 mg/kg/day dose groups. An overall reduction of body weight gain was evident in the 50 mg/kg/day dose group as well as a body weight loss during the first three days of DPG administration. Intrauterine survival was not affected by treatment at the 10 and 50 mg/kg/day dose levels. Based on the results of this study, dose levels of 5, 25, and 50 mg/kg/day were selected for the definitive

teratology study with DPG.

**Reliability** : (1) valid without restriction

06.09.2001 (102)

Species : rat Sex : female

**Strain** : Sprague-Dawley

Route of admin. : gavage

**Exposure period** : days 6-15 of gestation

Frequency of treatm. : once daily

**Duration of test** : animals were sacrificed at day 20 of gestation

Doses : 5, 25 or 50 mg/kg/day
Control group : yes, concurrent vehicle
NOAEL maternal tox. : = 5 mg/kg bw

NOAEL treatogen. : = 25 mg/kg bw

Method : other: EPA Health Effects Test Guidelines 560/6-82-001

Year : 1982 GLP : yes Test substance : no data

Method

Potential maternal, embryotoxic and teratogenic effects of DPG were evaluated in this study in rats. DPG was admixed in 0.5% aqueous Methocel and administered orally by gavage to three groups of 25 bred Charles River COBS CD female rats as a single daily dose from days 6 through 15 of gestation. Dose levels of 5, 25 and 50 mg/kg/day were selected. For comparative purposes, 25 control females were concurrently dosed with 0.5% aqueous Methocel on a comparable regimen at 10 ml/kg/day. Throughout gestation, all females were observed twice daily for toxicity and body weights were recorded at appropriate intervals. On day 20 of gestation, all surviving females were sacrificed for Cesarean section; fetuses were weighed, sexed and examined for external, skeletal and soft tissue anomalies and developmental variations.

Result

CLINICAL OBSERVATIONS AND SURVIVAL Alopecia on the forepaws and forelegs was observed in one animal in the 50 mg/kg/day group prior to dosing on gestation day 6 and in all study groups during the treatment period, with an increased incidence and duration noted in the 50 mg/kg/day group. During the treatment period, hair loss was extensive in the 50 mg/kg/day group in the pelvic, abdominal, thoracic, urogenital, inguinal, dorsal back and tail areas. All animals in this dose group were lethargic and had tachypnea and decreased limbtone during the treatment period and with one exception all animals were prostrate and ataxic. A few animals were hypersensitive to the touch, salivated and had piloerection during the treatment period. Clonic convulsions, lacrimation, clear nasal discharge, dried red material around the nose, red urogenital discharge and yellow urogenital matting were observed as single incidences in the 50 mg/kg/day group.

100 / 146

Lethargic behavior, salivation prior to dosing, hair loss in

the pelvic and abdominal areas and dried brown material around the mouth were each noted once in different animals in the 25 mg/kg/day group and may be related to treatment with DPG. No clinical signs of toxicity were observed in the 5 mg/kg/day group.

One female in the 5 mg/kg/day group delivered 6 externally normal full-term pups on presumptive gestation day 19. Based on the size and development of the pups, there was an obvious error in the detection of mating. The dam was internally normal except for enlarged mesenteric I ymph nodes. All other females survived to the scheduled sacrifice.

## **BODY WEIGHTS**

Mean maternal body weight gain in the 50 mg/kg/day dose group was significantly decreased at all intervals during the treatment period. The most severe decrease (p < 0.01) occurred during the last four days of treatment (gestation days 12-16). The mean body weight gain in the 50 mg/kg/day group was very slightly increased after the treatment period (gestation days 16-20) when compared to the vehicle control group. This resulted in significantly decreased (p < 0.01) body weight gains for the entire gestation period (days 0-20).

Group mean body weights were slightly decreased on gestation day 9 and significantly decreased at p < 0.01 on gestation days 12, 16 and 20 in the 50 mg/kg/day group.

Mean body weight gain in the 25 mg/kg/day group was very slightly decreased during the overall treatment period (gestation days 6-16) when compared to the vehicle control group. This effect may be related to treatment as there was also a very slight increase in body weight gain following treatment. However, mean body weights in the 25 mg/kg/day group were comparable to the vehicle control group throughout gestation. Body weights and body weight gains in the 5 mg/kg/day group were not affected by treatment with DPG.

# GESTATION DAY 20 CESAREAN SECTION DATA

In all groups treated with DPG, foetal sex ratios, the mean numbers of viable foetuses, implantation sites and corpora lutea were comparable to the vehicle control group. Mean foetal weights in the 5 and 25 mg/kg/day groups were comparable to the vehicle control. Mean foetal weight in the 50 mg/kg/day group was significantly reduced (p < 0.05) when compared to the vehicle control group. Mean postimplantation loss was slightly increased in the 5 mg/kg/day group due to one female with twelve early resorptions. This increase was not considered biologically meaningful since the effect was not observed at the 25 mg/kg/day dose level. An increase in mean post-implantation loss was also apparent in the 50 mg/kg/day group. One female in the 50 mg/kg/day had all five of the late resorptions occurring in this study, which may be a secondary effect of maternal toxicity. Internal gross necropsy findings for females sacrificed at the scheduled laparotomy such as cystic ovaries, pitted kidneys, white foci or nodules on the lungs and hydronephrosis are considered normal for animals of this strain and age and could not be attributed to the compound.

FETAL MORPHOLOGICAL DATA

ld 102-06-7 5. Toxicity Date 14.11.2001

> The infrequent occurrence of foetal malformations observed in this study was not indicative of a response to treatment with DPG; each study group, including the control, had one foetus with malformations. One foetus in the control group had multiple anomalies including vertebral agenesis. mandibular microagnathia, a dome-shaped head and microphthalmia. Situs inversus was observed in one foetus in the 5 mg/kg/day group, anophthalmia and internal hydrocephaly were observed in one foetus in the 25 mg/kg/day group and a thread-like tail with anal atresia was observed in one foetus in the 50 mg/kg/day group. Developmental variations observed in the DPG groups were similar to those in the control group except for an increase in the number of fetuses with unossified sternebrae (#5 and/or #6), reduced ossification of the thirteenth ribs, 25 presacral vertebrae and bent ribs in the 50 mg/kg/day group. Reduced ossification would be expected in view of the foetal body weight inhibition at this dose level. The increased number of foetuses with bent ribs in the 50 mg/kg/day dose group is probably associated with maternal toxicity. Although three foetuses from one dam in the 25 mg/kg/day group had bent ribs, the incidence is within the range of our historical control data. In addition, maternal toxicity was slight at this dose level and foetal body weight inhibition was not apparent. The expression of bent ribs at the 25 mg/kg/day dose level was not considered compound-related.

Source Conclusion MLPC, Rion-des-Landes, France

No deaths occurred in this study. Numerous clinical signs of toxicity were observed in many animals in the 50 mg/kg/day group such as extensive hair loss, tachypnea, decreased limbtone, prostrate and lethargic behavior, ataxia, hypersensitivity to touch, salivation and piloerection. Lethargic behavior, salivation prior to dosing, hair loss in the pelvic and abdominal areas and dried brown material around the mouth were each observed once in different animals in the 25 mg/kg/day group. No clinical signs of toxicity were observed in the 5 mg/kg/day dose group. Mean body weight gain in the 50 mg/kg/day group was significantly decreased during the treatment period (gestation days 6-16) when compared to the vehicle control group. The most severely decreased mean body weight gain occurred during the last four days of treatment (12-16). The body weight gain after the treatment period (days 16-20) in this group was greater than in the control group. Mean body weights in the 25 mg/kg/day group were comparable to the vehicle control throughout gestation. However, mean body weight gain over the treatment interval (gestation days 6-16) in this dose group was slightly reduced and considered compound-related. Mean maternal body weights and body weight gains in the 5 mg/kg/day group were not affected by treatment with DPG. A slight increase in mean post implantation loss and a significant decrease in mean foetal body weight occurred in the 50 mg/kg/day group. No biologically meaningful differences in the mean numbers of viable foetuses, post-implantation loss, implantation sites, corpora lutea, foetal body weights and foetal sex ratios were apparent in the 5 and 25 mg/kg/day groups when compared to the control group. Maternal gross necropsy findings and foetal malformation data did not indicate an adverse res ponse to treatment with DPG in any dose group. The increase in reduced ossification in the 50 mg/kg/day

foetuses would not be unexpected in view of the significantly reduced foetal weight at this dose level. Bent ribs are not associated with a teratogenic response in the absence of other malformations but are often associated with maternal stress and toxicity7. Bent ribs in the seven foetuses from three litters in the 50 mg/kg/day group are a result of maternal toxicity. Three foetuses from a single litter in the 25 mg/kg/day group had bent ribs, however, the data at this dose level suggests that this was a spontaneous expression of biological variation. The incidence of this particular variant is within the range of the historical control data and contrary to the results at the 50 mg/kg/day dose level, maternal toxicity was marginal and foetal body weight was not adversely affected.

In conclusion, DPG induced severe maternal toxicity at a dose level of 50 mg/kg/day. Foetotoxicity was also expressed at this dose level by a significantly reduced mean foetal body weight and by an increase in foetal variations. Maternal toxicity was slight at a dose level of 25 mg/kg/day although a foetotoxic response was not apparent. No sign of teratogenic induction was observed at any of the dose levels selected for investigation in this study.

Reliability : (1) valid without restriction
Flag : Critical study for SIDS endpoint

06.09.2001 (103)

Species: mouseSex: femaleStrain: ICRRoute of admin.: gavage

**Exposure period**: days 0-18 of gestation

Frequency of treatm. : once daily

 Duration of test
 : until day 18 of pregnancy

 Doses
 : 0.25, 1, 4 or 10 mg/kg/day

 Control group
 : yes, concurrent vehicle

**NOAEL maternal tox.** : = 4 mg/kg bw**NOAEL teratogen.** : >= 10 mg/kg bw

Method : other: similar to OECD Guide-line no 414

Year : 1980
GLP : no
Test substance : no data

Method

Mature ICR female mice were placed with males for 16 hours. Mature ICR female mice were placed with males for 16 hours. When a vaginal plug was found the following morning, it was considered to be day 0 of pregnancy, and these females were isolated. All animals were given standard pellets and water ad libitum.

DPG was suspended in 0.5 percent carboxymethyl cellulose solution and was given by gastric intubation. Since all non-pregnant mice given oral DPG in daily doses of 15 mg/kg of body weight died within six days, 10 mg/kg was chosen as the highest dose. Pregnant mice were given DPG daily orally in doses of 0.25, 1.0, 4.0, or 10 mg/kg of body weight from day 0 to day 18 of pregnancy. Control pregnant mice were given the vehicle alone. The volume of each treatment was 5 ml/kg. All treated mice were killed by cervical dislocation on day 18 of pregnancy. The uteri were removed and examined for site of implantation and foetal death. The live fetuses were weighed and examined for gross external malformations. About 50 percent of the foetuses per lifter were fixed in

Bouin's solution for soft tissue examination by the method of Barrow and Taylor (1968) under a dissecting microscope. The remaining fetuses were cleared in KOH and stained with alizarin red S by Dawson's method (1927) for detection of skeletal variations and the state of ossification. Student's t-test was employed for comparison of the maternal body weight, litter size, foetal body weight, and number of ossified bones among five groups. Comparison of frequency of dead or malformed foetuses and of incidence of skeletal variations or anomalous ossification among the five groups was done with thé rank-sum test (Wilcoxon and Wilcox, 1965). No abnormalities were detectable in either the experimental

No abnormalities were detectable in either the experimental or control mothers during pregnancy. There was no conspicuous difference in maternal body weight during pregnancy between treated and non-treated groups. There were no significant differences in the percentage of dead foetuses, early or late in gestation, average litter size, sex ratio, and body weight between the experimental mice and the controls. The mean number of implants was significantly lower in the mothers treated with 10 mg/kg/day than in the control mothers.

Effect of Diphenylguanidine on Pregnant Mice and Their Fetuses

Dose No. of	Total No.	Dead f	fetus
(mg/kg) pregnant mice (average no. of implants)	of implants No.	Early (%)	
0 20 (12.7±0.3)	253	4.3	2.8
0.25 19 (12.1±0.7)	229	6.1	1.3
1.0 20 (13.3±0.5)	266	5.3	1.9
4.0 20 (13.7±0.3)	261	5.7	8.0
10.0 7 (11.3 o_0.4)*	79	2.5	0.0

<sup>\*</sup> Significant ifference from control (P<0.05).

Dose (mg/kg	١	Live Fetus	
(mg/kg	average  No. in ratio	Sex	 Body Weight (g) 
	Litter (M/F ±SEM x100)	Mean ± SEM	Mean ± SEM
0 0.25 1.0	11.8±0.4 153 11.1±0.7 121 12.4±0.5 89	1.42±0.02 1.46±0.03 1.36±0.04	1.34±0.02 1.38±0.02 1.33±0.03
4.0 10.0	11.3±0.7 109 11.0±0.5 126	1.40±0.02 1.40±0.02	1.31±0.05 1.32±0.02

There were no significant differences in the incidence of 104 / 146

Result

malformed foetuses between the experimental and the control groups. As for the type of malformations, open eye lids were seen in both the control and the experimental groups except in the fetuses of mothers treated with 10 mg/kg/day. One case of postaxial polydactyly and one club foot were seen in foetuses of mothers treated with 1 mg/kg/day. The incidence of anomalies of the sternebrae was significantly lower than normal in the foetuses from mothers treated with 0.25 mg/kg. Ossification of the talus was significantly retarded in the foetuses from mothers treated with 4.0 mg/kg/day. No significant abnormalities were detected in the soft tissues of either experimental or control foetuses.

Effect of Diphenylguanidine on Mouse Fetus at Term.

Dose (mg/kg		Malformed fetus		
(1119/109	Frequency (%)	Type (No.)		
0 0.25 1.0	0.4 0.4 1.6	open eyelids (1) open eyelids (1) open eyelids (2) postaxial polydactyly (1) club foot (1)		
4.0 10.0	0.4 0	open eyelids (1) 		

Effects of Diphenylguanidine on Skeletal Development of Mouse Fetuses.

Dose (mg/l	(g)	Ту	Type of variation		
No. of	No. c	of		-	
observ	ed ma	alformed Sterr	nebrae Cervica	Lumbar	
fetuses	fetu	ses (%)	rib ri	b	
			(%) (%)		
0 115	0	7.8	1.7	16.5	
0.25 101	0	1.0*	6.9	24.8	
1.0 117	0	10.3	4.3	23.1	
4.0 119	0	8.4	0.8	14.3	
10.0 38	0	2.6	5.3	15.8	

<sup>\*</sup> Significant difference from control (P<0.05).

		Ossific	ation		
	,	No. of s phalanges in hindfoot	No. of ossified sacral vertebrae	ossifie	ed
	Mean ±SEM	Mean ±SEM	Mean ±SEM	(%)	talus (%)
					(70)
0	6.05±0.20	5.82±0.30	12.86±0.3	32 73.9	10.4
0.25	6.08±0.27	6.22±0.32	12.81±0.4	1 70.3	4.0
1.0	6.10±0.16	5.77±0.27	12.29±0.4	0 70.1	3.4
4.0	6.27±0.15	6.01±0.26	12.80±0.3	3 63.0	2.5*
		105 / 146			

10.0 5.60±0.35 5.47±0.45 12.44±0.39 57.9 5.3

-----

\* Significant difference from control (P<0.05).

Source : MLPC, Rion-des-Landes, France

**Reliability** : (2) valid with restrictions

Flag : Critical study for SIDS endpoint

06.09.2001 (104)

#### 5.8.3 TOXICITY TO REPRODUCTION, OTHER STUDIES

#### 5.9 SPECIFIC INVESTIGATIONS

#### 5.10 EXPOSURE EXPERIENCE

Remark : Toxicity:

occupational accidental exposure of workers to DPG can cause

burning of the eyelids, reddening of the eyes, a bitter

taste in the mouth and a painful sensation in the esophagus; flabbiness of the gums and a reduction in the acidity of the gastric juice, tending to achylia, were also reported (no

further information available). Occupational exposure

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.11.2000 (105)

**Remark**: Occupational medicine:

workers (29-58 years old) occupationally exposed for 3-15 years to DPG were checked up; from ca. 30 % of the examined

subjects different complaints were reported, mostly gastritis, cholangitis, cholecystitis, neurological

disturbances and dermatitis; beside these symptoms in some

patients bronchial asthma, rhinitis, neuropathy,

polyathritis, hypertonia and lithiasis were diagnosed and the liver function was disturbed: changes in the protein metabolism and increased bilirubin levels (no further

information available)
Occupational exposure

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

24.11.2000 (76)

Remark : At an employee who was working in the area of weigh out- and

preparation-procedure in a tyre factory, a work-place

concentration of 0.26 mg/mE3 test substance was measured by the US Occupational Safety and Health Administration (1980)

Occupational exposure

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

24.11.2000 (106)

Remark : Sensitization

**Result**: Patch testing of 49 human volunteers with 70 % DPG in

petrolatum produced no positive rections following initial application; 19 of the 49 subjects displayed positive reactions during subsequent exposures, two subjects displayed positive reactions upon rechallenge 2 weeks later.

Source : MLPC, Rion-des-Landes, France Reliability : (1) valid without restriction

24.11.2000 (107)

Remark : Sensitization

**Result** : 74 cases of contact eczema caused by rubber were

investigated; 2 were related to hypersensitivity to DPG.

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

24.11.2000 (108)

**Remark**: 5 patients with contact dermatitis caused by rubber filler

in eyelash curlers were tested with DPG in crystals, and in dilutions of 0.01, 0.1 and 0.25 % in 90 % alcohol; patch tests were applied for 48 h, and test sites were observed at 72 h, 92 h and 1 w eek. 0/5 patients reacted positively.

Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

24.11.2000 (109)

**Remark** : 24 patients with contact eczema were tested with a 1 %

solution of DPG in petrolatum (48 h), reactions were read 1

h after removal. 0/24 patients reacted positively.

Sensitization

**Source** : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

24.11.2000 (110)

**Remark**: 5 patients with contact eczema caused by rubber products

were tested; one patient showed hypersensitivity to DPG.

Sensitization

**Source**: MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (111)

**Remark** : 63 patients with contact eczema caused by rubber products

were tested (24 h, readings: 30 min and 24 h after removal);

15 patients showed a positive reaction to DPG.

Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (112)

**Remark**: 10 patients with contact dermatitis caused by rubber

products were tested; 3 patients showed a positive reaction

to DPG (1 % in Ungt. alc. lanae).

Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (113)

**Remark**: 17 patients with contact dermatitis caused by rubber

products were tested (readings: 24 h and 48 h); 6 patients

showed positive reactions to DPG (1 %).

Sensitization

**Source**: MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (114)

**Remark**: 3 patients with contact der matitis due to Spandex (a

synthetic polyurethane elastomer) were tested; one patient showed a positive reaction to DPG (2 % in petrolatum) with

erythema, edema, papules and vesicles.

Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (115)

**Remark** : 59 patients with possible contact dermatitis to footwear

were tested; no reactions to DPG (1 % in petrolatum) were

observed. Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (116)

**Remark**: 1/9 persons tested showed positive reactions to DPG.

Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (117)

**Remark**: 1600 patients of an allergy ambulatorium were tested; 25

showed positive reactions to DPG (1 % in petrolatum)

Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (118)

**Remark** : The patch tests were made on the first group of 4 patients

with current contact dermatitis caused by rubber products, the second group of 5 subjects with hyperpigmentation in the skin in the past and the third group of 27 healthy subjects, namely 36 subjects in the total; all patients of group 1

reacted positive on DPG and the reactions were stronger than in the other groups, in group 2 with a history of dermatitis one patient developed a slight erythema and in the group of

healthy subjects 2 reacted with slight erythema.

Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (119)

**Remark**: 35 patients with shoe dermatitis were tested (treatment: 48

h, readings: at 72 h and 96 h); 2 patients reacted positive

to DPG (1 % in petrolatum).

Sensitization

**Source**: MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (120)

**Remark**: 32 patients with different kinds of skin-disease were

tested; none of these patients reacted to DPG (1 % in soft

yellow paraffine).

Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (121)

**Remark**: 534 patients with hand eczema were tested (treatment: 48 h,

readings on the third day); 6 patients reacted positive to

DPG (1 and 2.1 % in ethanol).

Sensitization

Source : MLPC, Rion-des - Landes, France

**Reliability** : (4) not assignable

27.12.2000 (122)

Remark : A patient with facial contact dermatitis following scuba

diving probably caused by the mask was tested (treatment: 20

min, 48 h) with 10 rubber chemicals; he did not react

positive to DPG (1 % in petrolatum).

Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (123)

**Remark**: 15 patients with rubber boot dermatitis were tested

(treatment: 48 h, readings: 20 min after removal and when negative 96 h to one week later); 1 patient reacted at DPG

(1 %) with significant erythema.

Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (124)

**Remark**: 744 patients with contact dermatitis were tested (readings

at 48 and 96 h); 74 patients showed positive reactions to DPG (1 % in yellow paraffin); because of possible primary skin irritation caused by DPG some positive readings were

difficult to judge.

Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (125)

**Remark**: 47 bricklayers suffering from contact eczema were tested; 6

Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (126)

ld 102-06-7 5. Toxicity Date 14.11.2001

Remark : 844 patients with contact dermatitis were tested (readings

at 48 h and 96 h after removal); 44 showed positive

reactions to DPG (1 % in petrolatum).

Sensitization

MLPC, Rion-des-Landes, France Source

Reliability (4) not assignable

27.12.2000 (127)

Remark : 1 patient probably suffering from nylon-clothes friction

dermatosis was tested and showed a slight positive reaction

to DPG. Sensitization

MLPC, Rion-des-Landes, France Source

Reliability (4) not assignable

27.12.2000 (128)

Remark 106 patients with contact dermatitis due to rubber articles

were tested; DPG gave so many irritant reactions that it was

impossible to assess whether or not it was also a

sensitizer.

Sensitization

Source MLPC, Rion-des-Landes, France

Reliability (4) not assignable

27.12.2000 (129)

Remark Workers exposed to DPG and suffering from various complaints

> were tested after scarification of the skin: 3 % showed positive reactions to DPG (no further information

available). Sensitization

Source MLPC, Rion-des-Landes, France

Reliability (4) not assignable

27.12.2000 (76)

Remark 229 patients suffering from skin diseases, mostly eczematous

eruptions were tested; 18 patients showed positive reactions

to DPG (0.5 % in petrolatum).

Sensitization

Source MLPC, Rion-des-Landes, France

Reliability (4) not assignable

27.12.2000 (130)

Remark : 6 cattle farmers with occupational contact dermatitis due to

> rubber chemicals (main cause of rubber contact on the farms appeared to be the milking machine) were tested (readings at 48 h and 72 h, according to directions of the "International Contact Dermatitis Research Group"); 2 showed positive

reactions to DPG (1 %).

Sensitization

MLPC, Rion-des-Landes, France Source

Reliability (4) not assignable

27.12.2000 (131)

Remark 50 patients with occupational contact dermatitis were

tested; 2 showed positive reactions to DPG.

Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (132)

Remark : 119 eczema patients were tested; 3 showed positive reactions

to DPG (1 %). Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (133)

**Remark**: 34 agricultural workers with contact dermatitis were tested;

4 showed positive reactions to DPG; as "control" group 244 patients with contact dermatitis were tested; 13 showed positive reactions to DPG; the authors supposed that the increased sensitivity to DPG in agricultural workers is caused by a possible cross sensitivity to some pesticides derived from guanidine (e.g. Cyprex = dodecylguanidine) and to other products with related structures (e.g. cyanamides).

Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (134)

**Remark**: 31 subjects were tested (readings: 72 h p.a.; 2 showed

positive reactions to DPG (1 %)); no further information

available. Sensitization

Sensitization

Source : MLPC, Rion-des-Landes, France Reliability : (4) not assignable

27.12.2000 (135)

**Remark** : 61 patients with atopic contact dermatitis were tested

(readings: 48 h and 72 h p.a.); 2 showed positive reactions to DPG (1 %); the patients were subjected to a second patch test 3-15 years (average 7.3 years) following the first contact sensitivity examination; 3 showed positive reactions to DPG (1 %); 2 patients were positivized and one was negativized; the authors suggest that contact reactions in atopic patients are not linked to susceptibility to skin

reactions and tend to increase with time.

Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (136)

**Remark**: 105 subjects were tested and 3 showed positive reactions to

DPG (1 %). Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (137)

**Remark**: A worker of a rubber factory had symptoms of allergic

rhinitis only while working and breathing the special atmosphere of the factory area where tires are completed;

patch tests showed a positive urticarial immediate type reaction to DPG (1 % in petrolatum); the 48-h reactions of

the patient were negative.

Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

27.12.2000 (138)

Remark : 1 patient with contact urticaria caused by rubber gloves was

tested with DPG (scratch chamber test); patch test was applied for 48 h, and test was read at 20 and 60 min, 48 and

96 h. No reaction was observed.

Sensitization

Source : MLPC, Rion-des-Landes, France

27.12.2000 (139)

**Remark**: The purpose of this study was to examine the results of

patch testing with the rubber components on a standard screening tray and compare them with the results of testing with a special series of 27 rubber components (rubber tray). 1670 patients were patch tested with the screening tray and 317 of these were also tested with the rubber tray. 4.4% of

those tested with DPG had a positive response.

Sensitization

Source : MLPC, Rion-des-Landes, France

**Reliability** : (2) valid with restrictions

27.12.2000 (140)

**Remark** : Additional references cited in the summary table of section

7.1.

Sensitization

**Source** : MLPC, Rion-des-Landes, France

26.06.2001 (141) (142) (143) (144) (145) (146) (147) (148) (149) (150) (151) (152) (153)

(154) (155)

#### 5.11 ADDITIONAL REMARKS

Type : Toxicokinetics

**Result** : Absorption and disposition.

A comparison of DPG tissue distribution and excretion following oral vs iv administration of 15.15  $\mu mol/kg$  indicates that gastrointestinal absorption of DPG was near complete and that tissue distribution and excretion were not significantly affected by the route of administration (Table 1). A comparison of tissue distribution and excretion over the 100-fold dose range studied indicates that absorption and disposition of DPG are not significantly affected by

dose in the range studied (Table 1).

Table 1: Distribution and excretion of radioactivity 1 day after administration of [14C]-DPG to F344 male rats

Percentage total dose

Intravenous oral

•				
Tissue	15.15	1.52	15.15	151.5 mmol/kg
Muscle Adipose Skin	1.37±0.08 1.18±0.08 0.56±0.07 0.52±0.07 0.24±0.01	1.08±0.02 0.62±0.03 0.40±0.41	1.23±0.11 1.08±0.01 0.47±0.03 0.41±0.05 0.23±0.01	1.09±0.08 0.49±0.03 0.39±0.02
Feces	creted 35.50±3.38 45.67±9.01 31.17±6.12	48.25±4.49	45.26±2.9	2 43.61±2.83 4 39.39±1.84 7 83.00±2.41

<sup>\*</sup> DPG-derived radioactivity excreted in urine and feces in 24 hr. The remainder is still present in tissues and intestinal contents.

Tissue distribution vs time.

Major organ and tissue volumes were sampled for radioactive content at various time points following iv administration of a 15.15-µmol/kg DPG dose. Initially the highest concentration (% total dose/g tissue) of DPG-derived radioactivity was observed in liver followed by kidney and lung (Table 2). The peak concentration in liver was reached in 45 min after administration whereas the DPG-derived radioactivity in other tissues with the possible exception of testes and adipose tissues showed a decline. The concentration of DPG-derived radioactivity in liver was higher than in other tissues at every time point examined. At 24 hr post-exposure the concentration of DPG in liver was 5-10 times higher than in most other tissues. Interestingly, the brain and most lean tissues contained similar concentrations of DPG-derived radioactivity at comparable time points.

Table 2: Concentration of DPG-derived radioactivity in male F-344 rats vs time

	Percenta	ge tota	l dose	 #/g tissue
Tissue 15 m	in 45 min	2 hr	6 hr	24 hr

Liver  $2.20\pm0.23\ 2.44\pm0.41\ 1.21\pm0.33\ 0.42\ 0.09\ 0.17\pm0.02$  Kidney  $1.82\pm0.30\ 1.35\pm0.35\ 0.38\pm0.14\ 0.19\pm0.06\ 0.02\pm0.004$  Muscle  $0.44\pm0.04\ 0.26\pm0.08\ 0.08\pm0.04\ 0.02\pm0.01\ 0.01\pm0.009$  Blood  $0.24\pm0.02\ 0.18\pm0.03\ 0.07\pm0.02\ 0.03\pm0.006\ 0.02\pm0.001$  Skin  $0.20\pm0.05\ 0.18\pm0.02\ 0.08\pm0.02\ 0.03\pm0.01\ 0.02\pm0.002$  Adipose  $0.10\pm0.01\ 0.11\pm0.04\ 0.04\pm0.02\ 0.02\pm0.01\ 0.03\pm0.003$  Lungs  $1.05\pm0.16\ 0.35\pm0.12\ 0.19\pm0.06\ 0.06\pm0.03\ <0.01$  Spleen  $0.49\pm0.02\ 0.27\pm0.04\ 0.09\pm0.03\ 0.04\pm0.02\ <0.01$  Heart  $0.41\pm0.05\ 0.23\pm0.05\ 0.07\pm0.02\ 0.02\pm0.01\ <0.01$  Brain  $0.39\pm0.03\ 0.32\pm0.03\ 0.09\pm0.02\ 0.02\pm0.01\ <0.01$  Thymus  $0.34\pm0.01\ 0.27\pm0.03\ 0.07\pm0.01\ 0.02\pm0.01\ <0.01$  Testes  $0.10\pm0.02\ 0.19\pm0.05\ 0.14\pm0.02\ 0.06\pm0.002\ <0.01$  Adrenals  $0.14\pm0.03\ 0.06\pm0.03\ <0.01$ 

#15.15 mmol/kg, iv.

ld 102-06-7 5. Toxicity Date 14.11.2001

> The distribution of radioactivity in rat tissues at various time points following a single iv dose of DPG of 15.15 µmol/kg is presented in Table 3. DPG-derived radioactivity was readily cleared from all tissues so that within 24 hr after exposure the total tissue burden was approximately 10-fold lower than that observed at the earliest time point, 15 min (Table 3).

Table 3: DPG-DERIVED RADIOACTIVITY IN MAJOR F344 RAT TISSUES **VS TIME** 

Percentage total dose

Tissue 15 min 45 min 2 hr 6 hr

Blood 3.52±0.33 2.60±0.41 1.18±0.15 0.55±0.05 0.24±0.01 Liver 17.69±1.73 20.04±2.65 10.17±1.13 3.27±0.51 1.37±0.08

Kidney 3.05±0.61 2.24±0.72 0.62±0.21 0.30±0.08 0.03±0.01 Thymus 0.18±0.03 0.11±0.03 0.03±0.01 <0.01 <0.01 Skin 5.73±1.26 5.05±0.52 2.86±0.39 0.87±0.37 0.52±0.07 Adipose 1.89±0.13 2.08±0.87 0.80±0.12 0.44±0.34

0.56±0.07 Muscle 40.01±2.28 22.88±7.73 8.33±2.56 1.99±1.31 1.18±0.08

Brain 0.64±0.06 0.55±0.03 0.15±0.03 0.02±0.01 <0.01 Spleen 0.21±0.03 0.11±0.01 0.04±0.02 0.01±0.01 <0.01 Testes 0.24±0.05 0.43±0.11 0.32±0.04 0.15±0.01 <0.01 Lungs 0.96±0.10 0.39±0.12 0.22±0.08 0.06±0.03 <0.01 Heart 0.27±0.04 0.15±0.03 0.05±0.01 <0.01 <0.01 Small

intest, 0.82±0.22 1.28±0.48 1.90±0.46 0.50±0.15  $0.05 \pm 0.05$ 

Small intest. cont.

1.31±0.46 7.15±2.15 11.43±2.17 3.57±1.89 0.17±0.10 Large intest.

0.40±0.21 0.70±0.30 0.32±0.39 0.51±0.25 0.15±0.12 large intest. cont.

0.08±0.03 0.10±<0.01 0.10±0.05 7.74±3.71 1.44±0.29

#iv dose of 15.15 µmol/kg.

Clearance of DPG-derived radio-activity from the tissues followed a biphasic curve. The initial phase of the curve was rapid and accounted for a major portion of the dose. The second component was much slower. The rapid and relatively nonspecific distribution of DPG front blood to the other tissues is well illustrated by the amount of DPG in muscle. Muscle accounts for approximately 50% of the tissue volume of the rat, has no apparent affinity for DPG, and contained approximately 40%, of the DPG dose within 15 min after an iv administration. This radioactivity was rapidly cleared from muscle so that by 24 hr after injection only 1.2% of the total injected dose was still present (Table 3). The data in Table 2 indicate that clearance of DPG-derived radioactivity front most lean tissues occurred at rates similar to those described for muscle. Skin and adipose tissue receive a lower portion of the blood supply than do the lean tissues and thus received less DPG following the iv dose. The lower perfusion rate of adipose tissue may account for the fact that the peak concentration of DPG-derived radioactivity in

this tissue was observed at 45 rather than 15 min. The initial higher concentrations of DPG-derived radioactivity in liver and kidney may be accounted for by the higher perfusion of these tissues with blood. In kidney, this concentration decreases sharply from 6 to 24 hr which might suggest that DPG elimination through urine is near complete by 24 hr. On the other hand, DPG appears to have an affinity for liver as evidenced by the higher DPG concentrations in liver at all time points examined (Table 2). Clearance of most of the DPG-derived radioactivity from liver appears to be similar to that of other tissues. However, the concentration of DPG-derived radioactivity in liver remained high relative to other tissues because of the higher concentrations initially sequestered by liver. The initial higher concentration of DPG-derived radioactivity in kidney was cleared more rapidly than from other tissues.

#### Excretion

Total excretion of [14C]DPG-derived radioactivity was determined by daily collection of urine and feces from each animal held from 1 to 3 days. Approximately equal amounts of radioactivity were excreted in both urine and feces and the relative amounts of excretion by these routes were not affected by the dose in the range studied or the route of administration (Table 1). Approximately 80% of the radioactivity is excreted in urine and feces 24 hr after an iv dose and total excretion approaches 100% in 3 days. Total clearance followed a single component exponential decay with a half-life of approximately 9.6 hr. These results indicate that DPG is not at all persistent in the rat. The importance of the feces as a route of DPG elimination indicated that much of the DPG-derived radioactivity might be eliminated in bile. The elimination of DPG in bile was studied by cannulating the common bile duct of anesthetized rats. Approximately 50% of the injected dose was excreted within 2 hr and up to 75% of the total dose excreted in 6 hr. These results indicate that DPG excretion in feces (55% in 3 days) accounts for only a portion of the DPG excreted in bile. That portion of the DPG-derived radioactivity exereted in bile and not excreted in feces most probably undergoes extensive enterohepatic recirculation and is subsequently excreted in urine.

#### Metabolism.

The nature of the [14C]DPG derived radioactivity excreted in urine and bile was examined by direct HPLC analysis (Table 4). Bile contained only small amounts of parent compound at all time points examined. Most of the radioactivity in bile (95%) was in the form of a major metabolite (Peak II) of DPG with traces of another metabolite (Peak I). The major metabolite (Peak II) excreted in bile was resistant to hydrolysis by arylsulfatase, by strong acid, or by strong base. However, incubation of this metabolite with b-glucuronidase resulted in near complete hydrolysis to yield metabolite V. It is believe that this metabolite (Peak II) is in the form of a glucuronide, the position of alucuronidation has not been determined. DPG-derived radioactivity excreted in feces was primarily (94%) in the form of metabolite V. Therefore, it appears that the glucuronide present in bile (Peak II) was subsequently hydrolysed in the intestine, most probably by intestinal flora, to release metabolite V which accounted for most of

the radioactivity excreted in feces.

HPLC analysis of urine indicated that around 28% of the radioactivity excreted in urine was in the form of parent compound. The major metabolite (Peak II) in urine accounted for approximately 37% of the total radioactivity. Treatment of this metabolite with b-glucuronidase resulted in its hydrolysis to yield metabolite V. Comparison of excretion in bile versus feces indicates that as much as 30% of the total dose is reabsorbed from the intestine after excretion in bile. Since most of this material is metabolite V, reabsorption from the intestine and reconjugation may account for most of the metabolite II excreted in urine. Two other metabolites were detected in urine. Metabolite III which eluted from the column shortly after peak II accounted for approximately 32% of the radioactivity while the unconjugated metabolite V accounted only for 3% of the radioactivity.

The nature of radioactivity retained in some of the major tissue volumes was determined at several time points after an iv injection of 15.15 µmol/kg DPG. Tissues were extracted and the extracts analysed HPLC. With the exception of liver, all tissues examined at 45 min after DPG administration contained only the parent compound. In the liver, approximately 88% of the radioactivity was present as parent compound while the rest was present as a single metabolite, Peak II (Table 4). At the 2-hr time point, Peak II was present only in liver and muscle and accounted for approximately 18 and 10% of the radioactivity, respectively. At the 6-hr time point, Peak II increased slightly in liver. while in mus cle and kidney this peak accounted for 50 and 60% of the radioactivity, respectively. In liver a major metabolite (Peak III) appeared 24 hr after DPG administration and accounted for approximately 60% of the extracted radioactivity (Table 4). Radioactivity extracted from lung, skin, and adipose tissue at the 45-min and 2-hr time points was present only in the form of the parent compound. The radioactivity extracted from other tissues at the 24-hr time point was insufficient for accurate metabolite determination.

Table 4: relative amounts of DPG and DPG-metabolites present in male F344 rat liver and excreta.

DPG metabolite (%) Time Tissue (hr) I\* II III IV V DPG(%) 88±5.7 Liver 0.75 12±1.2 Liver 2.00 18±1.9 82±4.3 Liver 6.00 30±2.1 70±6.0 Liver 24.00 30±3.3 60±4.5 10±1.1 6.00 2±1.2 95±1.7 Bile#  $3\pm0.5$ 24.00 Urine 37±1.6 32±1.4 3±0.8 28±0.8 Feces 24.00 2±1.0 94±3.5 4±1.4

# Collected continuously for 6 hr after an IV injection of 15.15 µmol/kg DPG.

The residual radioactivity present in the liver after

<sup>\*</sup> DPG metabolites separated by HPLC. Percentage represents only extractable radioactivity. # Collected continuously for 6 hr after an iv injection of

ld 102-06-7 5. Toxicity Date 14.11.2001

> multiple exposures of rats to DPG was also extracted and analysed. The metabolites present were the same and at the same ratio as those metabolites (Peaks II and III) extracted from liver 24 hr after a single iv dose of DPG. The nature of the radioactivity retained in the tissues after extraction is not known.

#### Multiple exposures.

One, three, or nine daily doses of DPG were administered to groups of three rats each. Rats were sacrificed 24 hr after the last dose. Results of these studies indicated that most DPG-derived radioactivity was readily cleared from all tissues assayed and that DPG concentrations in all tissues except liver were as low or lower after nine daily doses as compared to a single dose. However, a minor portion of the dose in liver was cleared more slowly than observed for other tissues and the concentration of DPG-derived radioactivity in liver increased significantly relative to other tissues as the number of doses increased (Table 5). Extraction and analysis of the persistent radioactivity from liver demonstrated that it represented metabolites II and III (Table 4). An analysis for radioactivity covalently bound to liver macromolecules proved negative. Therefore, the mechanism which accounts for the slower clearance of this minor component from liver is unknown. Likewise, the relevance of this slower component to any toxicity which might be associated with DPG exposure is unknown.

Table 5: Effect of single and multiple DPG doses on tissue concentrations of DPG-derived radioactivity

Concentration (pmal/a)

	Con	centration (nm	oi/g) 
Tissue	1 Dose*	3 Doses	9 Doses
		7.00.0000	
	.86±0.282	7.38±0.363	11.89±0.811
sloud (	).44±0.022	0.10±0.012	0.20±0.041
Kidney	0.58±0.106	0.29±0.042	0.72±0.134
Skin 0	.49±0.063	0.09±0.020	0.28±0.090
Adipose	0.77±0.091	0.03±0.011	0.10±0.024

Muscle 0.36±0.024 0.04±0.005 0.02±0.005

(2) valid with restrictions

: Toxicokinetics Type

Remark

Source

Reliability

27.11.2000

Dermal absorption, distribution, and metabolism of 1,3-diphenylguanidine was studied in adult female Sprague-Dawley rats. Radiolabelled DPG (0.3 µmol = 0.063) mg/animal) was applied dermally and DPG showed 10% penetration through clipped back skin of the rats in 5 d. The first-order dermal absorption rate constant as determined by least square method was 0.021 ± 0.002 d-1 (T<sub>1</sub>½ = 33.6 d). Approximately 13% of the absorbed dose remained in the body in 5 d. Retention in skin, muscle, liver, intestine and fat contributed most to the body burden of DPG-derived radioactivity in 5 d. All tissues showed tissue to blood ratios greater than 1, with liver and intestine

(156)

<sup>\*</sup> Animals were administered DPG 15.15 µmol/kg orally and sacrificed 24 hr after last dose.

MLPC, Rion-des-Landes, France

ratios of 26 at 5 d. Approximately 61% of the absorbed dose was eliminated into urine and 27% into feces in 5 d showing rapid clearance of absorbed DPG from the body. High-pressure liquid chromatography (HPLC) analysis of urine revealed two major peaks (parent compound and metabolite(s)). Within 72 h, approximately 50% of the DPG-derived radioactivity excreted in the urine was parent compound. After 72 h, the DPG-derived radioactivity in the urine was present in the form of a single metabolite, and no parent compound was detected. No parent compound was detected in feces. Two metabolites, neither of which occurred in urine, were detected in feces. The HPLC analysis of the radioactivity at the application site showed only parent compound.

Source : MLPC, Rion-des-Landes, France

**Reliability** : (2) valid with restrictions

26.06.2001 (157)

Type : Toxicokinetics

**Remark**: A pharmacokinetic analysis of DPG did not reveal

bioaccumulation of the DPG in the testes after ip

administration. The amount of DPG recovered in mice testes after a single ip administration of 25 mg/kg was 0.46  $\mu g$  at 5 min. Two or more hours after treatment, the amount of DPG

in the testes was below the limit of detectability.

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

24.11.2000 (158)

**Type** : Biochemical or cellular interactions

**Remark**: The influence of DPG on lipid metabolism in rats was

investigated after oral application: one application of 375 mg/kg = LD50, 7 applications (once daily) of 188 mg/kg = 0.5 of LD50 and 20 applications (once daily) of 0.2 of LD50; in the livers of all treated animals increased levels of triglycerides and choesterol ethers were determined; in the plasma the levels of triglyceride, cholesterol and of all phospholipide fractions were lowered and the levels of free

fatty acids increased; it was considered that these changes

were based on an inhibition of the synthesis of

phospholipids (especially lecithins) accompanied with an

increased activity of lipase in the fatty tissue

Source : MLPC, Rion-des-Landes, France

**Reliability** : (4) not assignable

06.12.2000 (159) (160) (161) (162) (163)

Type : other: Chronic toxicity

Remark : The chronic exposure of C57Bl/J6 X DBA2 mice to DPG induced

an enlargement of the spleen and a time-dependent increase of the DNA-synthesis in spleen cells (no further information

available)

Source : MLPC, Rion-des-Landes, France

Reliability : (3) invalid

24.11.2000 (164)

**Type** : other: Toxicity in chicken embryos

Remark : 3 days old White Leghorn chicken embryos were injected by

dropping the test substance (0.06-0.96 umol/egg) into the air chamber of the egg (20-30 eggs/dose); 10 control eggs

were injected with the vehicle (5  $\mu$ l acetone) only; the ED50 (concentration that induced malformations or death in 50 % of the embryos) of DPG was 0.2 umol/egg, the total mortality (on day 14) LD50 was 0.29 umol/egg, the early deaths (days

3-5) LD50 was 0.31 umol/egg.

Source : MLPC, Rion-des-Landes, France

**Test substance** : purity: technical grade

**Reliability** : (3) invalid

27.12.2000 (165) (166)

#### 6. Analyt. Meth. for Detection and Identification

ld 102-06-7 **Date** 14.11.2001

- 6.1 ANALYTICAL METHODS
- 6.2 DETECTION AND IDENTIFICATION

### 7. Eff. Against Target Org. and Intended Uses

ld 102-06-7 **Date** 14.11.2001

7.1	FUNCTION
	FITTOTO AN ADDAMINATO DE CONTROLLED
7.2	EFFECTS ON ORGANISMS TO BE CONTROLLED
7.3	ORGANISMS TO BE PROTECTED
7.4	USER
	30 <u>1</u> 1
7.5	PERIOTANICE
7.5	RESISTANCE

### 8. Meas. Nec. to Prot. Man, Animals, Environment

ld 102-06-7 **Date** 14.11.2001

8.1	METHODS HANDLING AND STORING
8.2	FIRE GUIDANCE
8.3	EMERGENCY MEASURES
8.4	POSSIB. OF RENDERING SUBST. HARMLESS
8.5	WASTE MANAGEMENT
8.6	SIDE-EFFECTS DETECTION
0.0	
8.7	SUBSTANCE REGISTERED AS DANGEROUS FOR GROUND WATER
0.7	SUBSTANCE REGISTERED AS DANGEROUS FOR GROUND WATER
8.8	REACTIVITY TOWARDS CONTAINER MATERIAL
0.0	NEAGHVILL IGWANIAGGANTAINEN WATENIAL


(1)	Bayer AG
(2)	MLPC Rion des Landes.
(3)	Monsanto Chemical Company >99%
(4)	Bayer AG, unpublished data
(5)	Fraser, D.A. & Rappaport, S., Environ. Health Perspect. 17, 45-53 (1976)
(6)	MLPC International internal data
(7)	Sax, N.I. & Lewis, R.J., Sr., Hawley's condensed chemical dictionary. Van Nostrand Reinhold Company, New York, 428 (1987)
(8)	Naunton, W.J.S., J. Soc. Chem. Ind. 45, 376-384 (1926)
(9)	Biodegradation and Bioaccumulation, Data of Existing Chemicals Based on CSCL Japan, Compiled under the Supervision of Chemical Products Safety Division, Basic Industries Bureau MITI, Ed. by CITI, October 1992. Published by Japan Chemical Industry Ecology-Toxicology & Information Center
(10)	Keith, L.H. & Walters, D.B., Compendium of safety data sheets for research and industrial chemicals. Verlag Chemie, Weinheim, 732-733 (1985)
(11)	Windholz, M., The Merck index, 10th ed Merck & Co Inc., Rahway, 486 (1983)
(12)	Mladenov, I. et al., Plaste Kautschuk 36, 227-229 (1989)
(13)	Weast, R.C., CRC Handbook of chemistry and physics, 69th ed CRC Press, Inc., Boca Raton, C -293 (1988)
(14)	Bayer AG, unpublished data -internal report 1988
(15)	Monsanto Co., unpublished data - internal report 1992
(16)	Syracuse Research Corporation KOWWIN model
(17)	Bayer AG, unpublished data 1989
(18)	Busev, A.I. et al., Latv. PSR Zinat. Acad. Vestis, Kim. Ser. 4, 477-481 (1974)
(19)	Monsanto report SR-85-X, 1980
(20)	MLPC Interantional internal report
(21)	Hall, N.F. & Sprinkle, M.R., J. Am. Chem. Soc. 54, 3469-3485 (1932)
(22)	Wohlfahrt, R. & Niebergall, H., Lebensmittelchem. Gerichtl. Chem. 38, 100-101 (1984)

(23)	Environment Aency Japan (1997) Chemicals in the Environment. Report on Environmental Survey and Wildlife Monitoring of Chemicals in F.Y. 1995. Environmental Health and Safety Division. June 1997
(24)	Biodegradation and biaccumulation data of existing chemicals based on the CSCL (Chemical substance Control Law) Japan. Edited by Chemicals Inspection and Testing Institute, October 1992.
(25)	Kondo, M. et al., Eisei Kagaku 34, 115-122 (1988)
(26)	Bayer AG (1988), unpublished data: Study report no. 85 A/89
(27)	Monsanto report # 92-9056
(28)	Chou TW, Mabey WR, Spanggord R, Smith JH, Haynes D, Baraze A & Burris D. Selected environmental fate studies on nine chemical compounds. SRI International. SRI project no. 8669. for Monsanto Chemical Company
(29)	Wilson, I.S., The treatment of chemical wastes. In: Isaac, P.C.G. (ed.) Waste treatment. Proceedings of the second symposium on the treatment of waste waters, 1419. September. Pergamon Press, Oxford, 206-222 (1960)
(30)	Loeb, H.A. & Kelly, W.H., Acute oral toxicity of 1496 chemicals force-fed to carp. Special Scientific Report-Fisheries No. 471. US Department of the Interior, Washington, D.C. (1963)
(31)	Study performed by ABC laboratories inc, USA (1979) Study no. 23807 (AB-79-1384358-1c) for Monsanto Chemical Company
(32)	Study performed by ABC laboratories inc, USA (1979) Study no. 23806 (AB-79-1384358-1b) for Monsanto Chemical Company
(33)	Study performed by ABC laboratories inc, USA (1979) Study no. 23805 (AB-79-1384358-1a) for Monsanto Chemical Company
(34)	Bayer AG, unpublished data Study report no. 85 A/89
(35)	Study performed by ABC laboratories inc, USA Study no. 23808 (AB-79-1384358-1d) for Monsanto Chemical Company
(36)	Bayer AG, unpublished data (1990) Report no. 85 A/89 AL
(37)	Bayer AG, unpublished data Report no. 85 A/89 AL
(38)	Study performed by EG&G, Bionomics Marine Research Laboratory (BMRL), Florida, USA Project no. H97-500 (BP-79-7-104) for Monsanto Chemical Company

(39)	Bayer AG, unpublished data Report no. 85 A/89 D
(40)	Danenberg, P.V. & Santi, D.V., J. Med. Chem. 18, 528-530 (1975)
(41)	Tomlinson, T.G. et al., J. Appl. Bact. 29, 266-291 (1966)
(42)	Bayer AG, unpublished data Report number 85 A/89 DL
(43)	Kefford, N.P. et al., Planta 67, 103-106 (1965)
(44)	Bayer AG - unpublished data
	Report no. C1PF Study peformed by: Schallnass H-J, Diehl Th & Knacker Th. (1995) ECT Oekotoxikologie GmbH.
(45)	Bempong, M.A. & McCoy, R., Newslett. Environ. Mutagen. Soc. 5, 25-28 (1972)
(46)	Williams, G.R., Int. Biodeter. 20, 173-175 (1984)
(47)	Schafer Jr., E.W. et al., Arch. Environ. Contam. Toxicol. 12, 355-382 (1983)
(48)	Schafer, E.W., Toxicol. Appl. Pharmacol. 21, 315-330 (1972)
(49)	Monsanto Compagny. Acute oral toxicity with diphenylguanidine. Younger laboratories study no. Y-77-61, April 27th, 1977.
(50)	Sumitomo Chemical Co., Ltd. Acute oral toxicity of Soxinol D in rats. Institute for Biological Science report no. C-77-115, December 1st, 1977.
(51)	Monsanto Chemical Company. The acute oral toxicity of diphenylguanidine for rats. Scientific Associates report dated June 18, 1954.
(52)	Arkhangel'skaya LN and Roshchina TA (1963) Brief account of toxic properties of vulcanisation accelerators diphenylguanidine and furfuramide. Sovjet Rubber Tech. 22, 38-39.
(53)	Arkhangel'skaya LN and Roshchina TA (1964) Toxicological characterization of furfuramide, a new vulcanization accelerator. Gig. Sanit. 29, 37-42.
(54)	Dieke SH, Allen GS and Richter CP (1947) The acute toxicity of thioureas and related compounds to wild and domestic Norway rats. J Pharm Exp Ther, 90, 260-270.
(55)	Vlasyuk MG (1971) Comparative study of the sensitivity of young and adult animals to diphenylguanidine. Gig. Primen., Toksikol. Pestits. Klin. Otravl. 9, 363-366.

(56)	Arkhangel'skaya LN and Roshchina TA (1968) Toksikol. Nov. Khim. Veshchesto, Vnedrialnik, Moskau, 117-126. Cited in: Chem. Abstr. 71: 47801.
(57)	Vlasyuk MG (1978) Data for substantiation of the permissible quantity of diphenylguanidine migration from rubbers in contact with foods. Gig. Sanit, 7, 35-38.
(58)	American Cyanamid Company, pers. comm. Cited in: McCormick WE (1971) Rubber Chem Technol, 44, 512-533.
(59)	Hasegawa R et al. (1989) Sci Rep Res Inst, Tohoku Univ, -C, 36, 1-4.
(60)	Smyth HF (1931) The toxicity of certain benzene derivatives and related compounds. J Ind Hyg Toxicol, 13, 87-96.
(61)	Marhold J (1986) Prehled Prumyslove Toxikologie, Organicke Latky, Svazek 1, S. 974.
(62)	Valade P, Delga J et Salle J (1949) Etude expérimentale des effets physiologiques de la diphénylguanidine. Comptes Rendus Soc. Biol. 143, 815-817.
(63)	Monsanto Company. Acute dermal toxicity study in rabbits with 1,3-diphenyl guanidine. Springborn Laboratories report no. 3044.271 (Monsato report no. SB-91-448), April 9, 1992.
(64)	Monsanto Compagny. Acute dermal toxicity with diphenylguanidine. Younger Laboratories report no. Y-77-61, April 27th, 1977.
(65)	Doull J, Plzak V and Brois SJ (1962) A survey of compounds for radiation protection (Report No. AD 277689). USAF Aerospace Medical Division, Brooks Air Force Base, Texas.
(66)	Kowalski Z and Bassendowska E (1965) Vorläufige Intersuchungen über die toxischen Wirkungen einiger Vulkanisationsbeschleuniger (D, M DM, DFT and P-extra-N). Med Pracy, 16, 35-43.
(67)	Alles GA (1926) J Pharm Exp Ther, 28, 251-276.
(68)	Monsanto Company.Primary skin irritation with diphenylguanidine. Younger laboratories report no. YO -77-61, April 27, 1977.
(69)	Monsanto Company. Acute eye irritation with diphenylguanidine. Younger Laboratories report no. Y-77-61, April 27, 1977.
(70)	Monsanto Company. Acute eye irritation with diphenylguanidine. Younger Laboratories report no. Y-77-254, October 17, 1977.
(71)	MLPC. 1,3-diphenylguanidine. Skin sensitization test in guinea-pigs (Maximization method of Magnusson and Kligman). CIT report no. 12244 TSG, February 8, 1995.

(72)Monsanto Europe SA. Diphenylguanidine: 2 week toxicity study in rats with oral administration via the diet. Inveresk Research international report no. 1774, August 1980. (73)Monsanto Europe SA. Diphenylguanidine: Toxicity study in rats (oral administration via the diet for 13 weeks). Inveresk Research international report no. 2311, June 1982 (Monsanto study no. IN-81-303). (74)NTP (1995) Technical report no. 42 on toxicity studies of 1,3-diphenylguanidine administered in feed to F344/N rats and B6C3F1 mice. McCormick WE (1971) Environmental health control for the (75)rubber industry. Rubber Chem Technol, 44, 512-533. (76)Orlov NS, Vlasyuk MG and Glinyanaya AG (1973) The effect of diphenylguanidine on humans and animals (clinical experiments). Gig Prim Polim Mat Stroit, 133-137. (77)Burov, Y.A., Farmakol. Toksikol. 27, 714-717 (1964) (78)Verchovski (1952) cited in: Kowalski Z and Bassendowska E (1965) Med Pracy, 16, 35-43. (79)Mortelmans K, Haworth S, Lawlor T, Speck W, Tainer B, and Zeiger E (1986) Salmonella Mutagenicity Tests: II. Results From the Testing of 270 Chemicals. Environ Mutagen, 8, 1-119. (80)Monsanto Company. Ames/Salmonella Mutation assay and S. cerevisiae Mutation assay. Litton Bionetics Inc. report no. 2683, December 30, 1976 (Monsanto Study BO-76-276). (81)JETOC (1996) Mutagenicity test data of existing chemical substances based on the toxicity investigation system of the industrial safety and health law. Ministry of Labour, Japan. (82)Crebelli R, Falcone E, Aquilina G and Carere A (1984) In vitro mutagenicity of rubber chemicals and thier nitrosation products. Toxicol Lett, 23, 307-313. (83)Crebelli R, FalconeE, Aquilina G and Carere A (1984) Mutagenicity studies in a tyre plant: in vitro activity of urine concentrates and rubber chemicals. IARC Sci Publ, 59, 289-295. (84)Crebelli R, Paoletti A, Falcone E, Aquilina G, Fabri G and Carere A (1985) Mutagenicity studies in a tyre plant: in vitro activity of workers' urinary concentrates and raw materials. Br J Ind Med, 42, 481-487. Bempong MA and Mantley RJ (1985) Body fluid analysis of (85)1,3-diphenylguanidine for mutagenicity as detected by Salmonella strains. Environ Pathol Toxicol Oncol, 6, 293-301. (86)Bempong, M.A., unpublished data



(101)	Bempong MA (1983) Reproductive toxicity of 1,3-diphentIguanidine: analysis of damaged sperm and fertility index. J. Am. Coll. Toxicol. 2, 241.
(102)	Monsanto Company. A Range-Finding Teratology Study in Rats with DPG. Wil report no. WIL-50003, September 13,1985 (Monsanto report no. WI-85-105).
(103)	Monsanto Company. A Teratology Study in Rats with DPG. Wil report no. WIL-50004, April 24, 1986 (Monsato study no. WI-85-197).
(104)	Yasuda Y and Tanimura T (1980) Effect of diphenylguanidine on development of mouse fetuses. J Environ Pathol Toxicol, 4, 451-456.
(105)	Arkhangel'skaya LN and Roshchina TA (1963) Sovjet Rubber Tech. 22, 38-39.
(106)	IARC, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. The rubber industry, Vol. 28. International Agency for Research on Cancer, Lyon (1982)
(107)	Monsanto Company (1982) Evaluation to determine potential hazards of dermal contact with SH-82-006, N,N'-diphenylguanidine. Product Investigation report no. 2581 (monsanto report no. SH-82-006).
(108)	Bonnevie P and Marcussen PV (1944) Rubber products as a widespread cause of eczema. Report of 80 cases. Acta Derm Venereol, 25, 163-177.
(109)	Curtis GH (1945) Contact dermatitis of eyelids caused by an antioxidant in rubber fillers of eyelash curlers. Arch Derm Syph, 51, 262-265.
(110)	Blank IH and Miller OG (1952) A study of rubber adhesives in shoes as the cause of dermatitis of the feet. J Am Med Assoc, 149, 1371-1374.
(111)	Bandmann HJ (1956) Vulkanisationbeschleuniger als Kontaktekzemallergene. Hautarzt, 7, 419-421.
(112)	Herrmann WP and Schulz KH (1960) Hilfsstoffe der Gummiindustrie als Ekzemnoxen. Dermatologica, 120, 127-138.
(113)	Höfer W and Hönemann W (1967) Über beruflich bedingte Akzeme nach Gummieinwirkung bei Bergleuten. Dtsch Ges Wes, 20, 1110-1114.
(114)	Götz H and Istvanovic N (1963) Die Bedeutung von Gummiallergenen insbesondere bei Bergleuten. Hautarzt, 14, 345-348.
(115)	Van Dijk E (1968) Contact dermatitis due to spandex. Acta Derm Venereol, 48, 589-591.
(116)	Dahl MV (1975) Allergic contact dermatitis from footwear. Minnesota Med, 58, 871-874.

(117)	De Vries HR (1964) Allergic dermatitis due to shoes. Dermatologica, 128, 68-75.
(118)	Reifferscheid, T., Haeufigkeit und Verteilungsmuster der Kontaktallergene bei Patienten der Universitaets-Hautklinik Duesseldorf in den Jahren 1974-1976. Medizinische Dissertation, Universitaet Duesseldorf (1979)
(119)	Takeda K, Matsumoto A and Arakawa T (1964) Four cases of erythromelanosis. Effects of compound used in the rubber industries on the skin. J Exp Med, 10, 223-230.
(120)	Adams RM (1972) Shoe dermatitis. Calif Med, 117, 12-16.
(121)	Te Lintum JCA and Nater JP (1973) Contact-dermatitis caused by rubber chemicals in dairy workers. Berufsdermatosen 21, 16-22.
(122)	Agrup G (1969) Hand eczema and other hand dermatoses in south Sweden. Acta Derm. Venereol. 49, Suppl. 61, 91 S.
(123)	Tuyp E and Mitchell JC (1983) scuba diver facial dermatitis. Contact Dermatitis 9, 334-335.
(124)	Ross JB and Obst D (1969) Rubber boot dermatits in newfoundland: a survey of 30 patients. Can. Med. Ass. J. 100, 13-19.
(125)	Rudzki E and Kleniewska D (1970) The epidemiology of contact dermatitis in Poland. Br. J. Derm. 83, 543-545.
(126)	Rudzki E and Kohutnicki Z (1971) Professional allergens in bricklayers. Med. Pracy 22, 515-519.
(127)	Rajan VS and Khoo R (1980) Allergic contact dermatitis in singapore. Mod. Med. Asia 16, 54-56.
(128)	Ruocco V and Florio M (1986) Su di un caso di probabile malanosi frizionale. Ann. It. Derm. Clin. Sper. 40, 263-268.
(129)	Wilson HTH (1969) Rubber dermatitis - an investigation of 106 cases of contact dermatitis causer by rubber. Br. J. Derm. 81, 175-179.
(130)	Baer RL, Ramsey DL and Biondi E (1973) The most common contact allergens. Arch. Derm. 108, 74-78.
(131)	Nater JP (1975) Überempfindlichkeit gegen Gummi. Berufsdermatosen 23, 161-168.
(132)	Kilpikari I (1982) Occupational contact dermatitis among rubber workers. Contact Dermatitis 8, 359-362.
(133)	Lynde CW, Warshawski L and Mitchell JC (1982) Patch test results with a shoewear screening tray in 119 patients, 1977-80. Contact Dermatitis 8, 423-425.
(134)	Garcia-Perez, A, Garcia-Bravo B and Beneit JV (1984) Standard patch tests in agricultural workers. Contact Dermatitis 10, 151-153.

(135)	Kantoh H, Ishihara M, Itoh M Hosono K and Nishimura M (1985) Allergens in rubber products. Hifu. 27, 501-509.
(136)	Lisi P and Simonetti S (1985) Contact sensitivity in children and adults with atopic dermatitis - a chronological study. Dermatologica, 171, 1-7.
(137)	Bajaj AK, Gupta SC, Chatterjee AK and Singh KG (1988) Shoe dermatitis in india. Contact Dermatitis 19, 372-375.
(138)	Camarasa JMG and Alomar A (1978) Allergic rhinitis from diphenylguanidine. Contact Dermatitis 4, 242.
(139)	Helander I and Maekelae A (1983) Contact urticaria to zinc diethyldithiocarbamate (ZDC). Contact Dermatitis 9, 327-328.
(140)	Holness DL and Nethercott JR (1997) Results of patch testing with a special series of rubber allergens. Contact dermatitis, 36, 207-211.
(141)	Aguirre A, Manzano D, Zabala R, Raton JA and Perez JLD (1994) Contact allergy to captan in a hairdresser. Contact Dermatitis 31, 46.
(142)	Brunze M (1994) Diagnostic pearls in occupational dermatology. Occupational Dermatoses 12, 485-489.
(143)	Calan CD (1978) Diphenyl guanidine in rubber hoses. Contact Dennatitis 4, 241.
(144)	Conde-Salazar L, Del-Rio E, Guimaraens D and Domingo AG (1993) Type IV allergy to rubber additives: A 10-year study of 686 cases. Journal of the American Academy of Dermatology, 29 (2), 176-180.
(145)	Jung HD (1977) Gummi als Schadstoff beim Melkerekzem in der sozialistischen Landwirtschaft. Das Deutsche Gesundheitswesen, 32, 1866-1872.
(146)	Kanerva L, Estlander T and Jolanki R (1994) Occupational allergic contact dermatitis caused by thiourea compounds. Contact Dermatitis, 31, 242-248.
(147)	Kanerva L, Estlander T and Jolanki R (1996) Allergic patch test reactions caused by the rubber chemical cyclohexyl thiophthalimide. Contact Derm atitis, 34, 23-26.
(148)	Kiec-Swierczynska M (1995) Occupational sensitivity to rubber. Contact Dermatitis, 32, 171-190.
(149)	Knudsen BB, Larsen E, Egsgaard H, and Menné T (1993) Release of thiurams and carbamates from rubber gloves. Contact Dermatitis, 28, 63-69.
(150)	Koch P (1996) Occupational allergic contact dermatitis and airborne contact dermatitis from 5 fungicides in a vineyard worker / Cross-reactions between fungicides of the dithiocarbamate-group? Contact Dermatitis, 34, 324-329.

(151)Koch P, Nickolaus G and Geier J (1996) Kontaktallergien bie Lederherstellern, Lederverarbeitern und in der Schuhindustrie. Dermatosen 44, 257-262. Meneghini CL. Rantuccio F and Riboldi A (1963) (152)Klinisch-allergologische Beobachtungen bei beruflichen ekzematdsen Kontakt-Dermatosen, 11, 280-293. Roed-Petersen J and Menné T (1976) Allergic contact (153)dermatitis and lichen planus from black-and-white photographic developing. Cutis, 18, 699-705. (154)Saha M, Srinivas CR, Shenoy SD, Balachandran C and Acharya S (1993) Footwear dermatitis. Contact Dermatitis, 28, 260-264. (155)Suskind RR (1984) Personal Communication, March 16, 1984, cited in Fischer AA (1986), Contact Dermatitis, Lea & Febiger, Philadelphia, 636. (156)Ioannou YM and Matthews HB (1984) Absorption, distribution, and excretion of 1,3-diphenylguanidine in the male F344 rat. Fundam Appl Toxicol, 4, 22-29. (157)Shah PV, Sumler MR, Ioannou YM, Fisher HL and Hall LL (1985) Dermal absorption and disposition of 1,3-diphenylguanidine in rats. Toxicol Environ Health, 15, 623-633. (158)Hunter and Scully (personal communication) cited in: Bempong, M.A. & Hall, E.V., J. Toxicol. Environ. Health 11, 869-878 (1983). (159)Picin DG (1973) Einfluss von Diphenylguanidin auf die Inkorporation in vivo von 32P-orthophosphat in die Phospholipidfraktionen der Leber und des Blutserums von Ratten. Farmakol. Toksikol. 36, 444-446. (160)Picin DG and Trendafilova RB (1972) Einfluss des Diphenylguanidins auf den Gehalt an Lipidfraktionen in der Leber und im Blutplasma von Ratten bei akuter une subakuter Vergiftung. Farmakol. Toksikol. 35, 360-362. (161)Trendafilova R (1971) Change in some lipid fractions of liver and blood plasma in acute oral poisoning with diphenylguanidine (DPG). Khig. Zdraveopazvane. 14, 35-41. (162)Trendafilova R (1972) Die Phospholipid-Fraktionen von Leberund Blutplasma in akuten une subakuten Versuchen mit DPG. Khig. Zdraveopazvane. 15, 234-238. (163)Trendafilova R and Picin D (1971) The influence of diphenylguanidine (DFG) in vivo on the incorporation of 32P-orthophosphate in phospholipide fractions of liver and blood plasma of rats. Eksp. Med. Morphol. 10, 185-188. (164)Bempong MA (1984) In vivo and In vitro Mitogenicity of 1,3-Diphenylguanidine: Analysis of DNA Synthesis and Cell Proliferation, Environ Mutagen, 6, 431-432.

(165) Korhonen A, Hemminki K and Vainio H (1983) Embryotic effects of acrolein, methacrylates, guanidines, and resorcinol on three day chiken embryos. Acta Pharmacol Toxicol, 52, 95-99.

(166) Korhonen A, Hemminki K and Vainio H (1983) Toxicity of rubber chemicals towards three-day chicken embryos. Scand J Work Environ Health, 9, 115-119.

ld 102-06-7 **Date** 14.11.2001

#### 10.1 END POINT SUMMARY

Memo : Acute oral toxicity

Remark : 5.1.1

**Conclusion**: The acute effects of DPG are compiled in the following

table. The oral LD50 is given as 323-850 mg/kg bw in rats

and 150-520 mg/kg bw in mice.

Results of Experiments on the Acute Oral Toxicity of DPG

-----

Species Dose Main Effects Reference Reliability

(mg/kg)

-----

Rat 350 LD50 Monsanto, 1986 2 Rat 460 LD50 male Sumitomo, 1977 2

384 LD50 female > 170 mg/kg dyspnea

and ataxia

Rat 850 LD50 Monsanto, 1954 2 Rat 375 LD50 Arkhangel'skaya and

Roshchina; 1963, 1964 4

Rat 500 LD50 Dieke et al., 1947 3 Rat 250 maximum tolerated Arkhangel'skaya and

dose, spasms, Roshchina, 1963, 1968 4

liver weight

Rat 500 minimum lethal Arkhangel'skaya and

dose Roshchina, 1963 4

Rat 323 LD50 Vlasyuk, 1978 4

Mouse 290 LD50 Arkhangel'skaya and

Roshchina,1964 4

Mouse 250 maximum tolerated Arkhangel'skaya and dose; spasms, Roshchina, 1963, 1968 4

liver weight

Mouse 450 LD100 Arkhangel'skaya and

Roshchina, 1963, 1968 4

Mouse 258 LD50 Vlasyuk, 1978 4 Mouse 520 LD50 Amer. Cyan. Co.; cited in

McCormick (1971) 4

Mouse 150 LD50 male Hasegawa et al., 1989 4

211 LD50 female

Rabbit 246 LD50 Vlasyuk (1978) 4

Rabbit 250 minimum lethal Smyth, 1931 3

dose

Rabbit 250 LD50 Marhold, 1986 4

Guinea 250 minimum lethal Smyth, 1931 4

pig dose

Guinea 250 LD50 Marhold, 1986 4

pig

Dog 10 emetic dose Amer. Cyan. Co.; cited in

McCormick (1971)

.....

06.12.2000

**Memo** : Acute inhalation toxicity

#### 10. Summary and Evaluation

ld 102-06-7 **Date** 14.11.2001

**Remark**: The available data are not reliable to assess the acute

toxicity of 1,3-diphenylguanidine (Valade et al., 1949;

reliability 3).

5.1.2

06.12.2000

Memo : Acute dermal toxicity

**Remark** : 5.1.3

**Conclusion**: The dermal LD0 in rabbit is > 2000 mg/kg (Monsanto, 1992;

reliability 1).

06.12.2000

Memo : Skin irritation

Remark : 5.2.

**Conclusion**: DPG does not irritate the skin of rabbits (Monsanto, 1977;

reliability 2).

06.12.2000

Memo : Eye irritation

Remark : 5.2.2

**Conclusion** : DPG is irritating to the rabbit eye (Monsanto, 1977;

reliability 2).

06.12.2000

**Memo** : Sensitization

Remark : 5.3

Conclusion : According to the Magnusson and Kligman maximization test;

DPG is not sensitizer in guinea-pigs (MLPC, 1995;

reliability 1)).

06.12.2000

Memo : Repeated dose toxicity

Remark : 5.4

**Conclusion** : Subchronic feeding experiments in rats and/or mice have been

performed according to OECD guidelines and GLP in the frame of the US National Toxicology Program (1995) and by Monsanto

(1982).

In rats (F344/N) and mice (B6C3F1) which, in a dose-finding

study, received DPG for 14 days in their feed in

concentrations of 250, 500, 750, 1,500 and 3,000 ppm, only reduced feed intake and decreased body weights were observed as of 750 ppm (NTP, 1995). In the subsequent substration

as of 750 ppm (NTP, 1995). In the subsequent subchronic study, DPG was fed to the rat and mouse in the same concentrations as in the subacute study (equivalent to daily dose of 17/17, 32/32, 50/49, 100/95 and 181/184 mg/kg bw/d for male/female rats and 38/46, 75/93, 114/141, 231/285 and 457/577 mg/kg bw/d in male/female mice at 250, 500, 750,

1500 and 3000 ppm, respectively). Due to the poor palatability of the DPG-treated feed, a decreased feed

consumption and reduced body weights were observed as of 750 ppm compared to controls (750 ppm (m/f): 92%/93%; 1,500 ppm: 79%/86%; 3,000 ppm: 52%/-). Increased mortality was observed for both sexes after receiving 3,000 ppm in feed, whereby all females of this concentration group died. Primarily

substance-induced effects on the organs were not observed.

ld 102-06-7 **Date** 14.11.2001

The diverse deviations from the controls, determined also for the hematological and clinical-chemical parameters particularly in both highest concentrations (1,500 and 3,000 ppm), are seen exclusively as the result of emaciation by reduced feed intake.

With the average feed intake comparable with the controls, body weight retardation was observed in the mice also as of 750 ppm. The reduced organ weights occurring as of 1,500 ppm were evaluated not as a specifically toxic response but rather were correlated to the clearly reduced body weights. Histopathological changes and significant deviations from the controls for the hematological and clinical-chemical parameters were not observed.

The NOAEL for both species lies at 500 ppm (ca. 32 mg/kg b.w. and day for rats and ca. 75 mg/kg b.w. and day for mice) (NTP, 1995; reliability 1 (rat study) or 2 (mouse study)).

Dosing Sprague-Dawley rats with DPG in the diet at a concentration of 50, 150 or 500 ppm for 13 w eeks (equivalent to daily dose of 4, 11 and 37 mg/kg bw/d), produced a marked reduction in growth rate of both males and females at 500 ppm, with respect to controls. The food consumption of these animals was also reduced, when compared to the controls. The effects were most pronounced over the first few weeks of dosing, suggesting that the cause may partly be due to the unpalatability of the test substance.

Dose levels of DPG up to 500 ppm did not cause an increase in mortality or the appearance of any abnormal clinical signs.

Laboratory investigations revealed small differences between rats receiving DPG and the controls in both haematological and clinical chemical parameters, but as the same effects were not present at both Weeks 6 and 13 they are considered to be of little or no significance. Male rats receiving 500 ppm DPG tended to produce more concentrated urine than the controls at Weeks 6 and 13, with a slightly reduced pH on the latter occasion. Female rats at the same dose level also showed a slight aciduria, but at Week 13 only. These effects were only slight and could not be attributed to any obvious structural change to the kidney as seen on histopathological examination. The changes seen lacked a dose response and were of marginal magnitude, the reby confirming their insignificance.

The terminal studies revealed no dose related lesions; those lesions found were spread across the dose groups with roughly equal incidence and are considered to be common findings in rats of this age and strain.

The NOAEL lies at 150 ppm (11 mg/kg bw/d) (Monsanto, 1982; reliability 1).

Additional subacute and subchronic studies are compiled in the following table. These are insufficiently documented in some cases; most do not meet current requirements (reliability 3 or 4), such as those concerning dose selection. Thus the results should be assessed critically.

Results on the Toxicity of DPG after Repeated Administration

\_\_\_\_\_\_

Species Adminis - Dose/Day Main Effects Reference (Sex/ tration (mg/kg bw) Numb.) (Duration)

ld 102-06-7 **Date** 14.11.2001

feed 7, 75 75 mg/kg: feed McCormick, (28 d) intake as result 1971 growth retardation Rat oral reticulocytosis, Orlov et (4 mo) eosinophilia, al. (1973) erythrocytes, hemoglobin, inhibited catalase and peroxidase, total bilirubin, threshold of nerve and muscle irritability, mortality, no kidney findings Rabbit oral 10 % feed intake Arkhangel'skaya (not LD100 erythrocytes, and Roshchina, given) serum t-globulin 1963, 1968 Rabbit oral 50 severely inflamed Arkhangel'skaya (5.5 mo)liver parenchyma, and Roshchina bilirubin, 1963, 1968 dystrophy of convoluted tubules, unchanged blood picture Dog oral 10 "relatively well Amer. Cyan. (24 d) (21 tolerated" Co.: cited in administrations McCormick, 1971 Dog oral 5 Burov (1964) bile acids (not given) Rabbit dermal 1000 no systemic effect McCormick, 1971 (10 administrations) Rat inhal. about 220 Disturbed Arkhangel'skaya mg/m3/2h "oxidationand Roshchina, reduction" 1963, 1968 processes, functionally disturbed nervous system, blood pressure Guinea inhal. 100 mg/l lethal Verchovski, pig (repeated) 1952 Genetic toxicology "in vitro"

Remark : 5.5 Conclusion : Re

06.12.2000

Memo

: Results available on Ames tests are predominantly negative (Monsanto, 1976; JETOC, 1996; Crebelli et al., 1984, 1985;

Rannug et al., 1984; You et al., 1982; Yamaguchi et al.,

ld 102-06-7

Date 14.11.2001

1991). In one Ames test DPG caused a weak increased number of revertants after metabolic activation (S9 mix from hamster liver) (Mortelmans et al., 1986; NTP, 1995), while in another case the weakly positive result may have been due to contamination (Bempong & Mantley, 1985; Bempong, unpublished data).

All other in vitro investigations, gene mutation on Escherichia coli and Saccharomyces cerevisiae (JETOC, 1996; Monsanto, 1976), gene mutation assay on CHO (Donner, 1983) and mouse lymphoma cells (Monsanto, 1979) and cytogenetic assay on CHO cells (Monsanto, 1992) were consistently negative. DPG at a concentration of 7.5 ug/ml caused 50% inhibition of the colony formation in HeLa-S3 cells (Baba, 1980; reliability 4).

-----

Test System Metabol. Concen. Result Reference Reliab.

Activ. range

-----

Ames test on Salmonella typhimurium

TA98,100 +(1) 1-100 weakly Mortelmans et 1

µg/plate positive al, 1986, NTP,

1985

TA98,100,1535, +(2)/- 33-10 000 negative Mortelmans et 1 1537 μg/plate al., 1986; NTP, 1995

TA1535,1537 +(1) 100-10000 negative Mortelmans et 1 µg/plate al, 1986, NTP, 1995

TA98,100, +/- 2-500 negative JETOC, 1996 2 1535,1537,1538 µg/plate

TA98, 100  $\pm$ -- 200-5000 negative Crebelli et 2  $\pm$   $\pm$   $\pm$   $\pm$   $\pm$   $\pm$  2  $\pm$   $\pm$  2 al, 1984, 1985

TA98,100,1535, +/- 0.1-500 negative Monsanto, 1976 2 1537, 1538  $\mu$ g/plate

TA98,100, -/+ 0.036-36 weakly Bempong and 3 1535,1537,1538  $\mu$ g/plate positive Mantley, 1985

TA98,100, +/- not given negative Rannug et al., 3 1535,1537,1538 1984

TA98,100, +/- not given negative You et al., 1982 4

TA98,100 +/- 1-100 negative Yamaguchi et 4 µg/plate al. (1991)

E.coli WP2 - 2-500 negative JETOC, 1996 2 + 20-5000 negative µg/plate

HGPRT test - 100-500 negative Donner et al., 3 V79 cells mg/ml 1983

ld 102-06-7 **Date** 14.11.2001

TK test - 16.4-188 negative Monsanto, 1979 2 L5178Y cells + 32.8-525 negative µg/ml

S. cerevisiae +/- 1-500 negative Monsanto, 1976 2 D4 µg/plate

Cytogenetic +/- 125-750 negative Monsanto, 1992 2 assay, CHO cell µg/ml

-----

(1) 10 % hamster liver homogenate(2) 10 % rat liver homogenate

06.12.2000

Memo : Genetic toxicity "in vivo"

Remark : 5.6 Conclusion : Th

The micronucleus test on erythrocytes of the peripheral blood of mice, that obtained feed with a DPG-content of 250, 500, 750, 1,500 and 3,000 ppm in the subchronic test, led to a negative result in the male animals. The test result of the females was evaluated as "questionable" because of the statistically significant increase of the micronuclei-carrying normochromatic erythrocytes in the female animals of the middle concentration group (750 ppm) (NTP, 1995; reliability 1).

However, in a cytogenetic assay, DPG was administered via oral gavage to male and female rats at a target dose of 300 mg/kg body weight. Bone marrow was sampled at 6, 24 and 48 hours after dosing. No statistically significant increases in the proportion of aberrant cells or aberrations/cell were observed. Significant induction of toxicity, measured as mitotic index depression was observed at the 6 hour (35%) and 24 hour (31%) time points. No depression in mitotic index was observed at the 48 hour time point (Monsanto 1989; reliability 1).

A micronucleus test in mice was negative (further information not given; Bempong, unpublished data; reliability 4).

Bempong (1987) and Bempong and Mantley (1985) (reliability 3) administered a single i.p. dose of 0.036-36 mg DPG/kg bw to mice and then examined the peritoneal fluid, urine and feces daily for 4 days with S. typhimurium strain TA 100 (modified host-mediated assay). Only in the feces was a dose and time-related increase in the number of revertants seen. This result may have been due to contamination of the substance, as later investigations with the pure compound were negative. Further data are not available (Bempong, unpublished data).

06.12.2000

Memo : Carcinogenicity

Remark : 5.7

**Conclusion** : A carcinogenicity study which meets current requirements is

not available.

Bempong & Myers (1985; reliability 3) report on the

ld 102-06-7 Date 14.11.2001

> induction of adenocarcinomas in C578L/J6xDBA2 mice through chronic exposure to DPG, without giving data on the experimental procedure. According to a personal communication by Bempong DPG was administered in this experiment in oral doses of 4 and 8 mg/kg bw for 32 weeks (7 days/week) to groups of 50 female and male mice. DPG had not caused the appearance of tumors by the end of the experiment. After a 10 to 16 week post-obs ervation period. lymph gland adenosarcomas were determined in 3 of 50 animals in the 4 mg group (in 0 animals of the control group).

As data are missing on the number of accompanying control animals, contradictions occurred in the characterization of tumors, and tumors were seen in the low-dose group but not in the higher one, this study does not permit an assessment of a possible carcinogenic effect of DPG.

06.12.2000

Memo Toxicity to reproduction

Remark Conclusion 5.8.1

In addition to the results of the subchronic studies on the rat and mouse decribed in Section 5.4, special studies for recognizing reproductive toxic effects were also performed (NTP, 1995; reliability 1).

Female rats which had been administered feed having a DPG-content of 250, 500, 750, 1,500 and 3,000 ppm for 13 weeks, exhibited uterine hypoplasia and a prolonged reproductive cycle in the 750 ppm-group (ca. 49 mg/kg b.w. and day) and 1,500 ppm -group (ca. 95 mg/kg b.w. and day) in comparison with the controls. All females of the 3.000 ppm-group died during the study, so that comparable studies of these animals could not take palce. After subchronic feeding of DPG, the male rats only in the 1,500 ppm -group (ca. 100 mg/kg b.w. and day) showed diminished sperm motility. Alte rations in the reproductive organs (e.g. depletion of the prostate, hypospermia, reduced spermatogenesis) were occassionally found in the males of the 3,000 ppm-group (ca. 181 mg/kg b.w. and day). Also for the mice which obtained up to 3,000 ppm DPG in feed for 13 weeks, a prolonged reproductive cycle was observed in the females of the highest concentration group and, in the male animals, a decreased sperm motility. The increased number of spermatid heads in the testes paired with the lower number of sperm in the epididymis is evidence against an effect on spermatogenesis, whereas an effect on the release of sperm into the epididymis cannot be excluded. Comparisons of the parameter changes determined after the DPG-feeding in the rat and mouse, which can be used for assessing a possible reproductive toxic effect, with the results of tests with feed withdrawal (Chapin et al., 1993; Levin et al., 1993) infer that the effects observed in the DPG-treated animals in high concentration groups are a result of the poor general state of health (malnutrition, exhaustion) of the animals.

After doses of 4 or 8 mg DPG/kg bw/day, the following symptoms were found in mice and hamsters: reduced testicular weights, oligospermia, sperm anomalies and a decreased fertility index after mating with untreated females (Bempong, 1983; Bempong & Hall, 1983). Information on the

purity of the DPG is not available (reliability 3). In a later study with CD1 mice, 1,3-Diphenylguanidine (99.9%) was administered by daily gavage to male mice at dose levels of 0, 0.06, 0.25, 1, 4 and 16 mg/kg body wt. per day during an 8-week premating period. Females were not dosed at any time during the study. Sperm abnormality evaluation was performed in approximatively half the males. randomly selected from the control and 16 mg/kg dose group on completion of dosing. The remaining males in the control. 4 and 16 mg/kg body wt per day groups were mated with non-dosed females. Reproductive performance, necropsy findings and litter data were recorded. No differences were found between control and dosed groups in body weight gain during the dosing period, macroscopic observations and organ weights at necropsy. Microscopic examination of the testes and determination of the frequency of total sperm abnormalities in the 16 mg/kg body wt per day group, did not show any effect due to 1,3-diphenylguanidine dosing when compared to the control group, except for a slight increase in sperm with folded tails but normal heads. Male and female fertility as well as reproduction performance were comparable in the groups examined (0, 4 and 16 mg/kg body wt per day). Maternal necropsy findings and litter data did not reveal any dose-related effect.

At the opposite of Bempong's study, it was concluded that under the conditions of this study, 1,3-diphenylguanidine did not exert any significant adverse effects on fertility, reproductive capacity or embryonic/fetal development in CD-1 mice when administered to males at levels up to 16 mg/kg body wt per day (Koëter et al., 1992; WTR, 1989; reliability 1). The difference in these results may be explainable by contamination of the DPG employed in the studies carried out by Bempong.

26.06.2001

Memo : Developmental toxicity/Teratogenicity

Remark Conclusion

: 5.8.2

In female rats (Mo nsanto, 1986; reliability 1) and mice (Yasuda & Tanimura, 1980; reliability 2) fetotoxic, but not teratogenic, effects were seen after the oral administration of maternotoxic doses. In the rat study the NOEL was given as 5 mg/kg bw for the dams and 25 mg/kg bw for the fetuses. In the mouse study the NOEL was given as 4 mg/kg bw for the dams and > 10 mg/kg bw for the fetuses.

In 17 of 130 chicken embryos (control 1) DPG led to increased rates of mortality and malformation. The ED50 was 0.042 mg/egg (Korhonen et al., 1983; reliability 3). This test is not validated for reproduction toxicity.

01.12.2000

Memo : Toxicokinetics

Remark Conclusion : Y09-069

After a single oral administration to male F344 rats, 14C-DPG was absorded almost completely from the gastrointestinal tract and distributed rapidly in the organism, as was also the case after a single intravenous administration (dose 15.15 µmol and 3.2 mg/kg bw respectively). No difference in distribution or excretion were seen. Single oral administrations of different doses

(1.52-151.1 pmol and 0.32-32 mg/kg bw) also brought about no change in the absorption or distribution (loannou & Matthews, 1984; reliability 2).

In female Sprague-Dawley rats, which had received a single dermal application of 0.063 mg 14C-DPG/animal (0.3  $\mu$ mol), only 0.1-10% of the 14C activity penetrated the shaven skin of the back within 0.5-120 hours (T1/2. 33.6 days). Distribution throughout the entire organism also occurred here (Shah et al., 1985; reliability 2).

The highest 14C activities after intravenous or dermal administration were measured in the liver, kidneys, lungs, intestines with contents, and excreta; maximum tissue concentrations after intravenous administration were reached 15-45 minutes after the start of the experiment; after dermal application within 3-6 hours. With the exception of the liver, only 14C-DPG was detected in tissues 45 minutes after intravenous administration; the 14C activity in the liver was also higher than in other organs at all measurement times (loannou & Matthews, 1984; Shah et al., 1985).

Within 24 and 72 hours about 80 and >99% respectively of the 14C activity administered orally or intravenously was excreted about equally in the urine and feces (elimination half-life 9.6 hours). About 30% of the 14C activity eliminated in the bile was subjected to enterohepatic circulation and excreted in the urine (loannou & Matthews, 1984).

Within 6-120 hours after dermal application 34-64% of the absorbed 14C activity was excreted in the urine and <1-29% in the feces. Accumulation in the adipose tissue was not observed (Shah et al., 1985).

The following table gives an overview of the metabolites occurring, without identifying them specifically, however.

Relative Distribution (in% 14C-activity) of 14C-DPG or the metabolites (I-V) in Liver, Bile, Urine, Feces and Skin after Single Intravenous or Dermal Administration. The 14C-labelling was done by U-labelling on the phenyl rings (according to loannou & Matthews, 1984; Shah et al., 1985)

Excreta/ Time I II III IV V 14C-DPG Organ (h)

Liver(1) 0.75 - 12 - - 88

2 - 18 - - 82

6 - 30 - - 70

24 - 30 60 - 10

Bile (1) 6 2 95 - - 3

Urine(1) 24 - 37 32 - 3 28

Urine(2) 24 - 50 - - 50

48 - 53 - - 47

120 - 100 - - - 
Feces(1) 24 - - 2 94 4

Feces (2) 24 - - - 100 - 48 - - 15 85 - 120 - - 26 74 - 

Skin(2) 6-120 - - - - >95

(1) intravenous administration (3.2 mg/kg bw)

(2) dermal application (0.063 mg/animal)

Three and 9 oral administrations of 3.2 mg/kg 14C-DPG/kg/day (15.15 µmol) also caused no accumulation in the tissues (Ioannou & Matthews, 1984). In the liver there was a proportional 14C increase, the metabolites II and III being detected. Covalent binding to liver macromolecules was not determined (Ioannou & Matthews, 1984).

Additional, although insufficiently documented, studies in mice (Hunter & Scully; cited in Bempong & Hall, 1983) and rabbits (Kazarinova et al., 1975) indicate that DPG is excreted rather quickly and does not cumulate.

26.06.2001

Memo Experience with human exposure

Remark 5.10

Conclusion : Acute Poisoning No data available.

#### Chronic Poisoning

Following unintentionally increased workplace exposure to DPG, due to inadequate safety measures, the following symptoms were reported: eyelid pain and eye redness, a bitter taste and a painful feeling in the esophagus. Reduced gastric juice acidity and achylia were also determined. Further data are not available (Arkhangel'skaya & Roshchina, 1963; reliability 4).

#### Epidemiological Data

The only results available are from a poorly documented study, whose validity cannot be judged due to the lack of data on possible previous employment, the possibilities of contact with other substances, concentrations and control groups.

Orlov et al. (1973; reliability 4) examined workers ranging in age from 29 to 58 years, who had come into contact with DPG during production (no further information) over 3-15 years. About 30% of the test subjects showed symptoms, most suffering from stomach and gall-bladder complaints, neurological disorders or skin diseases. Another finding was liver metabolism disorder (disturbed protein metabolism, increased bilirubin values).

#### Sensitization

In persons suffering from a contact dermatitis positive DPG patch tests have occasionally been described (see Table). The following main contact possibilities were named: shoes (Blank & Miller, 1952; de Vries, 1964; Hjorth & Fregert, 1972; Song et al., 1979; Lynde et al., 1982; Bajaj et al., 1988), articles of clothing (Bandmann, 1956; van Dijk, 1968; Song et al., 1979), rubberized protective clothing (Fegeler, 1963; Götz & Istvanovic, 1963; Höfer & Hänemann, 1967; Ross & Obst, 1969) and other rubber articles, e.g. gloves or the rubber parts of milking machines (Nater, 1975; Song et al., 1979).

A tire production employee, whose allergic rhinitis symptoms occurred only at the workplace, had a positive patch test reaction with 1% DPG (Camarasa & Alomar, 1978).

Garcia-Perez et al. (1984) found that Spanish agricultural workers with a contact dermatitis had a significantly higher sensitization to DPG than a contact dermatitis control group working in another profession (11.76% to 5.320. The authors attributed this to possible cross-reactions with pesticides, as some of these substances (e.g. Cyprex) are guanidine derivatives and others (e.g. the cyanamides) possess a similar chemical structure.

The available data are summarised in the following table.

# Results of Patch Tests Performed with DPG

Subje	cts Pos. (n) (		Concentration Reference (%)
74	2 3		1) Bonnevie & arcussen, 1944
5	0 0		Curtis, 1945
24	0 0	1	Blank & Miller, 1952
5	1 20	1	Bandmann, 1956
63 1960	15 24	n.g.	Herrmann & Schulz,
17 1963	6 35	1	Götz & Istvanovic,
4	3 75	n.g.	Takeda et al., 1964
9	1 11	n.g.	de Vries, 1964
10 3	3 30 1 33	n.g. 2	Höfer & Hönemann, 1967 van Dijk, 1968
524			2.1 Agrup, 1969
15	1 7	1+2	Ross & Obst, 1969
106	-(2) -	1	
744	74(3)	9.9 1	
	(-)		970
47	6 I3	n.g.	Rudzki & Kohutnicki, 971
35	2 6		Adams, 1972
229	18 8	. '05	Raer et al 1973
n.g.	na 3	(4) na	Baer et al., 1973 Orlov et al., 1973
32	0 0	1	te Lintum & Nater,
1973	0 0	•	to Emilam a Hator,
59	0 0	1	Dahl, 1975
6	2 33	1	Nater, 1975
1600		.6 1	Reifferscheid, 1979
844	44 5		Rajan & Khoo, 1980
49	2 4	70	Monsanto, 1982
50	2 4	n.g.	Kilpikari, 1982
119	3 3	1	Lynde et al., 1982
1	0 0	1	Tuyp & Mitchell, 1983
34	4 12	n.g.	Garcia-Perez et , 1984
244	13 5	n.g.	Garcia-Perez et al., 984
31	2 7	1	Kantoh et al., 1985
61	2 3	1	Lisi & Simonetti, 1985
61	3 5	1	Lisi & Simonetti, 1985
1	1 100	-	Ruocco & Florio, 1986
105	3 3		Bajaj et al., 1988
. 55	5 5		Edjaj Ct al., 1000

144 / 146

# 10. Summary and Evaluation

ld 102-06-7 **Date** 14.11.2001

1	1	100	1	Calan, 1978
1	1	100	n.g.	Bruze, 1994
1	1	100	1	Aguirre et al., 1994
1	1	100	n.g.	Helander & Mäkelä,
			19	83
1	0	0	1	Koch, 1996
2	1	50	n.g.	Roed-Petersen & Menne,
			19	76
5	1	20	1	Kanerva et al., 1994
11	0	0	1	Kanerva et al., 1996
15	0	0	1	Knudsen et al., 1993
20	7	35	n.g.	Jung, 1977
30	1	3.3	1	Koch et al., 1996
46	4	8.7	1	Kiec-Swierczynska,
1995				
50	6	12	1	Saha et al.; 1993
502	7	1.4	2	Suskind, 1984
686	13	3 2.3	n.g.	Conde-Salazar et al.,
			19	93
1377	5	5 0.4	n.g.	Meneghini et al., 1963

<sup>1</sup> n.g. = not given

06.12.2000

#### 10.2 HAZARD SUMMARY

**Memo** : Assessment of human health hazards

Source Conclusion MLPC, Rion-des-Landes, France DPG is absorbed rapidly after oral uptake but only slowly after dermal application. The substance is metabolized quickly and eliminated in the urine and feces.

No information is available on the mode of action.

The oral LD50 is 323-850 mg/kg b.w. for the rat. The dermal LD0 is > 2,000 mg/kg b.w. in the rabbit. Intoxication is manifested by spasms, disturbed lipid metabolism, lung emphysema and kidney changes.

DPG is irritating to the eye and non-irritating to the skin.

DPG showed no sensitizing effect in the maximization test according to MAGNUSSON and KLIGMAN.

Three subchronic toxicity feeding studies in rats and mice have shown an increase of the mortality rate at high dose and a decrease of food consumption and body weight gain due to the poor palatability of the DPG-treated feed.

Treatment-related effects on the organs and the hematological, clinical-chemical parameters and urinalysis were not observed. The NOAEL/LOAEL lies at 32/50 mg/kg bw/d and 11/37 mg/kg bw/d for rats and 75/114 mg/kg bw/day in mice. Based on these data the best estimate for the NOAEL was 32 mg/kg bw/d for rats.

<sup>2</sup> no evaluation possible due to a number of irritating reactions

<sup>3</sup> possible irritating reactions could not be ruled out

<sup>4</sup> scarification of skin

# 10. Summary and Evaluation

ld 102-06-7 **Date** 14.11.2001

Most of the in vitro and in vivo investigations available give no indication of a genotoxic effect.

A carcinogenicity study which would meet present standards is not available.

Previous and unreliable reproductive toxicity studies in male mice and hamsters indicated a negative influence on fertility, which may have been due to impurities in the test substance. However, these results could not be reproduced in a later study in mice, in which a higher dose was administered. In addition to the results of the subchronic studies on the rat and mouse, special studies for recognizing reproductive toxic effects were also perfonned. Comparisons of the parameter changes with the results of tests with feed withdrawal infer that the effects observed in the DPG-treated animals in high concentration groups are a result of the poor general state of health (malnutrition, exhaustion) of the animals and not a direct toxic effect on the reproductive organs

In female rats and mice fetotoxic, but not teratogenic, effects were seen after the oral administration of maternotoxic doses. In the rat study the NOEL was given as 5 mg/kg bw for the dams and 25 mg/kg bw for the fetuses. In the mouse study the NOEL was given as 4 mg/kg bw for the dams and > 10 mg/kg bw for the fetuses.

In man, earlier studies described the following symptoms after workplace exposures to DPG: eye and mucous membrane irritation, gastric and bilious complaints and disturbed liver metabolism. Occasionally patients with contact dermatitis reacted positively in the patch test.

27.12.2000

#### 10.3 RISK ASSESSMENT

# 03 DEC 10

# ANNEX 2

# COVER PAGE SIDS INITIAL ASSESSMENT REPORT (SIAR) For SIAM

Chemical Name: 1,3-Diphenylguanidine

CAS No.: 102-06-7

Sponsor Country: France

National SIDS Contact Point in Sponsor Country:

Mme Laurence Musset Ministère de l'Environnement et de l'Aménagement du Territoire 20, avenue de Ségur 75302 Paris 07 SP France

History:

Testing:

No testing

(x)

Testing

 $\overset{\sim}{\sim}$ 

Comments: The national peer review consisted of a presentation and critical discussion at a national panel of experts in toxicology and ecotoxicology from administration, university and industry and nominated by the ministry of environment. In parallel, a review was performed by the national institute on environmental and industrial risk (INERIS) by request from the ministry of environment. For this particular substance, the verification of most underlying study reports was not necessary as it had already been performed by the German authorities within the national German programme on existing chemicals (BUA).

Deadline for Circulation:

Date of Circulation:

# **CONIENIS**

	<u>Page</u>
SIDS INITIAL ASSESSMENT REPORT	3
1. IDENTITY	3
1.1. Identity	3
1.2. Physico-chemical properties	3
1.3. Composition of the technical product	3
1.4. Production Volume/Uses:	3
1.5. Uses and Functions	4
2. GENERAL INFORMATION ON EXPOSURE	4
2.1. Environmental Exposure	4
2.1.1 General Discussion	4
<ul><li>2.1.2 Fate in Waste Water Treatment Plants</li><li>2.1.3 Distribution in Air, Water and Soil</li></ul>	4
2.1.4 Abiotic and Biotic Degradation in Air, Water and Soil	5 5
2.1.4.1 Atmospheric degradation.	5
2.1.4.2 Biodegradation	5
2.1.5 Bioaccumulation	5
2.1.6 Predicted Environmental Concentration	5
2.2. Human Exposure	5
2.2.1 Occupational exposure 2.2.2 Consumer exposure	6
<ul><li>2.2.2 Consumer exposure</li><li>2.2.3 Indirect exposure via the environment</li></ul>	6 6
3. HUMAN HEALTH HAZARDS	6
3.1. Effects on Human Health	6
3.1.1. Toxicokinetics & Metabolism	6
3.1.1.1 Oral administration	6
3.1.1.2 Dermal administration	7
3.1.1.3 Other informations	8
3.1.2. Acute toxicity 3.1.3. Repeated Dose Toxicity	8 9
3.1.3.1. Animal data	9
3.1.3.2. Human data	11
3.1.4. Genetic Toxicity	12
3.1.5 Carcinogenicity	13
3.1.6. ReproductiveToxicity	13
3.1.7. Developmental Toxicity 3.1.8. Other: irritation, Sensitization	18
3.1.8.1. Irritation	18 18
3.1.8.2. Sensitisation	19
3.2 Initial Assessment for Human Health	20
3.2.1. Effects on human health	20
3.2.2. Occupational exposure	21
3.2.3. Consumer exposure	21
<ul><li>3.2.4. Indirect exposure via environment</li><li>4. HAZARDS TO THE ENVIRONMENT</li></ul>	21
4. HAZARDS TO THE ENVIRONMENT 4.1 Effects on the Environment	21 2 <i>1</i>
4.1.1 Aquatic Effects	21
4.1.1.1 Acute toxicity to fish	21
4.1.1.2 Acute toxicity to daphnia	22
4.1.1.3 Acute toxicity to algae	22
4.1.1.4 Acute toxicity to micro-organisms	23
4.1.1.5 Chronic toxicity to daphnids 4.1.1.6 PNEC for the aquatic environment	23 23
4.2 Terrestrial Effects	23
5. CONCLUSIONS AND RECOMMENDATIONS	24
5.1 Conclusions	24
5.2 Recommendations	25
6 REFERENCES	27

#### SIDS INITIAL ASSESSMENT REPORT

#### 1. IDENTITY

# 1.1. Identity

Name (IUPAC) : 1,3-Diphenylguanidine CA Index name : Guanidine, N,N'-diphenyl


Common Name: Diphenylguanidine

DPG

CAS Number: 102-06-7 EINECS n°: 203-002-1

 $\begin{array}{ll} \mbox{Molecular Weight:} & 211.27 \ \mbox{g/mol} \\ \mbox{Empirical Formula:} & C_{13}\mbox{H}_{13}\mbox{N}_{3} \end{array}$ 

Structural Formula:



# 1.2. Physico-chemical properties

Form: solid Boiling Point: >170°C

Vapor Pressure: 174 x 10<sup>6</sup> kPa at 20° C

Melting Point: 145-150°C

Solubility in Water: 475 mg/l to 1 g/l at pH 7 and 25°C, to 519 g/l at strongly acid pH and 20°C

Log pKa: Two protonation steps. First protonation 10.12

Log Kow: 1.69 (measured) pH of test unknown. Probably this result relates to the

protonated molecule but whether in cationic or dicationic form unknown

2.9 (calculated SYRACUSE)2.41 (calculated EPIWIN)

Flammability: no data
Odor: slight

Convertion factors : 1 ppm (v/v) = 4.1 mg/m3

1 mg/m3 = 0.24 ppm (v/v)

#### 1.3. Composition of the technical product

Bayer AG (1989, cited in BUA, 1992) reported that the substance is marketed with a 1,3-diphenylguanidine content of 97.5%. Impurities in this product, which is considered to be typical, are aniline (<0.04%); nitrogenous polymers and other unknown compounds (about 0.7%), inorganic components (about 0.2%) and water (<0.1%). Solvent residues related to production (e.g. odichlorobenzene, toluene, xylene) amount to <50 ppm. Formulation components also contained in the commercial product are 1% mineral oil and 0.5% emulsifier (e.g. fatty alcohol- or nonylphenolpolyglycol ether).

Acidimetric analysis performed routinely by MLPC (2001) on the formulated DPG (containing 1.5-2% mineral oil), indicate a purity of about 99% for the active material.

# 1.4. Production Volume/Uses:

The expected production volume of 1,3-Diphenylguanidine in year 2000 is 2400 tonnes/year in Europe, 2400 tonnes/year in the USA, an amount of 5300 tonnes/year for Asia and 11100 tonnes per year for the world.

The producers or importers and locations are listed below:

United States: none

Europe: MLPC (France), BAYER (Germany), FLEXYS (Belgium) Other: PRONOVA (Russia), SUMITOMO CHEMICAL (Japan)

#### 1.5. Uses and Functions

1,3-diphenylguanidine is used as a primary accelerator in vulcanisation of rubber, as secondary accelerator for sulphur-containing compounds such as thiazoles, sulfenamides and thiurams and as a minor use as a primary material for standardising acids.

Depending on the specific application, the concentration of 1,3-diphenylguanidine used in the production of rubber compounds may vary from 0.25% to 2.0% by weight. The main use is as a vulcanisation activator during which process it is incorporated in the rubber compound but much reverts after processing, leaching of DPG may occur from rubber.

DPG may be of concern locally in aqueous discharge from production and downstream use sites.

Rubber containing 1,3-diphenylguanidine has been used in footwear, tyres, and moulded goods.

# 2. GENERAL INFORMATION ON EXPOSURE

#### 2.1. Environmental Exposure

#### 2.1.1 General Discussion

1,3-Diphenylguanidine is soluble in water and is not expected to adsorb strongly to suspended solids or to bioaccumulate in biota. The substance hydrolyses at high pH and has been found to be inherently biodegradable in a closed bottle test using adapted activated sludge. Due to these properties and its low volatility 1,3-Diphenylguanidine is expected to be found mainly in the aquatic compartment.

1,3-diphenylguanidine has three forms: unionised, primarily protonated and secondarily protonated. The pKa at which the first protonation occurs is 10.12 while the pKa for the second protonation is unknown and as this will be less than 10.12 it is not known whether this state will be reached at normal environmental pHs between 6 and 8. This leads to problems in interpretation of the environmental fate of the substance.

#### 2.1.2 Fate in Waste Water Treatment Plants

Based on the SIMPLETREAT model and its inherent biodegradability, 1,3-diphenylguanidine is expected to partially degrade in sewage treatment plants. The results using a calculated log Kow of 2.41 (EPIWIN) and a unitless H of  $3.07 \times 10^6$  (EPIWIN) provide the following results:

Air: 0% Water: 49% Sludge: 1% Degraded: 51%

While using a log Kow of 2.9 (SYRACUSE) the results are:

Air: 0% Water: 46% Sludge: 6% Degraded: 48%

#### 2.1.3 Distribution in Air, Water and Soil

Due to the physico-chemical properties of 1,3-diphenylguanidine (soluble in water at the gram per litre range, low volatility and low adsorption to suspended solids), this substance is expected to be found mainly in the aquatic compartment.

# 2.1.4 Abiotic and Biotic Degradation in Air, Water and Soil

#### 2.1.4.1 Atmospheric degradation.

#### 2.1.4.2 Biodegradation

1,3-Diphenylguanidine is not readily biodegradable (0% after 20 days in the OECD 301 D assay) using non-adapted inoculum. However, use of inoculum, pre-adapted for 14 days led to 76% degradation at 1,3-Diphenylguanidine concentrations of 2.4 mg/l and 74% at 0.8 mg/l (Bayer, 1990a). Furthermore, Chou et al. (1980) conducted a study of primary degradation of 1,3-Diphenylguanidine at a pH of 7.5 (measured at the beginning of the test) and found total loss of the parent substance within 14 days of exposure to unadapted river water. The substance can therefore be considered as inherently biodegradable.

#### 2.1.5 Bioaccumulation

1,3-diphenylguanidine has a log  $P_{\rm ow}$  of 1.69 (measured; Chou et al., 1980) and a measured BCF of <20 at 0.01 mg/l and <2 at 0.1 mg/l (limit of quantification) with an exposure period of 42 days. The substance is therefore not expected to bio-accumulate.

#### 2.1.6 Predicted Environmental Concentration

1,3-Diphenylguanidine is produced on a scale estimated as 2400 tonnes in Europe in year 2000, 2400 tonnes in the USA 5300 tonnes in Asia and an amount of 11100 tonnes for the total world) and the vast majority is consumed as a vulcanising agent.

Due to its relatively high solubility and low partition coefficient 1,3-Diphenylguanidine may be present in surface water at very low concentrations.

Sources of release into the environment are multiple e.g. during production, during processing in rubber industry or during the use of rubber articles as well as during the elimination of rubber articles. In the rubber processing industry, waste water can occur during cleaning of equipment, vulcanisation (use of steam) and processing of used rubber.

During the use of rubber articles, releases to the environment may occur directly from the articles as well as from particle abrasions from these articles. Contributions to the emissions due to abrasion are especially relevant for tyres.

The Japanese Environmental Agency measured 42 water and sediment samples from non-industrial sites in Japan (cited in BUA report, 1992). No DPG was found at detection limits of 2 to 5  $\mu$ g/l for water and 0.1 to 0.5 mg/kg in sediment.

# 2.2. Human Exposure

1,3-diphenylguanidine can be absorbed into the body by inhalation and by ingestion.

# 2.2.1 Occupational exposure

Exposure to 1,3-diphenylguanidine may occur during the manufacture of rubber and miscellaneous plastic.

No measurements are available on workplace concentration of 1,3-diphenylguanidine.

# 2.2.2 Consumer exposure

Exposure to 1,3-diphenylguanidine may occur as a result of contact with finished products.

# 2.2.3 Indirect exposure via the environment

Exposure is expected to be mainly local, from production and compoundingsites. Once DPG has been included in the vulacanisation process only residues are expected to be available for leaching from finished rubber compounds.

Little bioaccumulation is expected from bioavailable DPG due to the low bioconcentration factor found in fish.

#### 3. HUMAN HEALTH HAZARDS

#### 3.1. Effects on Human Health

#### 3.1.1. Toxicokinetics & Metabolism

# 3.1.1.1 Oral administration

The absorption, distribution, metabolism and excretion of 1,3-diphenylguanidine was reported by Ioannou & Matthews (1984; reliability 2) after oral administration to male F344 rats.

A comparison of  $^{14}\text{C-1,3}$ -diphenylguanidine (the  $^{14}\text{C-labelling}$  was done by U-labelling on the phenyl rings) tissue distribution and excretion following single oral (dose levels 1.52 - 151.5  $\mu\text{mol/kg})$  versus intravenous (dose level 15.15  $\mu\text{mol/kg})$  administration to male F344 rats, indicates that gastrointestinal absorption of DPG was near complete and that tissue distribution and excretion were not significantly affected by the route of administration.

Within 24 and 72 hours about 80 and >99% respectively of the <sup>14</sup>C activity administered orally or intravenously was excreted about equally in the urine and faeces (elimination half-life 9.6 hours). About 30% of the <sup>14</sup>C activity eliminated in the bile was subjected to entero-hepatic circulation and excreted in the urine.

# Distribution and excretion of radioactivity 1 day after administration of <sup>14</sup>C-1,3-diphenylguanidine to F344 male rats.

		Percentage total dose					
	Intravenous		Oral				
Tissue	15.15 µmol/kg	1.52 µmol/kg	15.15 µmol/kg	151.5 µmol/kg			
Liver	$1.37 \pm 0.08$	$1.31 \pm 0.09$	$1.23 \pm 0.11$	$0.92 \pm 0.09$			
Muscle	$1.18 \pm 0.08$	$1.08 \pm 0.02$	$1.08 \pm 0.01$	$1.09 \pm 0.08$			
Adipose	$0.56 \pm 0.07$	$0.62 \pm 0.03$	$0.47 \pm 0.03$	$0.49 \pm 0.03$			
Skin	$0.52 \pm 0.07$	$0.40 \pm 0.01$	$0.41 \pm 0.05$	$0.39 \pm 0.02$			
Blood	$0.24 \pm 0.01$	$0.27 \pm 0.01$	$0.23 \pm 0.01$	$0.24 \pm 0.02$			
Total excreted							
In urine	$35.50 \pm 3.38$	$31.76 \pm 2.68$	$29.12 \pm 1.72$	$43.61 \pm 2.83$			
In feces	$45.67 \pm 9.01$	$48.25 \pm 4.49$	$45.26 \pm 2.94$	$39.39 \pm 1.84$			
Total <sup>a</sup>	81.17 ± 6.12	$80.01 \pm 6.24$	$74.38 \pm 1.27$	$83.00 \pm 2.41$			

<sup>&</sup>lt;sup>a</sup> DPG-derived radioactivity excreted in urine and faeces in 24 hr. The remainder is still present in tissues and intestinal contents

The following table gives an overview of the relative distribution (in % <sup>14</sup>C-activity) of <sup>14</sup>C-1,3-diphenylguanidine or the metabolites (without identifying them specifically, numbered I to V)) in liver, bile, urine and faeces after single intravenous administration.

# Relative amounts of DPG and DPG-metabolites present in male F344 rat liver and excreta

			DPG metabolite (%)				
Excreta or Organ <sup>1</sup>	Time(h)	I	П	Ш	IV	V	(%)
Liver	0.75	-	$12 \pm 1.2$	-	-	-	$88 \pm 5.7$
	2	-	$18 \pm 1.9$	-	-	-	$82 \pm 4.3$
	6	-	$30 \pm 2.1$	-	-	-	$70 \pm 6.0$
	24	-	$30 \pm 3.3$	$60 \pm 4.5$	-	-	$10 \pm 1.1$
Bile	6	$2 \pm 1.2$	$95 \pm 1.7$	-	-	-	$3 \pm 0.5$
Urine	24	-	$37 \pm 1.6$	$32 \pm 1.4$	-	$3 \pm 0.8$	$28 \pm 0.8$
Faeces	24	-	-	-	$2 \pm 1.0$	$94 \pm 3.5$	$4 \pm 1.4$

<sup>&</sup>lt;sup>1</sup> intravenous administration (15.15 µmol/kg)

Three or 9 oral administrations of  $15.15 \, \mu \text{mol/kg}^{14}\text{C-1,3-diphenylguanidine/kg/day}$  also caused no accumulation in the tissues. In the liver there was a proportional  $^{14}\text{C}$  increase, the metabolites II and III being detected. Covalent binding to liver macromolecules was not determined.

# 3.1.1.2 Dermal administration

The absorption and disposition 1,3-diphenylguanidine was reported by Shah et al. (1985; reliability 2) after dermal administration to female Sprague-Dawley rats.

In female Sprague-Dawley rats, which had received a single dermal application of 0.063 mg  $^{14}$ C-1,3-diphenylguanidine/animal (0.3 µmol), only 10% of the  $^{14}$ C activity penetrated the shaven skin of the back within 5 days with an apparent first-order dermal absorption rate of 0.021  $\pm$  0.002 d $^{1}$  and a t½ of 33.6 days. Distribution throughout the entire organism also occurred here.

The highest <sup>14</sup>C activities after dermal administration were measured in the liver, kidneys, intestines and its content, and excreta. Maximum tissue concentrations after dermal application were reached 3-6 hours after the start of the experiment.

Within 120 hours after dermal application 64% of the absorbed <sup>14</sup>C activity was excreted in the urine and 29% in the faeces. Accumulation in the adipose tissue was not observed.

Relative amounts of DPG and DPG metabolites present in treated skin and excreta

		% metabolites			<sup>14</sup> C-DPG
Excreta or Organ	Time(h)	П	IV	V	(%)
Urine	24	$50 \pm 5.3$	-	-	$50 \pm 5.3$
	48	$53 \pm 1.7$	-	-	$47 \pm 1.5$
	72	$57 \pm 5.2$	-	-	$43 \pm 5.2$
	96	100	-	-	0
	120	100	-	-	0
Faeces	24	-	-	100	-
	48	-	15	85	-
	72	-	20	80	-
	96	-	26	74	-
	120	-	26	74	_
Skin	6-120	-	-	-	>95

#### 3.1.1.3 Other informations

Additional, although insufficiently documented (reliability 3), studies in mice (Hunter & Scully; cited in Bempong & Hall, 1983) and rabbits (Kazarinova et al., 1975) indicate that 1,3-diphenylguanidine is excreted rather quickly and does not accumulate.

Conclusion: 1,3-Diphenylguanidine is absorbed rapidly after oral uptake but only slowly after dermal application. The substance is metabolised quickly and eliminated in the urine and faeces. No information is available on the mode of action and the identity of the metabolites.

# 3.1.2. Acute toxicity

In three studies reliable with restriction (not GLP), oral  $LD_{50}$  values of rats were 350 mg/kg b.w. (Monsanto Company, 1977a; reliability 2), 384 - 460 (Sumitomo Chemical, 1977; reliability 2) and 850 mg/kg b.w. (Monsanto Chemical, 1954; reliability 2).

In one reliable study (OECD guideline and GLP), dermal LD  $_{\rm 0}$  for rabbits was higher than 2000 mg/kg b.w. (Monsanto Company, 1992a; reliability 1).

The following table summarised the acute toxicity data performed following a protocol equivalent to OECD guidelines.

#### Acute toxicity data

Species	Route	Result	Main Effects	Reference	Reliability
Rat (male/female)	Oral	LD <sub>50</sub> = 350 (290- 420) mg/kg	Reduced appetite and activity, increasing weakness, collapse, and death. Gross autopsy of decedents: haemorrhagic	Monsanto Company, 1977a	2
Rat	Oral	$LD_{50}/male=460$ (320-662) mg/kg $LD_{50}/female=384$ (309-477) mg/kg	areas of the lungs  Decrease of spontaneous motor activity, irregular respiration and hind limb, dyspnea	Sumitomo Chemical, 1977	2

Rat	Oral	LD50 = 850  mg/kg	Prostration, coma,	Monsanto Chemical,	2
(male/female)			convulsion. Irritation of	1954	
			the mucous of the		
			stomach and intestinal		
			tract, dark liver and spleen		
Rat	Dermal	$LD_0 > 2000 \text{ mg/kg}$	No mortality, transient	Monsanto Company,	1
(male/female)			dermal irritation. Red	1992a	
			discoloration of the		
			pancreas or pancreatic		
			lymph nodes		

The other acute studies with a low reliability (3 or 4) are compiled in the following table.

Species	Route	Dose (mg/kg)	Main Effects	Reference
Rat	Oral	375	LD50	Arkhangel'skaya and Roshchina; 1963, 1964
Rat	Oral	c.a.500	LD50	Dieke et al., 1947
Rat	Oral	250	maximum tolerated dose, spasms, liver weight	Arkhangel'skaya and Roshchina, 1963, 1968
Rat	Oral	500	minimum lethal dose	Arkhangel'skaya and Roshchina, 1963
Rat	Oral	323	LD50	Vlasyuk, 1978
Mouse	Oral	290	LD50	Arkhangel'skaya and Roshchina,1964
Mouse	Oral	250	maximum tolerated dose; spasms, liver weight	Arkhangel'skaya and Roshchina, 1963, 1968
Mouse	Oral	450	LD100	Arkhanæl'skaya and Roshchina, 1963, 1968
Mouse	Oral	258	LD50	Vlasyuk, 1978
Mouse	Oral	520	LD50	Amer. Cyan. Co.; cited in McCormick (1971)
Mouse	Oral	150	LD50 male	Hasegawa et al., 1989
Mouse	Oral	211	LD50 female	Hasegawa et al., 1989
Rabbit	Oral	246	LD50	Vlasyuk (1978)
Rabbit	Oral	250	minimum lethal dose	Smyth, 1931
Rabbit	Oral	250	LD50	Marhold, 1986
Guinea pig	Oral	250	minimum lethal dose	Smyth, 1931
Guinea pig	Oral	250	LD50	Marhold, 1986
Dog	Oral	10	emetic dose	Amer. Cyan. Co.; cited in McCormick (1971)
Rabbit	Dermal	>794	LD50	Monsanto Company, 1977b

Conclusion: 1,3-diphenylguanidine is moderately toxic by ingestion, the oral LD50 is 350-850 mg/kg b.w. for the rat. By dermal route, 1,3-diphenylguanidine is practically non toxic, the dermal LD0 is > 2,000 mg/kg b.w. in the rabbit. After oral administration, the symptoms were normally of a nervous character, but post mortem examination revealed liver effects (dark color) and severe irritation of the gastro-intestinal tract.

# 3.1.3. Repeated Dose Toxicity

# 3.1.3.1. Animal data

Sub-chronic feeding experiments in rats and/or mice have been performed according to OECD guidelines and GLP in the frame of the US National Toxicology Program (1995, reliability 1) and by the Monsanto Europe (1982, reliability1).

In F344/N rats and B6C3F1 mice which, in a dose-finding study, received 1,3-diphenylguanidine (98.9%) for 14 days in their feed in concentrations of 250, 500, 750, 1,500 and 3,000 ppm, only reduced feed intake and decreased body weights were observed as of 750 ppm (NTP, 1995; reliability 1).

In the subsequent sub-chronic 13-week study, 1,3-diphenylguanidine (98.9%) was fed to the F344/N rat and B6C3F1 mouse in the same concentrations as in the sub-acute study (equivalent to daily dose of 17/17, 32/32, 50/49, 100/95 and 181/184 mg/kg bw/d for male/female rats and 38/46, 75/93, 114/141, 231/285 and 457/577 mg/kg bw/d in male/female mice at 250, 500, 750, 1500 and 3000 ppm, respectively).

In rats, due to the poor palatability of the 1,3-diphenylguanidine-treated feed, a decreased feed consumption and reduced body weights were observed as of 750 ppm compared to controls (final weight relative to controls: 750 ppm (m/f): 92%/93%; 1,500 ppm: 79%/86%; 3,000 ppm: 52%/-). Increased mortality was observed for both sexes after receiving 3,000 ppm in feed, whereby all females of this concentration group died. Primarily substance-induced effects on the organs were not observed. The diverse deviations from the controls, determined also for the haematological and clinical-chemical parameters particularly in both highest concentrations (1,500 and 3,000 ppm), are seen exclusively as the result of emaciation by reduced feed intake.

With the average feed intake comparable with the controls, body weight retardation was observed in the mice also as of 750 ppm. The reduced organ weights occurring as of 1,500 ppm were evaluated not as a specifically toxic response but rather were correlated to the clearly reduced body weights. Histopathological changes and significant deviations from the controls for the haematological and clinical-chemical parameters were not observed.

Based on the secondary toxic effects, due to the poor palatability of the 1,3-diphenylguanidine-treated feed, the NOAEL for both species lies at 500 ppm (ca. 32 mg/kg b.w. and day for rats and ca. 75 mg/kg b.w. and day for mice) (NTP, 1995; reliability 1).

In an other sub-chronic toxicity study, dosing Sprague-Dawley rats with 1,3-diphenylguanidine (97.7%) in the diet at a concentration of 50, 150 or 500 ppm for 13 weeks (equivalent to daily dose of 4, 11 and 37 mg/kg bw/d), produced a marked reduction in growth rate of both males and females at 500 ppm, with respect to controls. The food consumption of these animals was also reduced, when compared to the controls. These effects were most pronounced over the first few weeks of dosing, suggesting that the cause may partly be due to the unpalatability of the test substance. Dose levels of 1,3-diphenylguanidine up to 500 ppm did not cause an increase in mortality or the appearance of any abnormal clinical signs.

Laboratory investigations revealed small differences between rats receiving DPG and the controls in both haematological and clinical chemical parameters, but as the same effects were not present at both weeks 6 and 13 they are considered to be of little or no significance. Male rats receiving 500 ppm DPG tended to produce more concentrated urine than the controls at weeks 6 and 13, with a slightly reduced pH on the latter occasion. Female rats at the same dose level also showed a slight aciduria, but at week 13 only. These effects were only slight and could not be attributed to any obvious structural change to the kidney as seen on histopathological examination. The changes seen lacked a dose response and were of marginal magnitude, thereby confirming their insignificance. The terminal macroscopic and histopathologic examinations revealed no dose related lesions; those lesions found were spread across the dose groups with roughly equal incidence and are considered to be common findings in rats of this age and strain. Based on the marked reduction of the growth rate at 500 ppm, due to the poor palatability of the 1,3-diphenylguanidine-treated feed, the NOAEL lies at 150 ppm (11 mg/kg bw/d) (Monsanto, 1982; reliability 1).

Additional subacute and subchronic studies are compiled in the following table. These are insufficiently documented in some cases; most do not meet current requirements (reliability 3 or 4), such as those concerning dose selection. Thus the results should not be assessed critically.

Species	Administration	Dose/Day	Main Effects	Reference
(sex/number)	(duration)	(mg/kg b.w./d)		
Rat	Feed (28 d)	7, 75 and 75	75 mg/kg: gowth retardation	McCormick, 1971
Rat	Oral (4 mo)	32	reticulocytosis, eosinophi lia, erythrocytes, hemoglobin, inhibited catalase and peroxidase, total bilirubin, threshold of nerve and muscle irrita bility, mortality, no kidney findings	Orlov et al. (1973)
Rabbit	Oral (not given)	10% LD100	feed intake, erythrocytes, serum t-globulin	Arkhangel'skaya and Roshchina, 1963, 1968
Rabbit	Oral (5.5 months)	50	severely inflamed liver parenchyma, bilirubin, dystrophy of convoluted tubules, unchanged blood picture	Arkhangel'skaya and Roshchina, 1963, 1968
Dog	Oral (24 d)	10 (21 administrations)	"relatively well tolerated"	Amer. Cyan. Co.; cited in McCormick, 1971
Dog	Oral (not given)	5	bile acids	Burov (1964)
Rabbit	Dermal (10 administrations)	1000	no systemic effect	McCormick, 1971
Rat	Inhalation	about 220 mg/m3/2h	Disturbed "oxidation- reduction" processes, functionally disturbed nervous system, blood pressure	Arkhangel'skaya and Roshchina, 1963, 1968
Guinea pig	Inhalation (repeated)	100 mg/l	Lethal	Verchovski, 1952

Conclusion: Three sub-chronic 13-week toxicity feeding studies in rats or mice have shown an increase of the mortality rate in rats at high dose (3000 ppm) and a decrease of food consumption in rats (as of 500-750 ppm) and body weight gain in rats and mice (as of 500-750 ppm) due to the poor palatability of the 1,3-Diphenylguanidine-treated feed. Treatment -related effects on the organs and the haematological, clinical-chemical parameters and urinalysis were not observed. The NOAEL/LOAEL lies at 500/750 ppm (32/50 mg/kg bw/d) and 150/500 ppm (11/37 mg/kg bw/d) for rats and 500/750 ppm (75/114 mg/kg bw/d) in mice.

Based on these data, a conservative NOAEL can be established at 32 mg/kg bw/d for rats and 75 mg/kg/d for mice.

#### 3.1.3.2. Human data

The only results available are from a poorly documented study, whose validity cannot be judged due to the lack of data on possible previous employment, the possibilities of contact with other substances, concentrations and control groups. Orlov et al. (1973; reliability 4) examined workers ranging in age from 29 to 58 years, who had come into contact with 1,3-diphenylguanidine during production (no further information) over 3-15 years. About 30% of the test subjects showed symptoms, most suffering from stomach and gall-bladder complaints, neurological disorders or skin diseases. Another finding was liver metabolism disorder (disturbed protein metabolism, increased bilirubin values).

Following unintentionally increased workplace exposure to 1,3-diphenylguanidine due to inadequate safety measures, the following symptoms were reported: eyelid pain and eye redness, a bitter taste and a painful feeling in the oesophagus. Reduced gastric juice acidity and achylia were also determined. Further data are not available (Arkhangel'skaya & Roshchina, 1963; reliability 4).

# 3.1.4. Genetic Toxicity

# In vitro assays

Results available on Ames tests are predominantly negative (8 out of 10 studies) (Monsanto, 1976; JETOC, 1996; Crebelli et al., 1984a, 1984b, 1985; Rannug et al., 1984; You et al., 1982; Yamaguchi et al., 1991). In one Ames test 1,3-diphenylguanidine caused a weak increased number of revertants after metabolic activation (S9 mix from hamster liver) (Mortelmans et al., 1986; NTP, 1995), while in another case the weakly positive result may have been due to contamination (Bempong & Mantley, 1985; Bempong, unpublished data).

All other in vitro investigations, gene mutation on Escherichia coli and Saccharomyces cerevisiae (JETOC, 1996; Monsanto, 1976), gene mutation assays on CHO (Donner, 1983) and mouse lymphoma cells (Monsanto, 1979) and cytogenetic assay on CHO cells (Monsanto, 1992b) were consistently negative. 1,3-diphenylguanidine at a concentration of 7.5  $\mu$ g/ml caused 50% inhibition of the colony formation in HeLa-S3 cells (Baba, 1980; reliability 4).

#### In vitro genetic toxicity

Test System	Metabolic activation	Concentration	Result	Reference	Reliability
Calman all a tombiomorium	+ <sup>(2)</sup>	33-10000	Negative	Mortelmans et al,	1
Salmonella typhimurium	+` ′		Negative		1
TA98, 100, 1535, 1537		μg/plate	NT	1986; NTP, 1995	2
Salmonella typhimurium	+/-	2-500 µg/plate	Negative	JETOC, 1996	2
TA98, 100, 1535, 1537,					
1538	,	0.1.700 / 1		3.5	
Salmonella typhimurium	+/-	$0.1-500 \mu g/plate$	Negative	Monsanto, 1976	2
TA98, 100, 1535, 1537,					
1538	(1)				
Salmonella typhimurium	+(1)	100-10000	Negative	Mortelmans et al,	2
TA1535, 1537		µg/plate		1986; NTP, 1995	
Salmonella typhimurium	+/-	200-5000	Negative	Crebelli et al, 1984,	2
TA98, 100		µg/plate		1985	
Salmonella typhimurium	+(1)	1-100 µg/plate	Weakly	Mortelmans et al,	2
TA98, 100			positive	1986; NTP, 1995	
Salmonella typhimurium	+/-	0.036-36	Weakly	Bempong and	3
TA98, 100, 1535, 1537,		µg/plate	positive	Mantley, 1985	
1538			1		
Salmonella typhimurium	+/-	No data	Negative	Rannug et al., 1984	3
TA98, 100, 1535, 1537,					
1538					
Salmonella typhimurium	+/-	No data	Negative	You et al., 1982	4
TA98, 100					
Salmonella typhimurium	+/-	1-100 µg/plate	Negative	Yamaguchi et al.,	4
TA98, 100				1991	
Escherichia coli WP2	_	2-500 µg/plate	Negative	JETOC, 1996	2
	+	20-5000 µg/plate		,	
HGPRT test on V79 cells	-	100-500 mg/ml	Negative	Donner et al., 1983	3
TK +/- assay on L5178Y	-	16.4-188 μg/ml	Negative	Monsanto, 1979	2
cells	+	32.8-525 μg/ml			
Saccharomyces	+/-	1-500 µg/plate	Negative	Monsanto, 1976	2
cerevisiae D4					
Cytogenetic assay on	+/-	125-750 µg/ml	Negative	Monsanto, 1992b	2
CHO cells					

(1) 10 % hamster liver homogenate

(2) 10 % rat liver homogenate

12

#### In vivo assays

The micronucleus test on erythrocytes of the peripheral blood of mice, that obtained feed with a 1,3-diphenylguanidine-content of 250, 500, 750, 1,500 and 3,000 ppm in the sub-chronic test, led to a negative result in the male animals. The test result of the females was evaluated as "questionable" because of the statistically significant increase of the micronuclei-carrying normochromatic erythrocytes in the female animals of the middle concentration group (750 ppm) (NTP, 1995; reliability 1).

However, in a cytogenetic assay, 1,3-diphenylguanidine was administered via oral gavage to male and female rats at a target dose of 300 mg/kg body weight. Bone marrow was sampled at 6, 24 and 48 hours after dosing. No statistically significant increases in the proportion of aberrant cells or aberrations/cell were observed. Significant induction of toxicity, measured as mitotic index depression was observed at the 6 hour (35%) and 24 hour (31%) time points. No depression in mitotic index was observed at the 48 hour time point (Monsanto 1989; reliability 1).

A micronucleus test in mice was reported negative (further information not given; Bempong, unpublished data; reliability 4).

Bempong and Mantley (1985) (reliability 3) administered a single i.p. dose of 0.036-36 mg 1,3-diphenylguanidine/kg bw to mice and then examined the peritoneal fluid, urine and faeces daily for 4 days with *Salmonella typhimurium* strain TA 100 (modified host-mediated assay). Only in the faeces was a dose and time-related increase in the number of revertants seen. This result may have been due to contamination of the test substance, as later investigations with the pure compound were negative. Further data are not available (Bempong, unpublished data).

Conclusion: Most of the *in vitro* and *in vivo* investigations available give no indication of a genotoxic effect.

#### 3.1.5 Carcinogenicity

No relevant data available.

# 3.1.6. ReproductiveToxicity

In addition to the results of the sub-chronic studies on the rat and mouse described in Section 3.1.3 (NTP, 1995; Monsanto, 1982), special studies for recognising reproductive toxic effects were also performed (Koëter et al., 1992; WTR, 1989, NTP, 1995; reliability 1).

1,3-Diphenylguanidine (purity 99.9%) was administered by daily gavage to groups of 25 male CD-1 mice at dose levels of 0, 0.06, 0.25, 1, 4 and 16 mg/kg/d during an 8-week pre-mating period. Females were not dosed at any time during the study. Within 24 hours after the last treatment, 9 to 13 males, randomly taken from each group were killed and subject to gross examination at autopsy. A selected number of organs were weighted and preserved. Sperm abnormality evaluation was performed in the selected males from the control and 16 mg/kg dose group. The remaining males in the control, 4 and 16 mg/kg body wt per day groups were mated with non-dosed females. Reproductive performance, necropsy findings and litter data were recorded.

No differences were found between control and dosed groups in body weight gain during the dosing period, macroscopic observations and organ weights at necropsy. Microscopic examination of the testes in the 16 mg/kg/d group, did not show any effect due to 1,3-diphenylguanidine dosing when compared to the control group. Sperm abnormality evaluation in the 16 mg/kg/d group showed a slight but statistically significant increase (5% versus 2% in control) in sperm with folded tails but normal heads. However, since the total number of abnormal sperm cells as well as the number of specified sperm abnormalities was similar, the observed increased number of sperm cells with folded tails is considered of doubtful significance. Male and female fertility as well as reproduction performance were comparable in the groups examined (0, 4 and 16 mg/kg/d). Maternal necropsy findings and litter data did not reveal any dose-related effect.

It was concluded that under the conditions of this study, 1,3-diphenylguanidine did not exert any significant adverse effects on fertility, reproductive capacity or embryonic/foetal development in CD-1 mice when administered to males at levels up to 16 mg/kg/d (Koëter et al., 1992; WTR, 1989; reliability 1)...

Male and female F344/N rats and B6C3F1 mice had been administered feed having a 1,3-diphenylguanidine (purity 98.9%) content of 250, 500, 750, 1,500 and 3,000 ppm for 13 weeks (NTP, 1995; reliability 1).

Female rats exhibited uterine hypoplasia and a prolonged reproductive cycle in the 750 ppm-group (ca. 49 mg/kg b.w. and day) and 1,500 ppm-group (ca. 95 mg/kg b.w. and day) in comparison with the controls. All females of the 3,000 ppm-group died during the study, so that comparable studies of these animals could not take place. The male rats, only in the 1,500 ppm-group (ca. 100 mg/kg b.w. and day), showed diminished sperm motility. Alterations in the reproductive organs (e.g. depletion of the prostate, hypospermia, reduced spermatogenesis) were occasionally found in the males of the 3,000 ppm-group (ca. 181 mg/kg b.w. and day).

Also for the mice which obtained up to 3,000 ppm 1,3-diphenylguanidine in feed for 13 weeks, a prolonged reproductive cycle was observed in the females of the highest concentration group and, in the male animals, a decreased sperm motility. The increased number of spermatid heads in the testes paired with the lower number of sperm in the epididymis is evidence against an effect on spermatogenesis, whereas an effect on the release of sperm into the epididymis cannot be excluded. Comparisons of the parameter changes determined after the 1,3-diphenylguanidine-feeding in the rat and mouse, which can be used for assessing a possible reproductive toxic effect, with the results of tests with feed withdrawal (Chapin et al., 1993a and 1993b; Levin et al., 1993) infer that the effects observed in the 1,3-diphenylguanidine-treated animals in high concentration groups are a result of the poor general state of health (malnutrition, exhaustion) of the animals.

In conclusion, no reprotoxic effect was observed in male and female rats up to 500 pmm (32 mg/kg bw/d) and in mice up to 1500 ppm (231-285 mg/kg bw/d) in feed. At higher concentrations, the effects on the reproductive parameters were due to reduced nutrient intake and are consistent with similar changes observed in other studies of feed restricted rats and mice.

Bempong analysed the effects of 1,3-diphenylguanidine (purity not reported, probably of low purity according to correspondence with the author) on seminal cytology, testicular development and fertility (Bempong, 1983a and 1983b; Bempong & Hall, 1983; reliability 3). Dose-levels of 4 and 8 mg/kg bw/day 1,3-diphenylguanidine, administered by the oral route up to 15 weeks, induced a time- and dose-dependent increase in the frequency of sperm abnormalities in both mice and hamsters from week 4, a significant decrease in sperm count and testes weight from week 5, and irregularly shaped seminiferous tubules in mice. The fertility index and the number of implants per pregnant female mice were decreased in a dose-dependent fashion, but the effect did not seem to be time-dependent. The frequency of early or late dead foetuses per litter was significantly increased at the 5th and 7th week of dosing at the high dose levels.

Taken into account the uncertainties related to the study protocol (lack of details on compound purity, mode of administration, number of treated animals/dose, food and water consumption, clinical signs and body weight, poor statistical evaluation and no GLP) and the conflicting results with the other available information, these studies were considered as not reliable (category 3) and not taken into account to evaluate the reprotoxicity of 1,3-diphenylguanidine. The difference in these results may be explainable by contamination of the 1,3-diphenylguanidine employed in the studies carried out by Bempong.)

The reliable available data on reprotoxicity of 1,3-diphenylguanidine are summarised in the following table.

Conclusion: Taken into account the reliable studies, 1,3-diphenylguanidine did not affect the fertility of male mice when administered by gavage up to the maximal tested dose level of 16 mg/kg/d. In addition to the results of the feeding sub-chronic studies on the rat and mouse, special studies for recognising reproductive toxic effects were also performed. Comparisons of the parameter changes with the results of tests with feed withdrawal infer that the effects observed in the 1,3-Diphenylguanidine-treated animals in high concentration groups are a result of the poor general state of health (malnutrition, exhaustion) of the animals and not a direct toxic effect on the reproductive organs. Very conservative NOAELs, based on the effects on the reproductive organs, secondary to

malnutrition and exhaustion, can be established at 32 mg/kg bw/d for rats and from 16 to 231 mg/kg bw/d for mice.

# Reliable reprotoxicity studies available on 1,3-diphenylguanidine

	Koeter et al, 1992; WTR, 1989	NTP, 1995	NTP, 1995	Monsanto, 1982
QUALITY ASSESSMENT				
Product purity	99.9%, Industrial batch	98.9% <u>+</u> 0.6%	98.9% <u>+</u> 0.6%	97.7%
Check of DPG stability in vehicle	No. Solution prepared freshly once a week	Yes	Yes	Yes
GLP	Yes	Yes	Yes	Yes
Availability of raw data	Yes	Yes	Yes	Yes
Reliability	1	1	1	1
PROTOCOL		•	·	•
Treated animals	8-week-old male CD-1 mice	6- to 7-week-old B6C3F1 male and female mice	6- to 7-week-old F344/N male and female rats	6-week old male and female Sprague-Dawley rats
Route of administration	Gavage	Dietary ad libitum	Dietary ad libitum	Dietary ad libitum
Dose levels	0, 0.06, 0.25, 1.0, 4.0, & 16.0 mg/kg/d	0, 250, 500, 750, 1500, & 3000 ppm (equivalent to 38, 75, 114, 231, & 457 m g/kg/d for the males and 46, 93, 141, 285 and 577 mg/kg/d for the females)	0, 250, 500, 750, 1500, & 3000 ppm (equivalent to 17, 32, 50, 100, & 181 mg/kg/d for the males and 17, 32, 49, 95 and 184 mg/kg/d for the females)	0, 50, 150, & 500 ppm (approx. 4, 11 or 37 mg/kg/day)
Duration of treatment	8 weeks	13 weeks	13 weeks	13 weeks
RESULTS		•	·	•
Body weight gain	Not affected	<b>♦</b> from 750 ppm and upward	<b>♦</b> from 1500 ppm and upward	<b>↓</b> at 500 ppm
Testis Organ weight	Not affected	Not affected	◆ at 3000 ppm in relation with the body weight loss	Not affected
Histology	Not affected	Not affected	◆ spermatogenesis at 3000 ppm secondary to body weight loss	Not affected
Ovaries				
Organ weight Histology	Not relevant Not relevant	Not affected Not affected	Not affected Not affected	Not affected Not affected
Uterus Length of the	Not relevant	↑ at 3000 ppm in relation with	$\spadesuit$ at > 750 ppm in relation with	Not evaluated

estrous cycle		the body weight loss	the body weight loss	
Sperm				
Count	Not evaluated	Not affected	Not affected	Not evaluated
Morphology	No effects on the total number of abnormal sperm	Not evaluated	Not evaluated	Not evaluated
Motility	Not evaluated	◆ at 3000 ppm secondary to poor body condition	<b>♦</b> at 1500 ppm secondary to poor body condition	Not evaluated
Male fertility after mating with untreated	Not affected	Not evaluated	Not evaluated	Not evaluated
female				
CONCLUSION			·	•
	No testicular toxicity and no	No direct toxicity on	No direct toxici ty on	No toxicity on reproductive
	effects on fertility	reproductive organs	reproductive organs	organs
NOAEL for reprotoxicity	≥ 16 mg mg/kg/d	231 mg/kg/d	32 mg/kg/d	≥ 37 mg/kg/d

#### 3.1.7. Developmental Toxicity

Two studies, one in rats (Monsanto, 1986; reliability 1) and one in mice (Yasuda & Tanimura, 1980; reliability 2), are available for the evaluation of the effects of 1,3-diphenylguanidine on the development.

Potential maternal, embryotoxic and teratogenic effects of 1,3-diphenylguanidine were evaluated in rats. 1,3-diphenylguanidine was administered orally by gavage to three groups of 25 bred CD female rats as a single daily dose of 0, 5, 25 and 50 mg/kg/day from days 6 through 15 of gestation. Throughout gestation, all females were observed twice daily for toxicity and body weights were recorded at appropriate intervals. On day 20 of gestation, all surviving females were sacrificed for Cesarean section; foetuses were weighed, sexed and examined for external, skeletal and soft tissue anomalies and developmental variations.

No unscheduled deaths occurred in any study group. Severe clinical signs of toxicity, decreased maternal body weights and body weight gains, a slight increase in post-implantation loss and a significantly decreased mean foetal weight were evident in the 50 mg/kg/day dose group. A slight increase in foetuses with reduced ossification (associated with reduced foetal weights) and an increase in bent ribs (attributed to maternal toxicity in this group) were observed at the 50 mg/kg/day dose level. Scattered, infrequent clinical findings and a slightly reduced body weight gain over the treatment period (gestation days 6-16) occurred at the 25 mg/kg/day dose level. The 5 mg/kg/day group was comparable to the vehicle control group in all parameters measured. The infrequent occurrence and nature of the malformations were not indicative of a teratogenic response in any dose group. In conclusion, 1,3-diphenylguanidine induced severe maternal toxicity at a dose level of 50 mg/kg/day. Fetotoxicity was also expressed at this dose level by a significantly reduced mean foetal body weight and by an increase in foetal variations. A dose level of 25 mg/kg/day was considered a marginal NOEL for maternal toxicity; a foetotoxic response was not apparent. A dose level of 5 mg/kg/day was considered a NOEL (Monsanto, 1986; reliability 1).

Groups of 20 pregnant mice of the ICR-JCL strain were given 1,3-diphenylguanidine orally in doses of 0.25, 1.0, 4.0, or 10.0 mg/kg of body weight/day throughout pregnancy. Control mice were fed the vehicle atone. On day 18 of pregnancy, all mice were killed and the foetuses were examined. Disturbances in implantation were seen in the mothers treated with 10 mg/kg/day (the highest dose) of DPG. Retarded ossification of the talus was seen in the foetuses of mothers treated with 4.0 mg/kg/day, but there was no dose-response relationship to this finding. Although malformations such as open eyelids or polydactyly were seen sporadically, these were categorised as spontaneous anomalies. Thus, DPG seems to have no detrimental effects on the development of mouse foetuses in doses of 4 mg/kg or less (Yasuda & Tanimura, 1980; reliability 2).

In 17 of 130 chicken embryos (control 1) 1,3-diphenylguanidine led to increased rates of mortality and malformation. The ED50 was 0.042 mg/egg (Korhonen et al., 1983a and 1983b; reliability 3). This test is not validated for reproduction toxicity.

Conclusion: In female rats and mice foetotoxic, but not teratogenic, effects were seen after the oral administration of maternotoxic doses. In the rat study the NOEL was given as 5 mg/kg bw for the dams and 25 mg/kg bw for the foetuses. In the mouse study the NOEL was given as 4 mg/kg bw for the dams and higher than 10 mg/kg bw for the foetuses.

#### 3.1.8. Other: irritation, Sensitization

#### 3.1.8.1. Irritation

In one study reliable with restriction (not GLP), no skin irritation was observed after a 24-hour occlusive application of 500 mg on the skin of 6 rabbits (Monsanto Company, 1977c; reliability 2). In two studies reliable with restriction (not GLP), slight to moderate irritation was observed after the instillation of 20 or 100 mg in the eye of 6 rabbits (Monsanto Company, 1977d and 1977e; reliability 2).

#### 3.1.8.2. Sensitisation

#### Animal data

According to the Magnusson and Kligman maximization test performed according to GLP and OECD guidelines, 1,3-diphenylguanidine is not sensitizer in guinea-pigs (MLPC, 1995; reliability 1).

#### Human data

In persons suffering from a contact dermatitis positive 1,3-diphenylguanidine patch tests have **occasionally** been described (see the following table). The following main contact possibilities were named: shoes (Blank & Miller, 1952; de Vries, 1964; Hjorth & Fregert, 1972; Song et al., 1979; Lynde et al., 1982; Bajaj et al., 1988), articles of clothing (Bandmann, 1956; van Dijk, 1968; Song et al., 1979), rubberized protective clothing (Fegeler, 1963; Götz & Istvanovic, 1963; Höfer & Hänemann, 1967; Ross & Obst, 1969) and other rubber articles, e.g. gloves or the rubber parts of milking machines (Nater, 1975; Song et al., 1979).

A tire production employee, whose allergic rhinitis symptoms occurred only at the workplace, had a positive patch test reaction with 1% 1,3-diphenylguanidine (Camarasa & Alomar, 1978).

Garcia-Perez et al. (1984) found that Spanish agricultural workers with a contact dermatitis had a significantly higher sensitization to 1,3-diphenylguanidine than a contact dermatitis control group working in another profession (11.76% versus 5.32%). The authors attributed this to possible cross-reactions with pesticides, as some of these substances (e.g. Cyprex) are guanidine derivatives and others (e.g. the cyanamides) possess a similar chemical structure.

The available data are summarised in the following table.

Results of Patch Tests Performed with 1,3-diphenylguanidine

Subjects (n)	Positive	+ve reaction	Concentration	Reference	
	(n)	(%)	(%)		
35	2	6	1	Adams, 1972	
524	6	0.01	1+2.1	Agrup, 1969	
1	1	-	1	Aguirre et al., 1994	
229	18	8	0.5	Baer et al., 1973	
105	3	3	3	Bajaj et al., 1988	
5	1	20	1	Bandmann, 1956	
24	0	0	1	Blank & Miller, 1952	
74	2	3	n.g.*	Bonnevie & Marcussen, 1944	
1	1	-	n.g.	Bruze, 1994	
1	1	-	1	Calan, 1978	
686	13	2.3	n.g.	Conde-Salazar et al., 1993	
5	0	0	0.25	Curtis, 1945	
59	0		1	Dahl, 1975	
9	1	11	n.g	de Vries, 1964	
34	4	12	n.g.	Garcia-Perez et al., 1984	
244	13	5	n.g.	Garcia-Perez et al., 1984	
17	6	35	1	Götz & Istvanovic, 1963	
1	1	-	n.g.	Helander & Mäkelä, 1983	
63	15	24	n.g	Herrmann & Schulz, 1960	
10	3	30	n.g.	Höfer & Hönemann, 1967	
20	7	35	n.g.	Jung, 1977	
5	1	20	1	Kanerva et al., 1994	
11	0	0	1	Kanerva et al., 1996	
31	2	7	1	Kantoh et al., 1985	
46	4	8.7	1	Kiec-Swierczynska, 1995	
50	2	4	n.g.	Kilpikari, 1982	
15	0	0	1	Knudsen et al., 1993	

Results of Patch Tests Performed with 1,3-diphenylguanidine (continued)

Subjects (n)	Positive	+ve reaction	Concentration	Reference
	( <b>n</b> )	(%)	( <b>%</b> )	
30	1	3.3	1	Koch et al., 1996
1	0	-	1	Koch, 1996
61	2	3	1	Lisi & Simonetti, 1985
61	3	5	1	Lisi & Simonetti, 1985
119	3	3	1	Lynde et al., 1982
1377	5	0.4	n.g.	Meneghini et al., 1963
49	2	4	70	Monsanto, 1982
6	2	33	1	Nater, 1975
n.g.	n.g.	3****	n.g.	Orlov et al., 1973
844	44	5	1	Rajan & Khoo, 1980
1600	25	1.6	1	Reifferscheid, 1979
2	0	-	n.g.	Roed-Petersen & Menne, 1976
15	1	7	1+2	Ross & Obst, 1969
744	74***	9.9	1	Rudzki & Kleniewska, 1970
47	6	13	n.g.	Rudzki & Kohutnicki, 1971
1	1	-	n.g.	Ruocco & Florio, 1986
50	6	12	1	Saha et al.; 1993
502	7	1.4	2	Suskind, 1984
4	3	75	n.g	Takeda et al., 1964
32	0	0	1	te Lintum & Nater, 1973
1	0	-	1	Tuyp & Mitchell, 1983
3	1	33	2	van Dijk, 1968
106	_**	-	1	Wilson, 1969

<sup>\*</sup> n.g. = not given

Conclusion: Human cases have shown that contact dermatitis patients, for whom a rubber intolerance was often present, occasionally reacted positively to 1,3-diphenylguanidine in the patch test. Taken into account the negative Guinea pig maximization assay, it can be infer that the positive reactions observed in human p atients with contact dermatitis reflected cross-reactions rather than a direct sensitizing effect of 1,3-diphenyl guanidine.

#### 3.2 Initial Assessment for Human Health

# 3.2.1. Effects on human health

1,3-diphenylguanidine is absorbed rapidly after oral uptake but only slowly after dermal application. The substance is metabolised quickly and eliminated in the urine and faeces. No information is available on the mode of action and the identity of the metabolites.

The oral LD50 is 323-850 mg/kg b.w. for the rat. The dermal LD0 is > 2,000 mg/kg b.w. in the rabbit. Intoxication is manifested by spasms, disturbed lipid metabolism, lung emphysema and kidney changes.

Three subchronic toxicity feeding studies in rats and mice have shown an increase of the mortality rate at high dose and a decrease of food consumption and body weight gain due to the poor palatability of the 1,3-diphenylguanidine-treated feed. Treatment -related effects on the organs and the haematological, clinical-chemical parameters and urinalysis were not observed. The NOAEL/LOAEL lies at 32/50 mg/kg bw/d and 11/37 mg/kg bw/d for rats and 75/114 mg/kg bw/day in mice. Based on these data the best estimate for the NOAEL was 32 mg/kg bw/d for rats and 75 mg/kg/d for mice.

<sup>\*\*</sup> no evaluation possible due to a number of irritating reactions

<sup>\*\*\*</sup> possible irritating reactions could not be ruled out

<sup>\*\*\*\*</sup> scarification of skin

Most of the *in vitro* and *in vivo* investigations available give no indication of a genotoxic effect.

A carcinogenicity study which would meet present standards is not available.

1,3-diphenylguanidine did not affect the fertility of male mice when administered by gavage up to the maximal tested dose level of 16 mg/kg/d. In addition to the results of the feeding sub-chronic studies on the rat and mouse, special studies for recognising reproductive toxic effects were also performed. Comparisons of the parameter changes with the results of tests with feed withdrawal infer that the effects observed in the 1,3-Diphenylguanidine-treated animals in high concentration groups are a result of the poor general state of health (malnutrition, exhaustion) of the animals and not a direct toxic effect on the reproductive organs. Very conservative NOAELs, based on the effects on the reproductive organs, secondary to malnutrition and exhaustion, can be established at 32 mg/kg bw/d for rats and from 16 to 231 mg/kg bw/d for mice.

In female rats and mice foetotoxic, but not teratogenic, effects were seen after the oral administration of maternotoxic doses. In the rat study the NOEL was given as 5 mg/kg bw for the dams and 25 mg/kg bw for the foetuses. In the mouse study the NOEL was given as 4 mg/kg bw for the dams and higher than 10 mg/kg bw for the foetuses.

1,3-diphenylguanidine is irritating to the eye and non-irritating to the skin.

Human cases have shown that contact dermatitis patients, for whom a rubber intolerance was often present, occasionally reacted positively to 1,3-diphenylguanidine in the patch test. Taken into account the negative Guinea pig maximization assay, it can be infer that the positive reactions observed in human patients with contact dermatitis reflected cross-reactions rather than a direct sensitizing effect of 1,3-diphenyl guanidine.

In man, earlier and unconfirmed studies described the following symptoms after workplace exposures to 1,3-diphenylguanidine: eye and mucous membrane irritation, gastric and bilious complaints and disturbed liver metabolism.

# 3.2.2. Occupational exposure

No data available.

# 3.2.3. Consumer exposure

No data available.

#### 3.2.4. Indirect exposure via environment

No data available.

#### 4. HAZARDS TO THE ENVIRONMENT

# 4.1 Effects on the Environment

# 4.1.1 Aquatic Effects

1,3-Diphenylguanidine has been shown to be toxic to fish and algae and harmful to daphnia (fish: 96 h LC50 = 4.2-11 mg/l; algae: EC50 = 1.7-7.5 mg/l; daphnid: 48 h EC50 = 17-62.4 mg/l)

#### 4.1.1.1 Acute toxicity to fish

Three studies on three fish species can be considered valid with restrictions. The lowest 96 h LC50 of 4.2 mg/l (ABC, 1979a) was observed for *Pimephales promelas* in a static test and based on nominal concentrations. The test is considered valid despite the lack of analysis as the test substance has been shown to be stable in water at the pH range required for this test. The remaining studies are not considered valid for use in hazard assessment due to the low study duration but the results support the valid studies.

species	duration	results	remarks	references	reliability
Pimephales	96 h	LC50 = 4.2  mg/l	Static, no analysis	ABC laboratory	2
promelas				(1979a)	
Oncorhynchus	96 h	LC50 = 11 mg/l	Static, no analysis	ABC laboratory	2
mykiss				(1979b)	
Lepomis	96 h	LC50 = 9.6  mg/l	Static, no analysis, O2	ABC laboratory	2
macrochirus			concentration dropped	(1979c)	
			below accepted limits		
			at 96 h		
Oryzias latipes	48 h	LC50 = 10  mg/l	Static or semi-static	MITI (1992)	3
Leuciscus idus	48 h	LC100 = 10  mg/l	Static	Bayer (1975a)	3
Leuciscus idus	72 h	LC0 = 1  mg/l	Static	Bayer (1975b)	3
Cyprinus carpio			Fed by oral application	Loeb & Kelly	3
			of substance in gelatin	(1963)	
			capsule		

# 4.1.1.2 Acute toxicity to daphnia

Two valid studies exist for daphnids but the lowest EC50 value was observed in the 48 h test (ABC, 1979d) and this is therefore considered to be the preferred study.

species	duration	results	remarks	references	reliability
Daphnia magna	48 h	EC50 = 17  mg/l	No analysis	ABC (1979d)	2
Daphnia magna	24 h	EC50 = 62.4  mg/l	No analysis	Bayer (1990b)	2

# 4.1.1.3 Acute toxicity to algae

There are two acute toxicity tests available for algae. While both studies are valid with restrictions, due to the lack of analysis, the test using *Selenastrum capricornutum* is preferred as it provides the lowest EC50 value and was the longer study of the two. Moreover, the 96 h result is calculated using the US EPA method which is based more on biomass (number of cells or chlorophyll with no logarithmic calculation to determine specific growth rat e). While the NOEC for biomass from the Bayer (1990) study provides the lowest overall value, the concentration effect curve for biomass was sigmoid in shape, flattening out from 1 mg/l DPG and lower resulting in an abnormally low determination of EbC10. Examination of the log cell number against time leads to the conclusion that significant reduction in cell number compared to the control does not occur below 1 mg/l. Indeed, linear extrapolation of the concentration effect graph for biomass leads to a NOEC of 0.3 mg/l instead of 0.013 mg/l for the *S. subspicatus* study. The NOEC of 0.3 mg/l calculated from the *S. capricornutum* study is therefore considered the more appropriate value to be used in this case.

species	duration	results	remarks	references	reliability
Scenedesmus subspicatus	72 h	ErC50 = 7.5 mg/l NOEC = 2.1 mg/l	No analysis	Bayer (1990c)	2
		EbC50 = 2.6 NOEC = 0.013			
Selenastrum capricornutum	96 h	EC50 = 1.7 mg/l NOEC = 0.3 mg/l	No analysis	BMRL (1979)	2

# 4.1.1.4 Acute toxicity to micro-organisms

Three studies exist but only one (Bayer, 1990d) is considered valid for use. The study followed OECD guideline 209 and determined an EC50 for sludge respiration inhibition of 147 mg/l.

#### 4.1.1.5 Chronic toxicity to daphnids

One Daphnia reproduction test following the 1984 version of OECD 202 part b is available (Bayer, 1990e). The study is considered to be valid without restriction and comprises analytical measurements of 1,3-Diphenylguanidine and was performed to GLP.

The NOEC for immobilisation of the parent generation is 1.9 mg/l and of reproduction was 0.6 mg/l.

# 4.1.1.6 PNEC for the aquatic environment

Using the lowest aquatic toxicity result from three acute tests together with a factor of 1000 the PNEC would be  $1.7 \mu g/l$  based on the *Selenastrum capricornutum* study. However, if the NOECs from the algae (0.3 mg/l) and daphnid chronic (1.9 mg/l) studies are used (excluding the EbC50 results), and applying a uncertainty factor of 50, the PNEC would be  $6 \mu g/l$ .

# 4.2 Terrestrial Effects

Studies are available on terrestrial plant emergence, soil microorganism effects and bird acute oral toxicity.

One plant study (Kefford et al., 1965) examined germination induction of *Lactuca sativa* by 1,3-Diphenylguanidine rather than inhibition of emergence and so cannot be considered valid for hazard assessment. The second plant study examined the effect of the substance on the mitosis cycle of *Vicia faba* (Bempong & McCoy, 1972) and so no relevant end point for risk assessment can, be determined for this study either.

The soil micro-organism studies were also unconventional and cannot be used for hazard assessment. Both studies were performed by the same authors (Williams & Biodeter, 1984). In the first, inoculated aqueous soil extract  $(3.0 \times 10^7 \text{ ind./ml})$  in nutrient agar containing the test substance (concentration not specified) was incubated for a period of 4-14 d. The 4 d EC50, compared to the growth rate of the control, was described as less than or equal to 0.1 % (1 g/l). In the second study the effect of test substance (concentration not specified) on growth rate of soil micro-organisms on a polycarbonate membrane or embedded in epoxy resin (Araldite) was determined. No colony formation was observed within the test period of 3 months.

The only plant study that can be considered valid was the 16 d plant study by Schallnass et al. 1995, following OECD 208 and using two plant species *Avena sativa* and *Brassica rapa*. All seedlings places in spiked or control soil emerged by day 9 of the test. All control plants emerged by day 3 of the test. For *Avena sativa*:

EC50 = 1169 mg/kg based on plant fresh weight LOEC = 1000 mg/kg based on plant fresh weight

NOEC = 316 mg/kg based on plant fresh weight

For Brassica rapa:

EC50 = 358 mg/kg based on plant fresh weight LOEC = 316 mg/kg based on plant fresh weight NOEC = 100 mg/kg based on plant fresh weight

The LOEC based on observed toxic effects = 100 mg/kg - dry leaf edges observed in 12 out of 20 plants, however, at 31.6 mg/kg this symptom was noted in 1 out of 20 plants. The LC50 could not be calculated as no plant mortality was found at any concentration.

#### 4.3 Other Environmental Effects

The avian study (Schafer, 1983) reported acute oral toxicity up to a limit concentration of 100 mg/kg on three species of song birds *Agelaius phoeniceus, Sturnus vulgaris* and *Passer domesticus*. After a single oral application of test substance (dissolved in propyleneglycol) following a settling in-phase of 2-6 weeks, no acute effects were observed.

# 4.4 Initial Assessment for the Environment

1,3-diphenylguanidine has three forms: unionised, primarily protonated and secondarily protonated. The pKa at which the first protonation occurs is 10.12 while the pKa for the second protonation is unknown and as this will be less than 10.12 it is not known whether this state will be reached at normal environmental pHs between 6 and 8. This leads to problems in determining the environmental fate of the substance.

Due to the relatively high solubility, low octanol water partition coefficient and low volatility of 1,3-Diphenylguanidine the substance is not expected to adsorb to sediment and will mainly be present in the aqueous phase. A bioconcentration test on fish provided a BCF of <20 (LOQ). The substance is therefore likely to remain bioavailable and, although not readily biodegradable, has been shown to mineralise rapidly in the presence of adapted micro-organisms. Based on the above the substance can be considered inherently biodegradable while bioaccumulation in biota is not expected for this substance.

1,3-diphenylguanidine has been shown to be toxic to fish and algae and harmful to Daphnia in several acute studies (fish: 96 h LC50 = 4.2-11 mg/l; algae: EC50 = 1.7-7.5 mg/l; daphnid: 48 h EC50 = 17-62.4 mg/l).

The PNEC can be determined using the NOECs from the algae (0.3 mg/l) excluding the lowest EbC50 results, and daphnid chronic (0.6 mg/l) studies, by applying an uncertainty factor of 50. The resulting PNEC would be  $6 \mu g/l$ .

A terrestrial plant study conducted on monocotyledons and dicotyledons did not show a high level of concern for DPG in these species

Due to its major use as a vulcanisation activator during which process it is incorporated in the rubber compound but much reverts after processing, leaching of DPG may occur from rubber compounds but the substance represents a relatively low percentage of content in the finished product (1-2%). DPG may be of concern locally in aqueous discharge from production and downstream use sites.

# 5. CONCLUSIONS AND RECOMMENDATIONS

#### 5.1 Conclusions

1,3-diphenylguanidine has three forms: unionised, primarily protonated and secondarily protonated. The pKa at which the first protonation occurs is 10.12 while the pKa for the second protonation is unknown and as this will be less than 10.12 it is not known whether this state will be reached at normal environmental pHs between 6 and 8. This leads to problems in determining the environmental fate of the substance.

Due to its sole use as a vulcanisation activator during which process it is incorporated in the rubber compound but much reverts after processing, leaching of DPG may occur from rubber compounds but the substance represents a relatively low percentage of content in the finished product (1-2%). DPG may be of concern locally in aqueous discharge from production and downstream use sites.

Due to the relatively high solubility, low octanol water partition coefficient and low volatility of 1,3-Diphenylguanidine the substance is not expected to adsorb to sediment and will mainly be present in the aqueous phase. A bioconcentration test on fish provided a BCF of <20 (LOQ). The substance is therefore likely to remain bioavailable and, although not readily biodegradable, has been shown to mineralise rapidly in the presence of adapted micro-organisms. Based on the above the substance can be considered inherently biodegradable. Bioaccumulation in biota is not expected for this substance.

1,3-diphenylguanidine has been shown to be toxic to fish and algae and harmful to Daphnia in several acute studies (fish: 96 h LC50 = 4.2-11 mg/l; algae: EC50 = 1.7-7.5 mg/l; daphnid: 48 h EC50 = 17-62.4 mg/l).

The PNEC can be determined using the NOECs from the algae (0.3 mg/l) excluding the lowest EbC50 results, and daphnid chronic (0.6 mg/l) studies, by applying an uncert ainty factor of 50. The resulting PNEC would be  $6 \mu g/l$ .

A terrestrial plant study conducted on monocotyledons and dicotyledons did not show a high level of concern for DPG in these species

1,3-Diphenylguanidine is absorbed rapidly after oral uptake but only slowly after dermal application. The substance is metabolised quickly and eliminated in the urine and faeces. No information is available on the mode of action.

The oral LD50 is 323-850 mg/kg b.w. for the rat. The dermal LD0 is > 2,000 mg/kg b.w. in the rabbit. Intoxication is manifested by spasms, disturbed lipid metabolism, lung emphysema and kidney changes.

Three subchronic toxicity feeding studies in rats and mice have shown an increase of the mortality rate at high dose and a decrease of food consumption and body weight gain due to the poor palatability of the 1,3-Diphenylguanidine-treated feed. Treatment -related effects on the organs and the haematological, clinical-chemical parameters and urinalysis were not observed. The NOAEL/LOAEL lies at 32/50 mg/kg bw/d and 11/37 mg/kg bw/d for rats and 75/114 mg/kg bw/day in mice. Based on these data the best estimate for the NOAEL was 32 mg/kg bw/d for rats.

Most of the in vitro and in vivo investigations available give no indication of a genotoxic effect.

A carcinogenicity study which would meet present standards is not available.

1,3-diphenylguanidine did not affect the fertility of male mice when administered by gavage up to the maximal tested dose level of 16 mg/kg/d. In addition to the results of the feeding sub-chronic studies on the rat and mouse, special studies for recognising reproductive toxic effects were also performed. Comparisons of the parameter changes with the results of tests with feed withdrawal infer that the effects observed in the 1,3-Diphenylguanidine-treated animals in high concentration groups are a result of the poor general state of health (malnutrition, exhaustion) of the animals and not a direct toxic effect on the reproductive organs. Very conservative NOAELs, based on the effects on the reproductive organs, secondary to malnutrition and exhaustion, can be established at 32 mg/kg bw/d for rats and from 16 to 231 mg/kg bw/d for mice.

In female rats and mice foetotoxic, but not teratogenic, effects were seen after the oral administration of maternotoxic doses. In the rat study the NOEL was given as 5 mg/kg bw for the dams and 25 mg/kg bw for the foetuses. In the mouse study the NOEL was given as 4 mg/kg bw for the dams and > 10 mg/kg bw for the foetuses. 1,3-Diphenylguanidine is irritating to the eye and non-irritating to the skin.

Human cases have shown that contact dermatitis patients, for whom a rubber intolerance was often present, occasionally reacted positively to 1,3-diphenylguanidine in the patch test. Taken into account the negative Guinea pig maximization assay, it can be infer that the positive reactions observed in human patients with contact dermatitis reflected cross-reactions rather than a direct sensitizing effect of 1,3-diphenyl guanidine.

In man, earlier and unconfirmed studies described the following symptoms after workplace exposures to 1,3-diphenylguanidine: eye and mucous membrane irritation, gastric and bilious complaints and disturbed liver metabolism.

#### 5.2 Recommendations

# **Environment**

Based on current information no clear conclusion can be drawn. While the fate properties suggest that the substance will not bioaccumulate in the environment and that degradation will occur, the PNEC, be it based on flora or fauna is relatively low and the downstream use is such that the substance is likely to be found (within or outside polymer matrix) in the environment mainly due to abrasion from car tyres.

In the absence of knowledge on the leaching behaviour of the substance from abraded rubber compounds, further work to provide a reasonable estimate of the environmental concentration is considered necessary.

# **Human Health**

Low priority for further work.

#### 6. REFERENCES

ABC laboratories inc, USA: Study no. 23805 (AB-79-1384358-1a) for Monsanto Chemical Company

ABC laboratories inc, USA: Study no. 23806 (AB-79-1384358-1b) for Monsanto Chemical Company

ABC laboratories inc, USA: Study no. 23807 (AB-79-1384358-1c) for Monsanto Chemical Company

ABC laboratories inc, USA: Study no. 23808 (AB-79-1384358-1d) for Monsanto Chemical Company

Adams RM (1972) Shoe dermatitis. Calif Med, 117, 12-16.

Agrup G (1969) Hand eczema and other hand dermatoses in south Sweden. Acta Derm. Venereol. 49, Suppl.  $61,91\,\mathrm{S}$ .

Aguirre A, Manzano D, Zabala R, Raton JA and Perez JLD (1994) Contact allergy to captan in a hairdresser. Contact Dermatitis 31, 46.

Alles GA (1926) J Pharm Exp Ther, 28, 251-276.

American Cyanamid Company, pers. comm. Cited in: McCormick WE (1971) Rubber Chem Technol, 44, 512-533.

Arkhangel'skaya LN and Roshchina TA (1963) Brief account of toxic properties of vulcanisation accelerators diphenylguanidine and furfuramide. Sovjet Rubber Tech. 22, 38-39.

Arkhangel'skaya LN and Roshchina TA (1964) Toxicological characterization of furfuramide, a new vulcanization accelerator. Gig. Sanit. 29, 37-42.

Arkhangel'skaya LN and Roshchina TA (1968) Toksikol. Nov. Khim. Veshchesto, Vnedrialnik, Moskau, 117-126. Cited in: Chem. Abstr. 71: 47801.

Baba T (1980) Öffentlich hygienische Untersuchungen über Gummiwaren für Lebensmittel. J Osaka City Medical Center, 29, 807-827.

Baer RL, Ramsey DL and Biondi E (1973) The most common contact allergens. Arch. Derm. 108, 74-78.

Bajaj AK, Gupta SC, Chatterjee AK and Singh KG (1988) Shoe dermatitis in india. Contact Dermatitis 19, 372-375.

Bandmann HJ (1956) Vulkanisationbeschleuniger als Kontaktekzemallergene. Hautarzt, 7, 419-421.

Bayer AG (1975a), unpublished data

Bayer AG (1975b), unpublished data

Bayer AG (1990a), unpublished data: Study report no. 85 A/89

Bayer AG (1990b), unpublished data: Study report no. 85 A/89 D

Bayer AG (1989c), unpublished data: Report no. 85 A/89 AL

Bayer AG (1990d), unpublished data: Study report no. 85 A/89 D

Bayer AG (1990e), unpublished data: Report number 85 A/89 DL

Bempong, M.A. & McCoy, R. (1972) Newslett. Environ. M utagen. Soc. 5, 25-28.

Bempong MA (1983a) Effect of 1,3-Diphenylguanidine on sperm count, testicular histopathology and implantation frequency in mice. Environ Mutagen, 5, 494-495.

Bempong MA (1983b) Reproductive toxicity of 1,3-diphenylguanidine: analysis of damaged sperm and fertility index. J. Am. Coll. Toxicol. 2, 241.

Bempong MA and Hall EV (1983) Reproductive toxicology of 1,3-diphenylguanidine: analysis of induced sperm abnormalities in mice and hamsters and reproductive consequences in mice. J Toxicol Environ Health, 11, 869-878.

Bempong MA and Mantley RJ (1985) Body fluid analysis of 1,3-diphenylguanidine for mutagenicity as detected by Salmonella strains. Environ Pathol Toxicol Oncol, 6, 293-301.

Bempong MA. Personal communication beetween Bempong M, Norfolk State University, Norfolk, VA and NTP, Bethesta, MD. November 21, 1986.

Bempong, M.A., unpublished data

Blank IH and Miller OG (1952) A study of rubber adhesives in shoes as the cause of dermatitis of the feet. J Am Med Assoc, 149, 1371-1374.

Bonnevie P and Marcussen PV (1944) Rubber products as a widespread cause of eczema. Report of 80 cases. Acta. Derm. Venereol., 25, 163-177.

Brunze M (1994) Diagnostic pearls in occupational dermatology. Occupational Dermatoses 12, 485-489.

BUA (1992). BUA report 96 (August 1992) on N,N'-Diphenylguanidine. German Chemical Society. S. Hirzel, Wissenschaftliche Verlagsgesellschaft, Stuttgart 1994

Burov, Y.A., Farmakol. Toksikol. 27, 714-717 (1964)

Busev, A.I. et al., Latv. PSR Zinat. Acad. Vestis, Kim. Ser. 4, 477-481 (1974)

Calan CD (1978) Diphenyl guanidine in rubber hoses. Contact Dennatitis 4, 241.

Camarasa JMG and Alomar A (1978) Allergic rhinitis from diphenylguanidine. Contact Dermatitis 4, 242.

Chapin RE, Gulati DK, Fail PA, Hope E, Russel SR, Heindel JJ, et al. (1993a) The effects of feed restriction on reproductive function in Swiss CD-1 mice. Fund Appl. Toxicol., 20, 15-22.

Chapin RE, Gulati DK, Barnes LH and Teague JL (1993b) The effects of feed restriction on reproductive function in spregue-Dawley rats. Fund Appl. Toxicol., 20, 23-29.

Chou TW, Mabey WR, Spanggord R, Smith JH, Haynes D, Baraze A & Burris D. (1980) Selected environmental fate studies on nine chemical compounds. SRI International. SRI project no. 8669.

Conde-Salazar L, Del-Rio E, Guimaraens D and Domingo AG (1993) Type IV allergy to rubber additives: A 10-year study of 686 cases. Journal of the American Academy of Dermatology, 29 (2), 176-180.

Crebelli R, Falcone E, Aquilina G and Carere A (1984a) In vitro mutagenicity of rubber chemicals and thier nitrosation products. Toxicol. Lett., 23, 307-313.

Crebelli R, Falcone E, Aquilina G and Carere A (1984b) Mutagenicity studies in a tyre plant: in vitro activity of urine concentrates and rubber chemicals. IARC Sci. Publ., 59, 289-295.

Crebelli R, Paoletti A, Falcone E, Aquilina G, Fabri G and Carere A (1985) Mutagenicity studies in a tyre plant: in vitro activity of workers' urinary concentrates and raw materials. Br J. Ind. Med., 42, 481-487.

Curtis GH (1945) Contact dermatitis of eyelids caused by an antioxidant in rubber fillers of eyelash curlers. Arch. Derm. Syph., 51, 262-265.

Dahl MV (1975) Allergic contact dermatitis from footwear. Minnesota Med., 58, 871-874.

Danenberg, P.V. & Santi, D.V. (1975) J. Med. Chem. 18, 528-530,

De Vries HR (1964) Allergic dermatitis due to shoes. Dermatologica, 128, 68-75.

Dieke SH, Allen GS and Richter CP (1947) The acute toxicity of thioureas and related compounds to wild and domestic Norway rats. J. Pharm. Exp. Ther., 90, 260-270.

Donner M, Husgafvel-Pursiainen K, Jenssen D and Rannug A (1983) Mutagenicity of rubber additives and curing fumes: results from five short-term bioassays. Scand. J. Work Environ Health, 9, 27-37.

EG&G, Bionomics Marine Research Laboratory (BMRL), Florida, USA: Project no. H97-500 (BP-79-7-104) for Monsanto Chemical Company

Fegeler F (1963) Kontaktekzeme durch Gummistiefel. Berufsdermatosen, 11, 18-24.

Fraser, D.A. & Rappaport, S. (1976) Environ. Health Perspect. 17, 45-53.

Garcia-Perez, A, Garcia-Bravo B and Beneit JV (1984) Standard patch tests in agricultural workers. Contact Dermatitis 10, 151-153.

Götz H and Istvanovic N (1963) Die Bedeutung von Gummiallergenen insbesondere bei Bergleuten. Hautarzt, 14, 345-348.

Hall, N.F. & Sprinkle, M.R. (1932) J. Am. Chem. Soc. 54, 3469-3485.

Hasegawa R et al. (1989) Sci Rep Res Inst, Tohoku Univ, -C, 36, 1-4.

Helander I and Mäkelä A (1983) Contact urticaria to zinc diethyldithiocarbamate (ZDC). Contact Dermatitis 9, 327-328.

Herrmann WP and Schulz KH (1960) Hilfsstoffe der Gummiindustrie als Ekzemnoxen. Dermatologica, 120, 127-138.

Hjorth N and Fregert S (1972) Contact dermatitis. In Fran Rook, A. (Hrsg) Textbook of dermatology, Linppincott, Philadelphia, 342-343.

Höfer W and Hönemann W (1967) Über beruflich bedingte Akzeme nach Gummieinwirkung bei Bergleuten. Dtsch Ges Wes, 20, 1110-1114.

Hunter and Scully (personal communication) cited in: Bempong, M.A. & Hall, E.V., J. Toxicol. Environ. Health 11, 869-878 (1983).

IARC, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. The rubber industry, Vol. 28. International Agency for Research on Cancer, Lyon (1982)

Ioannou YM and Matthews HB (1984) Absorption, distribution, and excretion of 1,3-diphenylguanidine in the male F344 rat. Fundam. Appl. Toxicol., 4, 22-29.

JETOC (1996) Mutagenicity test data of existing chemical substances based on the toxicity investigation system of the industrial safety and health law. Ministry of Labour, Japan.

Jung HD (1977) Gummi als Schadstoff beim Melkerekzem in der sozialistischen Landwirtschaft. Das Deutsche Gesundheitswesen, 32, 1866-1872.

Kanerva L, Estlander T and Jolanki R (1994) Occupational allergic contact dermatitis caused by thiourea compounds. Contact Dermatitis, 31, 242-248.

Kanerva L, Estlander T and Jolanki R (1996) Allergic patch test reactions caused by the rubber chemical cyclohexyl thiophthalimide. Contact Dermatitis, 34, 23-26.

Kantoh H, Ishihara M, Itoh M Hosono K and Nishimura M (1985) Allergens in rubber products. Hifu. 27, 501-509.

Kazarinova NF, Duchovnaja IS and Vlasjuk MG (1975) (1975) Bestimmung des Diphenylguanidins in biologischen Medien. Gig Sanit, 4, 63-65.

Kefford, N.P., Zwar J.A. & Bruce M.I., Enhancement of lettuce seed germination by some urea derivatives. Planta 67, 103-106 (1965)

Keith, L.H. & Walters, D.B., Compendium of safety data sheets for research and industrial chemicals. Verlag Chemie, Weinheim, 732-733 (1985)

Kiec-Swierczynska M (1995) Occupational sensitivity to rubber. Contact Dermatitis, 32, 171-190.

Kilpikari I (1982) Occupational contact dermatitis among rubber workers. Contact Dermatitis 8, 359-362.

Knudsen BB, Larsen E, Egsgaard H, and Menné T (1993) Release of thiurams and carbamates from rubber gloves. Contact Dermatitis, 28, 63-69.

Koch P (1996) Occupational allergic contact dermatit is and airborne contact dermatitis from 5 fungicides in a vineyard worker / Cross-reactions between fungicides of the dithiocarbamate-group? Contact Dermatitis, 34, 324-329.

Koch P, Nickolaus G and Geier J (1996) Kontaktallergien bie Lederherstellern, Lederverarbeitern und in der Schuhindustrie. Dermatosen 44, 257-262.

Koeter HB, Regnier J-F and van Marwijk MW (1992) Effect of oral administration of 1,3-diphenylguanidine on sperm morphology and male fertility in mice. Toxicology, 71, 173-179.

Kondo, M. et al., Eisei Kagaku 34, 115-122 (1988)

Kondo, M. et al., Eisei Kagaku 34, 188-195 (1988)

Korhonen A, Hemminki K and Vainio H (1983a) Embryotic effects of acrolein, methacrylates, guanidines, and resorcinol on three day chicken embryos. Acta Pharmacol Toxicol, 52, 95-99.

Korhonen A, Hemminki K and Vainio H (1983b) Toxicity of rubber chemicals towards three-day chicken embryos. Scand. J. Work Environ. Health, 9, 115-119.

Kowalski Z and Bassendowska E (1965) Vorläufige Intersuchungen über die toxischen Wirkungen einiger Vulkanisationsbeschleuniger (D, M DM, DFT and P-extra-N). Med Pracy, 16, 35-43.

Kurokawa, Y. & Ogawa, Y.; cited in: IARC, Directory of agents being tested for carcinogenicity. IARC, Lyon, 99 (1992).

Levin S, Semler D and Ruben Z (1993) Effects of two weeks of feed restriction on some common toxicologic parameters in Sprague-Dawley rats. Toxicol Pathol, 21(1), 1-14.

Lisi P and Simonetti S (1985) Contact sensitivity in children and adults with atopic dermatitis - a chronological study. Dermatologica, 171, 1-7.

Loeb, H.A. & Kelly, W.H., Acute oral toxicity of 1496 chemicals force-fed to carp. Special Scientific Report - Fisheries No. 471. US Department of the Interior, Washington, D.C. (1963)

Lynde CW, Warshawski L and Mitchell JC (1982) Patch test results with a shoewear screening tray in 119 patients, 1977-80. Contact Dermatitis 8, 423-425.

Marhold J (1986) Prehled Prumyslove Toxikologie, Organicke Latky, Svazek 1, S. 974.

McCormick WE (1971) Environmental health control for the rubber industry. Rubber Chem Technol, 44, 512-533.

Meneghini CL, Rantuccio F and Riboldi A (1963) Klinisch-allergologische Beobachtungen bei beruflichen ekzematdsen Kontakt - Derma-tosen. Kontakt - Dermatosen, 11, 280-293.

MITI (1992). Biodegradation and Bioaccumulation, Data of Existing Chemicals Based on CSCL Japan, Compiled under the Supervision of Chemical Products Safety Division, Basic Industries Bureau MITI, Ed. by CITI, October 1992. Published by Japan Chemical Industry Ecology -Toxicology & Information Center

Mladenov, I. et al., Plaste Kautschuk 36, 227-229 (1989)

MLPC (1995) 1,3-diphenylguanidine. Skin sensitization test in guinea-pigs (Maximization method of Magnusson and Kligman). CIT report no. 12244 TSG, February 8, 1995.

MLPC (2001) phone call of 30 October 2001 with Mr. Jacquier, head of the analysis laboratory.

Monsanto Chemical Company (1954) The acute oral toxicity of diphenylguanidine for rats. Scientific Associates report dated June 18, 1954.

Monsanto Company (1976) Ames/Salmonella Mutation assay and S. cerevisiae Mutation assay. Litton Bionetics Inc. report no. 2683, December 30, 1976 (Monsanto Study BO-76-276).

Monsanto Company (1977a) Acute oral toxicity with diphenylguanidine. Younger laboratories study no. Y-77-61, April 27th, 1977.

Monsanto Company (1977b) Acute dermal toxicity with diphenylguanidine. Younger Laboratories report no. Y-77-61, April 27th, 1977.

Monsanto Company (1977c) Primary skin irritation with diphenylguanidine. Younger laboratories report no. YO-77-61, April 27, 1977.

Monsanto Company (1977d) Acute eye irritation with diphenylguanidine. Younger Laboratories report no. Y-77-61, April 27, 1977.

Monsanto Company (1977e) Acute eye irritation with diphenylguanidine. Younger Laboratories report no. Y-77-254, October 17, 1977.

 $Monsanto\ Company\ (1979)\ Mouse\ Lymphoma\ TK\ LOCUS\ Mutation\ assay.\ Litton\ Bionetics\ Inc.\ report\ no.\ 20989,\ February\ 1979\ (Monsanto\ study\ no.\ BO-78-235).$ 

Monsanto Company (1980) internal report SR -85-X,

Monsanto Company (1982) Evaluation to determine potential hazards of dermal contact with SH -82-006, N,N'-diphenylguanidine. Product Investigation report no. 2581 (Monsanto report no. SH -82-006).

Monsanto Company (1986) A Teratology Study in Rats with DPG. Wil report no. WIL-50004, April 24, 1986 (Monsanto study no. WI-85-197).

Monsanto Company (1989) In vivo rat bone marrow cytogenetics study of 1,3-diphenylguanidine. Study no. ML-89-513.

Monsanto Company (1992a) Acute dermal toxicity study in rabbits with 1,3-diphenyl guanidine. Springborn Laboratories report no. 3044.271 (Monsanto report no. SB -91-448), April 9, 1992.

Monsanto Company (1992b) In vitro cytogenetics assay of 1,3-diphenylguanidine. Study ML-90-553, October 26, 1992.

Monsanto Company internal report #92-9056

Monsanto Europe SA (1982). Diphenylguanidine: Toxicity study in rats (oral administration via the diet for 13 weeks). Inveresk Research international report no. 2311, June 1982 (Monsanto study no. IN-81-303).

Mortelmans K, Haworth S, Lawlor T, Speck W, Tainer B, and Zeiger E (1986) Salmonella Mutagenicity Tests: II. Results From the Testing of 270 Chemicals. Environ Mutagen, 8, 1-119.

Nater JP (1975) Überempfindlichkeit gegen Gummi. Berufsdermatosen 23, 161-168.

Naunton, W.J.S., J. Soc. Chem. Ind. 45, 376-384 (1926)

NTP (1995) Technical report no. 42 on toxicity studies of 1,3-diphenylguanidine administered in feed to F344/N rats and B6C3F1 mice.

Orlov NS, Vlasyuk MG and Glinyanaya AG (1973) The effect of diphenylguanidine on humans and animals (clinical experiments). Gig Prim Polim Mat Stroit, 133-137.

Rajan VS and Khoo R (1980) Allergic contact dermatitis in Singapore. Mod. Med. Asia 16, 54-56.

Rannug A, Rannug U and Ramel C (1984) Genotoxic effects of additives in synthetic elastomers with special consideration to the mechanism of action of thiurames and dithiocarba mates. Prog Clin Biol Res, 141, 407-419.

Reifferscheid, T., Haeufigkeit und Verteilungsmuster der Kontaktallergene bei Patienten der Universitaets-Hautklinik Duesseldorf in den Jahren 1974-1976. Medizinische Dissertation, Universitaet Duesseldorf (1979)

Roed-Petersen J and Menné T (1976) Allergic contact dermatitis and lichen planus from black-and-white photographic developing. Cutis, 18, 699-705.

Ross JB and Obst D (1969) Rubber boot dermatits in newfoundland: a survey of 30 patients. Can. Med. Ass. J. 100, 13-19.

Rudzki E and Kleniewska D (1970) The epidemiology of contact dermatitis in Poland. Br. J. Derm. 83, 543-545.

Rudzki E and Kohutnicki Z (1971) Professional allergens in bricklayers. Med. Pracy 22, 515-519.

Ruocco V and Florio M (1986) Su di un caso di probabile malanosi frizionale. Ann. It. Derm. Clin. Sper. 40, 263-268.

Saha M, Srinivas CR, Shenoy SD, Balachandran C and Acharya S (1993) Footwear dermatitis. Contact Dermatitis, 28, 260-264.

Sax, N.I. & Lewis, R.J., Sr., Hawley's condensed chemical dictionary. Van Nostrand Reinhold Company, New York, 428 (1987).

Schafer, E.W., The acute oral toxicity of 369 pesticidal, pharmaceutical and other chemicals to wild birds. Toxicol. Appl. Pharmacol. 21, 315-330 (1972)

Schafer Jr., E.W., Bowles Jr WA & Hurlbut J., The acute oral toxicity, repellency, and hazard potential of 998 chemicals to one or more species of wild and domestic birds. Arch. Environ. Contam. Toxicol. 12, 355-382 (1983)

Schallnass H-J, Diehl Th & Knacker Th. (1995) BBA Guideline "Phtytotoxicity test to a monocotyledonous plant species (Avena sativa L.) and a dicotyledenous plant species (Brassica rapa ssp. rapa [DC.] Metzg.) " adopted March 1984. ECT Oekotoxikologie GmbH.

Shah PV, Sumler MR, Ioannou YM, Fisher HL and Hall LL (1985) Dermal absorption and disposition of 1,3-diphenylguanidine in rats. Toxicol. Environ. Health, 15, 623-633.

Smyth HF (1931) The toxicity of certain benzene derivatives and related compounds. J. Ind. Hyg. Toxicol., 13, 87-96.

Song M, Degreef H, De Maubeuge J, Dooms-Goossens A and Oleffe J (1979) Contact sensitivity to rubber additives in Belgium. Dermatologica, 158, 163-167.

Sumitomo Chemical Co., Ltd. Acute oral toxicity of Soxinol D in rats. Institute for Biological Science report no. C-77-115, December 1st, 1977.

Suskind RR (1984) Personal Communication, March 16, 1984, cited in Fischer AA (1986), Contact Dermatitis, Lea & Febiger, Philadelphia, 636.

Takeda K, Matsumoto A and Arakawa T (1964) Four cases of erythromelanosis. Effects of compound used in the rubber industries on the skin. J. Exp. Med., 10, 223-230.

Te Lintum JCA and Nater JP (1973) Contact-dermatitis caused by rubber chemicals in dairy workers. Berufsdermatosen 21, 16-22.

Tomlinson, T.G. et al., J. Appl. Bact. 29, 266-291 (1966)

Tuyp E and Mitchell JC (1983) scuba diver facial dermatitis. Contact Dermatitis 9, 334-335.

Van Dijk E (1968) Contact dermatitis due to spandex. Acta Derm Venereol, 48, 589-591.

Verchovski (1952) cited in: Kowalski Z and Bassendowska E (1965) Med Pracy, 16, 35-43.

Vlasyuk MG (1978) Data for substantiation of the permissible quantity of diphenylguanidine migration from rubbers in contact with foods. Gig. Sanit, 7, 35-38.

Weast, R.C., CRC Handbook of chemistry and physics, 69<sup>th</sup> ed.. CRC Press, Inc., Boca Raton, C-293 (1988)

Williams, G.R., Int. Biodeter. 20, 173-175 (1984).

Wilson HTH (1969) Rubber dermatitis - an investigation of 106 cases of contact dermatitis causer by rubber. Br. J. Derm. 81, 175-179.

Wilson, I.S., The treatment of chemical wastes. In: Isaac, P.C.G. (ed.) Waste treatment. Proceedings of the second symposium on the treatment of waste waters, 14.-19. September. Pergamon Press, Oxford, 206-222 (1960)

Windholz, M., The Merck index, 10th ed.. Merck & Co Inc., Rahway, 486 (1983)

Wohlfahrt, R. & Niebergall, H., Lebensmittelchem. Gerichtl. Chem. 38, 100-101 (1984)

WTR (1989) (International Working Group on the Toxicology of Rubber additive) Oral testicular toxicity and male fertility study with N,N'-diphenylguanidine in mice. TNO-CIVO Institutes report no. V 88.523, August 1989.

Yamaguchi-Takako, Yamauchi-Aiko, Yamazaki-Hiroyasu and Yakiuchi-Yasuo (1991) Mutagenicity of rubber additives in tire. Eisei Kagaku 37, 6-13.

Yasuda Y and Tanimura T (1980) Effect of diphenylguanidine on development of mouse fetuses. J. Environ. Pathol. Toxicol., 4, 451-456.

You, X. et al., Huanjing. Kexue. 3, 39-42 (1982); cited in: Chem. Abstr. 98: 84705.